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Small molecule chemotherapy drugs used in clinical practice are plagued by 
dose-limiting side effects due to off-target toxicities.   In addition, because of their 
low water solubility and poor bioavailability, they must be administered 
intravenously, leading to high treatment costs and recurring hospital visits.  There is a 
significant need for therapies that improve the bioavailability of chemotherapy agents 
and enhance specific drug release in the tumor environment.  
Dendrimers, a class of highly-branched, nanoscale polymers, share many 
characteristics with traditional polymeric carriers, including water solubility, high 
capacity of drug loading and improved biodistribution.  Poly (amido amine) 
(PAMAM) dendrimers have shown promise as oral drug carriers due to their compact 
size, high surface charge density and permeation across the intestinal epithelial 
  
barrier.  Attachment of chemotherapy drugs to PAMAM dendrimers has the potential 
to make them orally administrable and reduce off-target toxicities.  
In this dissertation we investigate the transport mechanisms of PAMAM 
dendrimers and their potential in oral drug delivery. We demonstrate that anionic 
G3.5 dendrimers are endocytosed by dynamin-dependent mechanisms and their 
transport is governed by clathrin-mediated pathways.  We show that dendrimer 
cellular internalization may be a requisite step for tight junction opening.  We also 
demonstrate that conjugation of small poly (ethylene glycol) chains to anionic 
dendrimers decreases their transport and tight junction opening due to reduction in 
surface charge, illustrating that small changes in surface chemistry can significantly 
impact transepithelial transport.  Knowledge of transport mechanisms and the impact 
of surface chemistry will aid in rational design of dendrimer oral drug delivery 
systems. 
The potential of dendrimers as oral drug delivery carriers is demonstrated by 
the evaluation of G3.5 PAMAM dendrimer-SN38 conjugates for oral therapy of 
hepatic colorectal cancer metastases, a pathology present in over 50% of colorectal 
cancer cases that is responsible for two-thirds of deaths. Conjugation of SN38, a 
potent chemotherapy drug with poor solubility and low bioavailability, to PAMAM 
dendrimers via a glycine linker increased intestinal permeability, decreased intestinal 
toxicity and showed selective release in the presence of liver carboxylesterase, 
illustrating that PAMAM dendrimers have the potential to improve the oral 
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Chapter 1 : Introduction 
 
1.1  Introduction 
1.1.1 Polymer Therapeutics 
Carrier-based drug delivery strategies have been used to improve the therapeutic 
profile of small molecule drugs by enhancing uptake at the site of action and minimizing 
off-target effects.  In particular, water-soluble polymer-based drug delivery systems can 
improve the efficacy of therapeutically active compounds with intrinsically poor water 
solubility and high toxicity [1].  In the field of nanomedicine, carriers such as polymeric 
nanoparticles and liposomes have also shown promise in altering the biodistribution of 
drugs, improving efficacy and enhancing intracellular accumulation [2].  Importantly, 
targeting moieties and imaging agents can be conjugated to delivery vehicles, making 
such carriers ideal for multifunctional drug delivery [3].   
Chemotherapy drugs are promising candidates for drug delivery strategies 
because they are often plagued by poor water solubility and dose-limiting toxicities.  
Conjugation of chemotherapeutics to linear water-soluble polymers such as poly 
(ethylene glycol) (PEG) and N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers 
can improve their therapeutic profile by increasing the drug concentration at the tumor 
site due to enhanced permeability and retention in the leaky tumor vasculature [4].  In 
addition, targeting moieties can be conjugated to the polymer backbone to further 
enhance tumor-specific uptake.  Finally, drug linkers can be designed to release the drug 





enzymes [5].  Increased tumor accumulation and selective release improve the overall 
therapeutic profile compared to the free drug by increasing the concentration of drug at 
the site of action and reducing side effects caused by drug accumulation in off-target 
tissues [6].  
 
1.1.2 Oral Drug Delivery 
Due to their low water solubility and poor bioavailability, chemotherapy agents 
are traditionally administered intravenously, requiring recurring hospital visits and 
significant direct and indirect costs to the patient [7].  While conjugation to water-soluble 
polymers can improve their solubility, the large size of these macromolecular constructs 
necessitates intravenous administration.   Because of the strong patient preference for oral 
therapy and the numerous advantages of polymeric drug delivery systems, there is a 
significant need for development of orally administrable polymer-drug conjugates that 
can improve the oral bioavailabilty of the drug as well as target the drug to the tumor site.   
Advantages of oral chemotherapy include the convenience of at-home administration, 
reduction of costs associated with hospital procedures and with transportation to and from 
the treatment center, a more flexible dosing regimen and a decreased burden on hospitals 
and the healthcare system [8, 9].  
Oral delivery is challenging because systems must have appropriate solubility, 
stability in the gastrointestinal pH and enzymatic environment, and the ability to 
permeate the epithelial barrier of the gut. The mucosa of the intestinal tract is composed 
of polarized enterocytes that form a tight barrier to transport, preventing the diffusion of 





some degree of lipophilicity to be transported via passive diffusion, otherwise, they are 
relegated to the paracellular pathway which is generally limited to small hydrophilic 
molecules of 100-200 Da [11].  Therefore, oral delivery of polymer-drug conjugates 
while convenient and beneficial to the patient is also challenging.   
 
1.1.3 Poly (amido amine) Dendrimers  
Dendrimers, a class of highly branched polymers, have been shown to be effective 
drug delivery vehicles due to their unique physical properties including near 
monodispersity and nanoscopic size [12, 13].  With each increase in dendrimer 
generation, the diameter increases linearly while the number of surface groups increases 
exponentially.  This creates a high density of surface groups that can be conjugated to 
drug molecules, targeting moieties, and imaging agents, making dendrimers a versatile 
drug delivery platform [14]. Dendrimers are more compact than traditional linear 
polymers and thus show potential in oral drug delivery.   Specifically, poly (amido 
amine) or PAMAM dendrimers have shown promise as oral drug delivery carriers due to 
their nanoscale size and high surface charge density.  
Originally developed by Tomalia in 1979, PAMAM dendrimers have an ethylene 
diamine core, an amido amine branching structure and are commercially available as 
cationic “full” generations (G1, G2, etc.) with amine-terminated branches, and anionic 
“half” generations (G1.5, G2.5, etc.) with carboxylic acid terminated branches. Previous 
studies indicate that PAMAM dendrimers in a specified size and charge window can 
effectively cross the intestinal epithelial barrier, making them suitable as drug delivery 





established that generation, charge and surface chemistry influence PAMAM dendrimer 
transport across the epithelial barrier, more needs to be done to investigate how surface 
modification and drug conjugation impact the degree and mechanism of dendrimer 
transport.  In addition, chemical linkers that promote stability of the dendrimer-drug 
conjugate in the gastrointestinal milieu while favoring release of drug in the tumor 
environment must be developed to achieve a functional delivery system.   
 
1.1.4 SN38 
Because of its low water solubility and poor bioavailability, SN38 (7-ethyl-10-
hydroxy-camptothecin) is an ideal candidate for polymeric delivery strategies.  SN38 is 
the active metabolite of Irinotecan, a water-soluble camptothecin analogue that is 
commonly used for treatment of metastatic colorectal cancer [21]. With more than 
140,000 new cases of colorectal cancer each year and over 51,000 deaths projected in 
2010, there is a significant need for novel, targeted therapies for colorectal cancer [22]. 
The most common site of colorectal cancer metastasis is the liver, with over 20% of 
patients presenting liver metastases at the time of diagnosis and 50% in the duration of 
the disease [23]. These liver metastases are responsible for two-thirds of all colorectal 
cancer deaths, indicating the grave need for novel treatments of this condition.  SN38 
works by inhibition of topoisomerase-1, and shows 100-1000 fold greater in vitro activity 
than Irinotecan.  However, it has had limited clinical success due to poor water solubility 
and adverse gastrointestinal effects.  Therefore a delivery system that improves SN38 





has the potential to significantly improve its therapeutic profile and increase the efficacy 
of colorectal cancer treatment. 
 
1.2 Specific Aims 
This dissertation seeks to investigate the mechanisms of transepithelial transport 
of anionic PAMAM dendrimers and their conjugates with SN38 and PEG, with the long-
term goal of delivering SN38 orally to colorectal cancer metastases in the liver. The 
global hypothesis of the dissertation is that anionic PAMAM dendrimers can be used to 
improve the oral bioavailability of SN38 for the treatment of colorectal hepatic 
metastases and that the degree and mechanism of transepithelial transport of PAMAM 
dendrimers will be impacted by surface modification and drug loading.  This global 
hypothesis was investigated by the following three Specific Aims: 
1. To determine the transepithelial transport mechanisms of anionic G3.5 
PAMAM dendrimers across Caco-2 monolayers as a model of the intestinal epithelial 
barrier. 
2. To evaluate the toxicity, transport and uptake of G3.5-SN38 conjugates in 
Caco-2 cell monolayers and the stability of the conjugates in simulated gastrointestinal 
and liver environments. 
3. To investigate the impact of surface modification of anionic PAMAM 








These Specific Aims are designed to test the following three hypotheses: 
1. Transepithelial transport of anionic PAMAM dendrimers occurs via several 
pathways including transcytosis, governed by specific endocytic mechanisms, and 
paracellular transport, driven by dendrimer-mediated tight junction opening. 
2. Conjugation of SN38 to G3.5 dendrimers via a glycine or β-alanine peptide 
linker will increase SN38 permeability while reducing intestinal toxicity.  The conjugates 
will be stable in the gastrointestinal environment and will release SN38 in the presence of 
liver carboxylesterase. 
3. Conjugation of PEG to anionic dendrimers will influence uptake and transport 
across Caco-2 cell monolayers. 
 
1.3 Scope and Organization 
 Chapter 2 provides background on the benefits and challenges of oral drug 
delivery as well as the current strategies used to improve oral bioavailabilty and the 
laboratory methods used to predict oral absorption.  Chapter 2 also offers background on 
dendrimers, a detailed description of PAMAM dendrimers and a literature review of 
current knowledge on these polymers in the context of oral drug delivery [24].  In 
addition, colorectal cancer and current limitations and delivery strategies for SN38 are 
reviewed in this Chapter.  Chapter 3 describes the mechanisms of transport, uptake, 
intracellular trafficking and tight junction opening of native, anionic G3.5 PAMAM 
dendrimers in Caco-2 cells [25].  In particular, Chapter 3 explores the role of endocytosis 
in dendrimer tight junction opening.   In Chapter 4, G3.5-SN38 conjugates are evaluated 





stability in simulated gastrointestinal environment and in the presence of liver 
carboxylesterase as well as their cellular uptake and transport across Caco-2 monolayers 
and efficacy in HT-29 cells are investigated.  Chapter 5 describes the evaluation of PEG 
surface modification of G3.5 and G4.5 dendrimers in the context of oral drug delivery, 
specifically examining the impact of PEGylation on dendrimer cytotoxicity, uptake, 
transport and tight junction modulation in Caco-2 cell monolayers [27].  Finally, Chapter 
6 summarizes the major findings of this dissertation and suggests future directions for 






Chapter 2 : Background 
 
2.1 Introduction 
The objective of drug delivery science is to control the spatial and temporal 
distribution of a drug molecule in the body in order to improve therapeutic effect and/or 
reduce toxicity [28].  Drug delivery technologies can alter a drug’s solubility, absorption, 
metabolism, elimination and biodistribution in vivo.  One of the most common drug 
delivery strategies is to attach therapeutic compounds to “carriers” by physical and 
chemical mechanisms, with the overall goal of modifying the drug’s biodistribution and 
controlling release from the carrier.  Examples of drug delivery carriers include 
nanoparticles, micelles, liposomes and water-soluble polymers [29-31].  These advanced 
“formulation strategies,” can be modified to yield an optimized delivery system for the 
cargo, which can improve the therapeutic index compared to the free drug.  In this 
dissertation we will explore poly (amido amine) (PAMAM) dendrimers as oral drug 
delivery vehicles for anti-cancer therapeutics.  This chapter will provide the pertinent 
background on the concepts of polymeric drug delivery, oral drug delivery, dendrimers, 
colorectal cancer and SN38 as well as a literature review on the current state of 
knowledge on poly (amido amine) (PAMAM) dendrimers as oral drug delivery carriers. 
 
2.2 Polymeric Drug Delivery 
 Polymeric systems are among the most widely used drug carriers.  Although 





water-soluble polymers were not conceptualized for use as targeted drug delivery systems 
until 1975 when Ringdsorf first wrote of “pharmacologically active polymers” [33].  In 
this concept, a drug molecule is covalently conjugated to a polymeric carrier through a 
selectively degradable chemical linker, which releases the drug at the site of action.  
Targeting moieties are conjugated to the polymer in order to enhance the accumulation of 
the polymer-drug conjugate at the site of action, maximizing efficacy and minimizing 
non-specific toxicities.   Several properties of the polymer backbone, including chemical 
composition, molecular weight and architecture, can be tailored for a given drug delivery 
application.  In addition, the number of drug molecules, choice of chemical linker and 
type of targeting moiety can be modified to create an optimized polymeric drug delivery 
system [6].  A schematic of polymer-drug conjugate design is shown in Figure 2.1. 
 
2.2.1 Therapeutic Advantages of Polymer-Drug Conjugates in Chemotherapy 
 One of the most common applications of polymer-drug conjugates is in the delivery 
of anti-cancer therapeutics.  Because chemotherapy drugs have high potency but low 
selectivity, their use is severely limited by unintended toxic effects to healthy tissues 
[34].  Conjugation of chemotherapeutics to polymeric carriers has the capacity to 
improve their therapeutic index by enhanced drug accumulation at the tumor site with 
fewer off-target effects [35].  One of the most widely studied properties of polymeric 
drug delivery systems is the enhanced permeability and retention (EPR) effect.  The EPR 
effect, coined by Hiroshi Maeda, describes the propensity of macromolecules to 






Figure 2.1. Design and Optimization of Polymer-Drug Conjugates. Several parameters 
can be optimized when designing polymer-drug conjugates including polymer backbone 
composition, molecular weight and architecture, drug cargo identity and amount, type of 






tumor formation, tumors have dense and leaky vasculature.  This leaky tumor 
vasculature, coupled with the long half-life of macromolecules, leads to higher 
accumulation of polymer-drug conjugates in the tumor compared to other tissues that 
have lesser fenestrations in endothelial cell layers.  Thus, passive targeting by the EPR 
effect allows for accumulation of the drug at the tumor site, improving the therapeutic 
index compared to the free drug.  Moreover, conjugation of antibodies and ligands to the 
polymer backbone that target specific receptors over-expressed on tumor cells can 
enhance tumor accumulation [37].  The ability of polymers to serve as backbones for the 
conjugation of drugs, targeting moieties and imaging agents makes them powerful 
multifunctional delivery systems. 
 In addition to promoting drug localization at the tumor site, polymer-drug 
conjugates can also be designed to optimize drug release at the site of action [6].  There 
are several chemical linkers that are cleaved by select enzymes.  For example, the amino 
acid sequence Gly-Phe-Leu-Gly (GFLG) has been shown to be selectively cleaved by 
cathepsin B, which is over-expressed in the lysosomes of tumor cells [38].  This linker 
can be used to optimize drug release in the tumor environment, thus minimizing side 
effects.  A commonly used linker in the context of colonic delivery is the azo spacer [39].  
Azo spacers are cleaved by azo-reductase enzymes produced by bacteria in the colon, 
confining drug release to the colonic environment.  Therefore, appropriate drug linker 
selection allows for specific release in the target site and further enhances the therapeutic 






2.2.2 Polymer-Drug Conjugates Currently in Clinical Trials 
 There are several promising polymer-drug conjugates that are currently being 
evaluated in clinical trials.  Two HPMA (N-(2-hydroxypropyl) methacrylamide)-based 
systems are currently in clinical trials for the delivery of Doxorubicin and Platinate [40].  
FCE 28068 contains Doxorubicin conjugated to 30 kDa HPMA copolymer via a GFLG 
spacer.  FCE28068 showed 2-5 fold less toxicity than free Doxorubicin with tumor 
responses documented in breast, non-small cell lung cancers and hepatocellular 
carcinoma [41, 42].  AP5346 is also in Phase II clinical trials and contains DACH 
(diaminocyclohexane) platinum, the active form of the marketed drug Oxaliplatin, 
conjugated to 25 kDa HPMA copolymer via a pH sensitive linker.  AP5346 showed 
promising pre-clinical activity in 11 different tumor models and has shown both safety 
and efficacy in ovarian cancer in clinical trials [43].    In addition, poly (ethylene glycol) 
(PEG) is currently being evaluated in clinical trials for the administration of 
Camptothecin, SN38, Irinotecan, Docetaxel and Paclitaxel [44].  
The most advanced polymer-drug conjugate currently in late stage Phase III 
clinical trials is PG-TXL, a conjugate of poly (L-glutamic acid) and Paclitaxel [45]. While 
this polymeric conjugate was originally synthesized to improve the solubility of 
Paclitaxel, preclinical studies showed enhanced tumor accumulation of PG-TXL compared 
to free Paclitaxel, contributing to its improved efficacy [46].  In addition, cathepsin B, 
which is over expressed in tumor cells, was found to proteolytically degrade the PG 
backbone, allowing for targeted release of Paclitaxel at the tumor site.  Clinical trials in 
several different tumor types demonstrated that PG-TXL was as effective as Paclitaxel, 





However, PG-TXL had several advantages over Paclitaxel, namely a reduction in the 
incidence of hair loss, nausea and hypersensitivity reactions, which are often limiting 
factors for chemotherapy. These trials demonstrate the promise for the clinical 
application of polymer-drug conjugates, as well as challenges they face in translation to 
the clinic.  
 
2.3 Administration of Drugs via the Oral Route 
Administration of drugs via the oral route is preferred by patients owing to its 
convenience and comfort, generally leading to higher patient compliance compared to 
parenteral treatments and self-administration routes such as transdermal and inhalation.  
In addition, oral drug administration provides a more flexible dosing regimen and a lower 
burden on hospitals and the healthcare system [8, 9].  Finally, in diseases such as cancer, 
oral therapy minimizes treatment costs due to hospital procedures as well as indirect costs 
associated with lost time at work, transportation to and from the treatment center and 
additional childcare [7].   
Oral delivery of therapeutics is challenging because drugs must have appropriate 
solubility, stability in the gastrointestinal pH and enzyme environment, and the ability to 
permeate the epithelial barrier of the gut [47].  Unfortunately, many current 
chemotherapy drugs are poorly water soluble with low oral bioavailability, necessitating 
administration by the intravenous route, which requires recurring hospital visits and 
significant direct and indirect costs to the patient. Because of the strong patient 
preference for oral therapy, much research is being done to find alternative orally 





therapies and preferably with lower off-target toxicities [48].  This section will provide 
the necessary background on oral drug administration.  
 
2.3.1 Physiology of the Gastrointestinal Tract 
2.3.1.1 Compartments and Functions 
 The gastrointestinal tract is composed of several unique sections which each have 
a distinct pH, residence time, absorptive area and group of enzymes which must be 
considered for oral drug delivery [49].  The gastrointestinal tract begins with the oral 
cavity where the drug comes in contact with saliva.  With the exception of specially 
designed sublingual and buccal formulations, negligible drug absorption occurs in the 
oral cavity.  After passage down the esophagus, the drug encounters the stomach.  The 
stomach is lined with approximately 3.5 million gastric pits, which contain cells that 
secret mucus and gastric juice.  This gastric juice contains hydrochloric acid, which 
maintains the acidic pH of the stomach, as well as pepsin.  Thus, any drug that enters the 
stomach must be resistant to acidic conditions and proteolysis by pepsin to prevent 
premature degradation.  The contents of the stomach are emptied at regular intervals, 
which are dependent on the fasted or fed state of the individual, amongst other factors 
including disease state or drug treatment.  After these pulsatile waves, the entire content 
of the stomach is propulsed into the small intestine [49]. 
 The small intestine serves as the major absorptive site in digestion and contains 
three distinct sections: the duodenum, jejunum and ileum.  Absorption is favored by a 
large surface area due to mucosal folds and villous formation thereby maximizing the 





addition, the large blood flow to the small intestine serves to maintain the concentration 
gradient across the intestinal barrier, again, enhancing absorption of nutrients and drug 
molecules.  Biliary secretion from the gallbladder into the duodenum enhances absorption 
of lipids by formation of mixed micelles, and lipid digestion is promoted by lipase 
enzymes secreted by the pancreas.  In addition, Brunners glands, located in the 
duodenum, secrete bicarbonate and neutralize the acidic stomach contents.  This neutral 
pH promotes enzymatic activity in the small intestine and influences the charged state of 
drug molecules, which can enhance absorption.  Food can also influence the absorption 
of drugs by binding to the drugs or competing for intestinal transporters.  Another 
potential barrier to absorption is the thick mucus layer that lines the intestinal epithelium, 
which creates a formidable barrier to drug diffusion.  In order to successfully penetrate 
through mucus, drugs must be small enough to avoid encumbrance by the dense mucin 
fiber mesh and avoid adhesion to the fibers [50]. Post-epithelial structures include the 
intraepithelial lymphocytes, basement membrane and lamina propria mononuclear cells.  
These specialized elements of the gut-associated lymphoid tissue contribute to the 
mucosal immune response and present antigens to the lymphatic system, but do not 
present a significant barrier to transport [51].   Once drugs and nutrients are absorbed in 
the small intestine, they are transported through the hepatic portal vein and undergo first-
pass metabolism in the liver before entering systemic circulation [49]. 
 Materials that are not absorbed in the small intestine are transferred to the large 
intestine for further processing. The large intestine is populated by a wide range of 
bacteria that produce enzymes to further break down foods and drugs.  Finally, the 





Table 2.1. Physiology of the Gastrointestinal Tract 
Compartment Absorptive 
Area (m2) 
Residence time Fasted pH Enzymes 
Oral cavity - - 7.0 Amylase 
Esophagus 0.02 3.5 s 6.0-7.0 - 
















Large Intestine 0.3 15-48 h - Diverse 
bacterial 
enzymes 
Colon 0.25 - 8.0 - 
Rectum - - 7.0 - 





summarizes the major compartments of the gastrointestinal tract as well as the absorptive 
area, residence time, pH and enzymatic activity in each compartment [49].   
 
2.3.1.2 Intestinal Epithelial Barrier 
 The intestinal epithelial barrier is the main site of intestinal absorption of drugs 
and nutrients. This barrier forms a boundary between the “external environment” and the 
“internal environment” and is designed to allow for the absorption of nutrients while 
preventing transport of “undesirable” components such as bacteria or toxins. While 
epithelial barriers like the skin are designed to be virtually impermeable, the intestinal 
epithelial barrier must be selectively permeable to permit fluid exchange and nutrient 
absorption, and is therefore relatively leaky in comparison [52].  The intestinal epithelium 
contains a monolayer of columnar absorptive cells, or enterocytes, that are oriented with 
the “apical membrane” facing the intestinal lumen and the “basolateral membrane” facing 
the serosal side.  The apical membrane contains a brush border of microvilli that, together 
with mucosal and villous folds, are responsible for the large absorptive surface area of the 
small intestine [53].  In addition to the absorptive cells, the intestinal barrier also contains 
specialized M-cells (microfold cells) located in Peyer’s patches of the gut-associated 
lymphoid tissue.  These cells continuously sample antigens in the intestine and present 
them to the mucosal lymphoid tissue for initiation of the immune response [54].  M-cells 
have been popular targets for viral drug delivery vectors as well as nanoparticles.  
Finally, the intestinal epithelium is covered by a mucus layer, which is secreted by the 
intestinal goblet cells, and prevents large particles from approaching the epithelial barrier 





serves as an unstirred layer, slowing the absorption of nutrients by limiting diffusion to 
the intestinal cells. The mucus layer can also enhance absorption of compounds produced 
by brush border enzymes by preventing diffusion of these molecules back into the 
intestinal lumen [53]. 
 The integrity of the intestinal epithelial barrier is maintained by three types of 
cell-to-cell contacts: tight junctions, adherens junctions and desmosomes [53]. 
Desmosomes and adherens junctions form the cell-to-cell contacts that maintain the 
integrity of the barrier and allow for communication between the intestinal cells.  Tight 
junctions are formed at the apical side of the epithelial barrier and serve to regulate the 
passage of hydrophilic molecules between the intestinal cells.  The structure of the tight 
junctions as well as the mechanism by which they regulate paracellular permeability is 
discussed in detail in Section 2.3.1.3.  A schematic showing the major proteins involved 
in cell-to-cell junctions is shown in Figure 2.2. Genetic mutations that compromise 
intestinal barrier function are responsible for the pathology of several intestinal diseases 
including Crohn’s disease, ulcerative colitis and Celiac disease [52].  These conditions 
illustrate the importance of preserving the integrity of the gastrointestinal barrier to 
maintain healthy function.   
 
2.3.1.3 Tight Junction Biology: Structure and Function 
 Tight junctions regulate the openings between the epithelial cells, allowing for 
paracellular transport.  Although the function of tight junctions has been known for 
decades, the precise protein composition and function of tight junctions was not 






Figure 2.2. Major Proteins Involved in Tight Junctions, Adherens Junctions and 
Desmosomes between the Intestinal Epithelial Cells.  In the tight junctions MLCK is 





first tight junction protein to be isolated, and was reported by Furuse and colleagues in 
1993 [56].  The cytosolic face of occludin is thought to interact with several zonulla 
occludens (ZO) as well as actin [57]. Subsequently, the same group reported the 
involvement of claudins in tight junctions in 1998 [58, 59].  There have been 18 different 
claudins reported with specific claudins being expressed in certain cell and tissue types 
[57].  Like occludin, claudins also interact with ZO proteins.  Both occludin and claudin 
were examined in knockout studies and were found to be critical for tight junction 
function.  Junction adhesion molecule (JAM) has also been implicated in tight junctions 
[60].  Finally, tricellulin, a 64 kDa polypeptide discovered in 2005, is a necessary 
component of tight junctions in areas where three cells come into contact [61].  In 
addition to these tight junctional components, actin and myosin form a perijunctional 
actomyosin ring that plays a role in the contraction of tight junctional proteins upon 
stimulation [53]. 
 Tight junction modulation is regulated by several complex signaling pathways 
including those controlled by protein kinases, rho kinases, myosin light chain kinase 
(MLCK) and mitogen activated protein kinase (MAPK) [62].  These pathways can be 
activated in normal physiological conditions and exploited by tight junction modulating 
drugs.  One of the most common instances of tight junction opening occurs during 
nutrient absorption.  Apical co-transport of Na+ and glucose activates an MLCK-
dependent signaling pathway that causes condensation of the perijunctional actomyosin 
ring, leading to opening of the tight junctions [63].  This allows for enhanced water and 
nutrient transport through the paracellular route.  This example illustrates the 





(Ca2+) are also critical for tight junction function.  Ma and co-workers [64] demonstrated 
that the removal of extracellular calcium caused an increase in the paracellular 
permeability and a drop in transepithelial electrical resistance (TEER) of Caco-2 
monolayers.  In addition, they observed a rapid contraction of actin and myosin filaments 
and movement of ZO-1 and occludin away from the membrane, which was initiated by 
MLCK activation.  Addition of Ca2+ was found to quickly reverse these effects, 
illustrating the critical role of extracellular calcium in the maintenance of tight junction 
integrity.  
 
2.3.2 Mechanisms of Transport Across the Intestinal Barrier 
 There are two major pathways of transport across the intestinal barrier: 
paracellular transport, which occurs between cells, and transcellular transport, which 
occurs across cells.  The following four sections discuss paracellular transport and 
transcellular transport, which can occur by passive diffusion, carrier-mediated transport 
and endocytosis. Importantly, molecules may follow one or more transport pathways and 
these pathways may be interconnected.  Figure 2.3 illustrates potential mechanisms of 
transport through the intestinal barrier. 
 
2.3.2.1 Paracellular Transport 
 Paracellular transport occurs when molecules pass between epithelial cells in the 
intestinal barrier.  This mechanism of transport is driven by the concentration gradient 
and is thus both energy-independent and unsaturable.  Because molecules permeate 






Figure 2.3.  Mechanisms of Transport through the Intestinal Barrier.  Transport may be 
either paracellular or transcellular.  Transcellular transport includes passive diffusion, 
carrier-mediated transport, which may be energy-independent (facilitated diffusion) or 






Da).  Studies of permeability of hydrophilic compounds across Caco-2 monolayers 
suggested a tight junction pore size of approximately 4.5-4.8 Å [65, 66].  Molecules such 
as mannitol, a small sugar alcohol, and lucifer yellow carbohydrazide, a fluorescent dye, 
are known to permeate across the intestinal barrier strictly by the paracellular route and 
thus can be used to monitor changes in paracellular flux [67, 68].  In general, the 
paracellular route is impermeable to macromolecules because they are too large to pass 
through the tight junction pores [69]. 
  
2.3.2.2 Passive Diffusion 
 Passive diffusion is the simplest mode of transcellular transport and occurs when 
membrane-permeable molecules are transported across the intestinal barrier from a region 
of high concentration on the apical side to a region of lower concentration on the 
basolateral side of the membrane.  This mechanism of transport is energy-independent 
and unsaturable.  Passive diffusion across the intestinal barrier is governed by Fick’s Law 
of Diffusion, which states that flux (J) is directly proportional to the concentration 
gradient (dC/dx), the lipid-water partition coefficient (K), the diffusion coefficient (D) 
and the area of transport (A): 
dx
dC
DAKJ !=  (Eq. 2.1) 
The partition coefficient, a ratio of the compound’s lipid solubility to water solubility, is a 
critical component in determining the overall flux since compounds must be able to 
diffuse into the lipid-rich cell membrane in order to be transported via the transcellular 
route.  Thus, more lipophilic molecules have higher rates of passive diffusion across the 





insoluble thus preventing their absorption.  Since uncharged molecules are always more 
lipid-soluble than charged molecules, the ionization state of a compound at pH of the 
intestine is a critical determinant of its passive permeability. Many orally administered 
drug compounds are lipophilic, allowing for passive diffusion across the intestinal 
barrier.   
 
2.3.2.3 Carrier-Mediated Transport 
 Carrier-mediated transport plays an important role in intestinal transport of 
compounds such as peptides, nucleic acids, monosaccharides, organic cations and 
monocarboxylic acids that cannot be transported via the paracellular pathway or passive 
diffusion [70].  In carrier-mediated transport, transmembrane proteins move cargo across 
the cell membrane.  After the cargo has been released, the transporters resume their initial 
configuration and are available to transport additional cargo.  Importantly, because there 
are a limited number of transporters, carrier-mediated transport is a saturable process.  
Carrier-mediated transport can occur by facilitated diffusion, which is energy-
independent and occurs down the concentration gradient or by active transport, which 
occurs against the concentration gradient and requires and energy source.   Active 
transport can either be driven directly by ATP (ATP binding cassette [ABC] 
transporters), or coupled to transport of ions such as H+ or Na+ (solute carrier [SLC] 
transporters).  Examples of types of membrane transport proteins include monocarboxylic 
acid transporters, human peptide transports, nucleoside transporters and organic cation 





 In addition to influx transporters, efflux transporters can also influence intestinal 
transport.  P-glycoprotein (P-gp), a member of the ABC superfamily and the multidrug 
resistance subfamily, is one of the most well characterized efflux transporters [70]. 
Although it is intended to protect the body from harmful toxins, it also causes efflux of 
many drugs.  Orally administered P-gp substrates often have poor intestinal permeability 
because of this efflux and must be co-administered with P-gp inhibitors to overcome this 
challenge.  Therefore it is important to consider if a drug may be a P-gp substrate when 
examining its intestinal permeability [70].  
 
2.3.2.4 Endocytosis  
 Endocytosis is a generalized term that refers to the active internalization of 
specific substrates into the cell by membrane engulfment.  Endocytosis is often used to 
transport macromolecules that are too large for paracellular transport or carrier-mediated 
mechanisms [71].  In the context of the intestinal epithelial barrier, endocytosis 
contributes to overall transport when the cargo endocytosed at the apical membrane is 
trafficked to the basolateral membrane and exits the cell.  Endocytosis can be divided into 
phagocytosis, which occurs in particle uptake by macrophages, and pinocytosis, in which 
the cell membrane invaginates to enclose extracellular fluid and any molecules bound to 
the cell surface.  Pinocytosis can be further classified to receptor-mediated endocytosis 
(RME), which is either clathrin or non-clathrin-mediated, as well as adsorptive and fluid-
phase endocytosis [71].  Adsorptive and fluid-phase endocytosis are non-specific 
mechanisms in which molecules are either physically adsorbed to the cell surface or 





mechanisms are non-specific, they are typically unsaturable and show low substrate 
affinity.  In contrast, receptor-mediated endocytosis is highly specific, saturable and 
shows high affinity for the substrate, making it a much more efficient transport method.   
Receptor-mediated endocytosis occurs when ligands bind to specific cell surface 
receptors and are internalized into the cell for further trafficking [72].  RME can be 
divided into classical clathrin-dependent RME and non-clathrin RME, such as caveolin-
mediated endocytosis (CME).  Clathrin-dependent endocytosis occurs when a ligand 
binds its receptor and concentrates in a clathrin coated-pit on the plasma membrane 
presenting specific adaptor proteins.  After ligand binding, the membrane closes around 
the ligand-receptor complex and dynamin, a small GTPase, pinches off the vesicle from 
the membrane.  Upon internalization, hydrogen pumps are recruited to the vesicle, 
thereby lowering its pH.  Consequently, the vesicle sheds its clathrin coat and matures 
into an early endosome.  From that point, the vesicle can be recycled to the apical 
surface, continue for degradation in the lysosomes or be transcytosed to the basolateral 
side of the cell.  Transferrin is a classical ligand for clathrin-mediated endocytosis and is 
often used as a control to monitor endocytosis and trafficking [71].  Caveolin-mediated 
endocytosis occurs by a similar process except instead of trafficking to early endosomes, 
the cargo is trafficked to caveosomes and then to the endoplasmic reticulum, thus 
eliminating the pH lowering step central to clathrin RME [73].  Avoidance of low pH and 
lysosomal enzymes makes the caveolar pathway more suitable for uptake of degradation-
sensitive bioactive agents than clathrin-mediated endocytosis.  Cholera Toxin B is a 
classical caveolin endocytosis ligand and can be used as a control to monitor caveolin 






Figure 2.4. Clathrin- and Caveolin-Mediated Endocytosis and Transcytosis.  A) In 
clathrin-mediated endocytosis, ligands are transported to the early endosomes where they 
can either be recycled to the apical side, transcytosed to the basolateral side or sent to the 
lysosomes for degradation.  B) In caveolin-mediated endocytosis, ligands can either be 





2.3.3 Physiochemical Properties that Govern Intestinal Absorption 
2.3.3.1 The Lipinski Rule of 5  
 Due to the restricted pathways of intestinal permeation, there are several key 
physicochemical properties that govern oral absorption.  The “Lipinski Rule of 5”,  
derived from a large dataset of compounds with favorable or unfavorable permeation 
properties, states that compounds likely to have poor intestinal absorption have at least 
one of the following: 1) a molecular weight greater than 500 Da, 2) log P greater than 5, 
3) more than 5 hydrogen-bond donors, and 4) more than 10 hydrogen-bond acceptors 
[74].   These parameters are derived from the requirement for small size and a minimum 
amount of lipophilicity for passive diffusion across the intestinal barrier.  However, 
compounds must also have sufficient aqueous solubility to dissolve in the aqueous 
intestinal environment, creating a delicate balance between solubility and lipophilicity 
[75]. Importantly, the Lipinski Rule of 5 does not apply to substrates of intestinal 
transporters such as antibiotics or vitamins. 
 
2.3.3.2 The Biopharmaceutics Classification System (BCS) 
 The Biopharmaceutics Classification System was developed in 1995 to 
characterize factors that determine the rate and extent of drug absorption in the 
gastrointestinal tract.  Solubility and permeability were found to be the key parameters 
that govern intestinal absorption [76] and compounds are designated as Class I- Class IV 
based on these factors (Figure 2.5). The BCS is used by the Food and Drug 
Administration and the World Health Organization to set bioavailabilty and 
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Figure 2.5. The Biopharmaceutics Classification System. Compounds are classified as 





vitro/ in vivo correlations of oral drug absorption as well as the rate-limiting step in 
absorption.  For Class I compounds, since the solubility and permeability are both high, 
the rate-limiting step in absorption is defined by gastric emptying. In contrast, for Class II 
compounds, dissolution is a rate-limiting step while for Class III compounds, membrane 
absorption is rate-limiting.  Finally, the gastrointestinal absorption of Class IV drugs is 
classified as highly unpredictable, thus these drugs present significant problems for oral 
delivery and are often administered intravenously [76].  
 
2.4 Models to Predict Oral Absorption and Oral Bioavailability 
There are several experimental models used to predict oral absorption in the human 
gastrointestinal tract.  This section will describe a series of in silico, in vitro, in vivo, ex 
vivo and in situ models as well as discuss the merits and drawbacks of each. 
 
2.4.1 In Silico Models 
 In silico models are often used to predict the gastrointestinal absorption and oral 
bioavailability of compounds in early drug development.  Because drug molecules often 
fail in later stages of development due to poor oral absorption, creation of efficient and 
predictive in silico models is critical for pharmaceutical development.  One of the most 
commonly used techniques is QSAR/QSPR, or Quantitative Structure Activity/ Property 
Relationship, in which datasets of compounds with known absorption properties are 
combined with a series of molecular descriptors to predict properties of novel drug 
molecules.  Molecular descriptors such as molecular weight, number of hydrogen bond 





(logP), apparent partition coefficient (logD), and intrinsic solubility have all been used to 
predict passive absorption [78].  These types of models are highly dependent on the size 
and quality of the dataset.  While many pharmaceutical companies have large in-house 
datasets, this information is often not available to the general public. Recently, Hou and 
colleagues published one of the largest intestinal absorption datasets with 647 drugs and 
drug like compounds [79], and a corresponding data set for oral bioavailabilty with 768 
compounds [80].  These robust datasets have the capability to dramatically improve the 
predictive quality of in situ models.  Many analysis algorithms have been developed 
including multiple linear regression, partial least squares, recursive partitioning and 
finally support vector machines, which have shown the highest predictive ability when 
used on training and test sets [78].   
 These in silico methodologies can aid in the prediction of absorptive behavior of 
novel compounds.  They are efficient as well as economical in early drug screening since 
they can be completed prior to compound synthesis.  However, as mentioned earlier, they 
are severely limited by the training dataset. In addition, while they can reliably predict 
gastrointestinal absorption via passive diffusion, they do not account for active transport, 
which can be a significant pathway of intestinal transport for certain molecules [78].  
Finally, they are very poor at predicting overall bioavailability since first pass 
metabolism can have a large impact on bioavailabilty and is difficult to model [80]. 
 
2.4.2 Parallel Artificial Membrane Permeability Assay 
 PAMPA, or the parallel artificial membrane permeability assay, was first 





[81].  This cell-free system uses artificial membranes to measure the permeability of 
compounds in a 96 well microplate format.  There have been several different variations 
of PAMPA that differ by the type of membrane, pore size, nature and percentage of lipids 
as well as the incubation time of the assay, which can range from 2-15 hours [82].   The 
most commonly used membrane material is a hydrophobic poly (vinylidene fluoride) 
(PVDF) membrane with 125 µm pore size.  Traditionally, detection was achieved by a 
UV plate reader, but more recently enhanced detection is accomplished by HPLC-UV 
and HPLC-MS/MS techniques. 
 There are several advantages of PAMPA, which have lead to its widespread use.  
It is a direct measure of passive permeability and mimics the membrane nature of the 
gastrointestinal barrier.  In addition, it is amenable to a 96 well plate format, making it a 
high-throughput method, which is critical for early pharmaceutical development.  It is 
simple to manipulate the membrane characteristics to design a system that is suited for a 
given application.  Finally, the effect of excipients on compound permeability can be 
easily studied [82].  Unfortunately, because PAMPA is a cell-free system, it can only 
measure passive permeability via the transcellular route and does not account for active 
transport or paracellular permeability, which can have significant contributions to the 
transport of certain types of compounds [82].  Therefore, while PAMPA is an excellent 







2.4.3 Caco-2 Monolayers 
 The Caco-2 monolayer model, first introduced by Hidalgo and colleagues in 1989 
[83], has become one of the most widely used absorption screening technologies in both 
academic and industrial laboratories [84, 85].  In this technique, Caco-2 cells grown on 
semi-permeable supports are used to mimic the intestinal barrier.  Caco-2 cells are 
derived from human colonic adenocarcinoma, and spontaneously differentiate into 
intestinal enterocytes when grown to confluence on semi-permeable membrane supports.  
After differentiation, the Caco-2 cells are polarized, display apical microvilli, form tight 
junctions and have apical enzymes and transport systems similar to absorptive 
enterocytes [86].   
Caco-2 cells are grown on semi-permeable membranes in a Transwell® system, 
containing an apical chamber, corresponding to the intestinal lumen, and a basolateral 
chamber, corresponding to the blood stream (Figure 2.6).  Caco-2 cells are seeded on the 
membrane and grown for 21-28 days to produce confluent, differentiated monolayers.  
Compounds can be added in either the basolateral or apical chamber to study directional 
transport.  Apical to basolateral transport corresponds to intestinal absorption while 
basolateral to apical transport corresponds to intestinal efflux [87]. Transwell® systems 
are available in microplate format from 6 to 96 wells, and can be adapted to work in a 
robotic system, allowing for simultaneous screening of many different compounds. The 
apparent permeability (Papp) of compounds in the apical to basolateral direction has been 
shown to correlate with human intestinal absorption, making the Caco-2 monolayer 
system an excellent high throughput technique to predict absorption properties of novel 






Figure 2.6.  Transwell® System used in the Caco-2 Monolayer Permeability Assay.  
Caco-2 cells are seeded on the membrane insert and allowed to grow for 21-28 days to 
produce confluent, differentiated monolayers.  Compound flux from the apical to 





 Because differentiated Caco-2 cells have well-defined tight junctions as well as 
developed active transport systems, the Caco-2 cell monolayer system can be used to 
study not only passive diffusion, but also active transport, paracellular transport and 
potential drug efflux.  Therefore, the Caco-2 monolayer system can be used as a tool to 
study both the amount of transport, which is predictive of human intestinal absorption, as 
well as the mechanism of transport of novel compounds [87].   
In order to form differentiated monolayers, Caco-2 cells must be grown on 
permeable supports for 21-28 days.  During this time, the cells achieve confluence and 
differentiate, forming tighter junctions and expressing proteins similar to absorptive 
enterocytes rather than colonic cells.  This transformation can be monitored by 
transepithelial electrical resistance (TEER), which quantifies the tightness of the 
monolayer.  TEER increases over time, and ultimately plateaus between 21 and 28 days 
when the cells can be used for experiments [87].  Typical TEER values of competent 
differentiated monolayers range from 600-800 ohm-cm2.  Measurement of TEER serves 
as a control for monolayer integrity before and during a transport assay.  Transport of 
paracellular markers such as mannitol and lucifer yellow, which should have Papp less 
than 1 x 10-6 cm/s, can also serve as controls for monolayer integrity [87]. 
 There are several advantages to using the Caco-2 monolayer system to predict 
intestinal absorption of novel compounds in humans.  The system can be performed in 
multiwell format, allowing for parallel testing of different compounds using minimal 
compound, reagents and assay time.  In addition, because Caco-2 cells mimic intestinal 
enterocytes, many aspects of intestinal absorption including passive transport, active 





Unfortunately, there are also several disadvantages to the Caco-2 monolayer 
system.  Because the cells must be cultured for 21 days, this assay is labor intensive and 
requires a significant amount of serum-enriched media, increasing the cost of the assay.  
In addition, studies using the monolayer system to measure permeability of compounds in 
different laboratories have shown that there is a high degree of variability in the assay, 
mostly due to the intrinsic variability in Caco-2 cells [86].  Caco-2 cells contain several 
different sub-populations, which can be inadvertently selected for depending on the 
culture conditions, causing shifts in the population over time.  These shifts can 
significantly affect the monolayer formation including the tightness of the tight junctions 
as well as protein expression [89].  Many experimental conditions can also affect the 
ultimate performance of the monolayers including cell passage number, seeding density, 
filter type and pore size, cell culture media, transport buffer and monolayer age.  
Therefore it is critical to control these parameters within a given laboratory so that 
experiments are comparable.  In addition, it is important to run standards of known 
permeability as well as measure the TEER to ensure monolayer consistency.  Despite 
these challenges, the Caco-2 monolayer system continues to be a powerful tool for 
studying the extent and mechanism of intestinal absorption.  
 
2.4.4 Fast-Caco-2 Assay 
 Because the 21-day growth period is both labor-intensive and expensive, 
alternative differentiation systems have been developed for faster Caco-2 assays.  
Beckton Dickenson (BD) markets the BD Biocoat Caco-2 HTS Assay system, which can 





Caco-2 cells are seeded at high density onto Transwell® filters coated with fibrillar 
collagen.  After the cells attach to the Transwells on the first day, differentiation medium 
containing butyric acid is added for the next two days, causing rapid differentiation of the 
cells into intestinal enterocytes [90].  The resulting monolayers are slightly leakier than 
traditional Caco-2 monolayers and show poor expression of transporters, but they can 
still provide rank order measurements for permeability.  Adding fetal bovine serum to the 
seeding medium reduces these problems as it facilitates cell attachment, making this 
assay system more closely mimic 21-day standard [90].  Therefore, although the 
monolayers are not exactly the same as the traditional 21-day Caco-2 monolayer system, 
the fast-Caco-2 assay can effectively determine rank order of permeability and provides 
significant time and labor savings.  
 
2.4.5 Other Types of Cell-Monolayer Systems 
 In addition to Caco-2 cells, several other cell types have been used to mimic the 
intestinal barrier in the Transwell® system.  MDCK cells, derived from the canine kidney, 
are useful alternatives to Caco-2 cells as they form differentiated monolayers in 3 days 
instead of 21 days.  They have looser tight junctions than Caco-2 cells and do not mimic 
the protein expression of human enterocytes as well as Caco-2 cells, but they are still 
useful as a rapid screening tool for passive permeability and paracellular transport [87, 
91].  In addition, MDCK cells can be stably or transiently transfected, which allows 
researchers to study the impact of selected transporters, which is not possible in Caco-2 
cells.  Recently, TC-7 cells, a subclone of Caco-2 cells, have been used to study intestinal 





expression in Caco-2 cells.  This allows for the simultaneous study of both transport and 
metabolism, which is important for compounds that are metabolized in the intestinal 
barrier.  Finally, co-cultures of mucus secreting HT-29 and MTX cells have been used 
[93].  While these show lower active transport than Caco-2 cells, they show higher 
paracellular transport and may more accurately predict the paracellular passage of 
hydrophilic molecules.  Importantly, all of these cell culture monolayer systems are able 
to isolate different elements of the intestinal transport process and are useful for studying 
a variety of compounds in a high throughput system that mimics the in vivo environment. 
  
2.4.6 Everted Rat Intestinal Sac 
 Often, it is desirable to use a tissue-based system rather than a cell-based system 
to more closely mimic gastrointestinal absorption.  The everted rat intestinal sac model, 
introduced by Wilson and co-workers in 1954, has been used to study intestinal 
absorption in an ex vivo environment [94].  In this method, the intestine is removed from 
a sacrificed rat, everted over a glass rod so that the mucosal side is facing outward and 
then sectioned into 2-4 cm sacs and filled with oxygenated cell culture medium.  The sacs 
are then placed in media containing the drug of interest and the amount of drug 
transported into the sac (mucosal to serosal direction) is quantified [87].  The assay time 
is limited by the viability of the intestinal tissues, which is usually 2 hours.  There are 
several advantages to the everted rat intestinal sac model compared to cell-based models, 
including the presence of a mucosal layer and the ability to study different sections of the 
intestine.  In addition, transport can be studied in conjunction with intestinal metabolism. 





However, the drug must cross the muscle layer in addition to the intestinal barrier, which 
can potentially underestimate permeability, and the method is low-throughput compared 
to cell-based assays.  Despite these drawbacks, the everted rat intestinal sac method is an 
effective way to measure intestinal permeability in an ex vivo environment. 
 
2.4.7 Isolated Intestinal Tissue 
 First conceptualized by Hans Ussing in 1949 [95] and later miniaturized by Grass 
and Sweetana in 1988 [96], the Ussing Chamber method uses isolated intestinal tissue to 
study transport of compounds across the gastrointestinal barrier.  Sections of intestinal 
tissue are placed between two chambers and exposed to Krebs Ringer Bicarbonate buffer 
gassed with 95:5 CO2:O2.  The gassing is used to maintain tissue viability and promote 
flow in the chambers.  Importantly, similar to the everted sac model, intestinal 
metabolism can be studied at the same time as absorption and transport.  This system 
allows for studying transport across different sections of the intestine as well as in 
different species, which can assist in choosing a relevant in vivo model [87].  In addition, 
the muscle layer can be removed from the tissue, allowing the study of the epithelial 
barrier in isolation.  While this method is very useful, there are several disadvantages, 
most notably the difficulty of preparation of the intestinal sheets, especially removing the 
muscle layer.  The viability of the tissue sheet during the experiment is also a significant 
concern and can vary dramatically.  Finally, this system is significantly lower throughput 
than in vitro cell-based models, but can provide more information and is closer to the in 





2.4.8 Rat Intestinal Perfusion 
 In situ perfusion of the rat intestine most closely mimics in vivo environment 
without using the whole animal. In this technique, compounds are added to the lumen of 
sections of the intestine in anesthetized rats and the disappearance of the compound is 
monitored over time.  This system allows the study of the gastrointestinal transport in 
isolation without confounding factors such as first pass metabolism, biliary excretion or 
enterohepatic circulation [87].   Importantly, most in situ perfusion experiments assume 
that disappearance of the compound from the lumen indicates transport across the 
intestinal barrier.  If there is significant metabolism of the compound or absorption in the 
intestinal barrier, this method can significantly overestimate transport.  Therefore, the 
assay can be amended to sample blood from the mesenteric vein to measure transport, 
although this becomes much more technically challenging.  In situ perfusion serves as a 
bridge between tissue-based models and in vivo models and combines the advantages of 
each into a powerful experimental technique. 
 
2.4.9 In Vivo Models 
 In vivo administration of compounds by the oral route in laboratory animals is a 
commonly used method to predict oral bioavailability in humans.  Because the epithelial 
barrier composition between mouse, rat and human are similar, gastrointestinal transport 
should be similar between species. However, differences in gastrointestinal transit time, 
expression of transporters and even pH can differ between species, so direct comparison 
is often not possible [87].  In oral bioavailability studies, dosing by the oral or 





time and the area under the curve (AUC) of the oral administration methods are 
compared to the intravenous route to get the fraction of the dose absorbed which is 
represented as the overall percent bioavailability. Administration of the compound 
intraduodenally instead of orally eliminates confounding factors from the stomach such 
as residence time and gastric absorption.   Importantly, measuring bioavailability by 
plasma concentration includes the effects of both gastrointestinal absorption as well as 
first pass metabolism.  Sampling from the portal vein before the liver instead of from the 
circulation allows for isolation of intestinal transport and can be useful in determining the 
impact of absorption and metabolism on overall bioavailability [87].  Because in vivo 
studies have all of the complexity of the human absorption system, they can often provide 
the closest estimate to oral absorption in humans.  However, there are several 
disadvantages of in vivo studies including the use of whole animals, difficult and tedious 
plasma sampling and analysis as well as the aforementioned interspecies differences.  
Despite these challenges, in vivo studies in laboratory animals are still the closest 
approximation to human intestinal absorption and are a good follow up experiment to 
evaluate promising candidates from high-throughput techniques. 
 
2.5 Current Strategies for Oral Drug Delivery 
 Unfortunately, many newly discovered drugs have low solubility and poor 
intestinal permeability, which would categorize them as problematic BCS Class IV 
compounds.  In fact, the bioavailability of novel chemotherapy drugs is often so low that 
these drugs must be administered intravenously.  There are several current strategies to 





including 1) prodrug approaches, 2) efflux and metabolic inhibitors, 3) tight junction 
modulators and 4) novel macromolecules. Each of these approaches will be discussed in 
further detail below. 
 
2.5.1 Prodrugs  
 A prodrug is defined as a drug molecule chemically conjugated to a promoiety 
that is used to improve the drug’s physicochemical properties and is cleaved to release 
the pharmacologically active, free drug [97].  Common drug delivery obstacles overcome 
by prodrug strategies include poor aqueous solubility, low permeability, fast elimination, 
off-target effects and premature metabolism [97]. In the context of oral drug delivery, 
prodrugs can be used to improve the aqueous solubility of a drug and permeability across 
the intestinal barrier.  Promoieties are subsequently cleaved by enzymatic mechanisms or 
by hydrolysis to yield the free, active drug.   
Poor aqueous solubility is becoming an increasingly common problem with 40% 
of new chemical entities discovered by pharmaceutical companies in combinatorial 
screening now identified as poorly water soluble [98].  In addition, traditional 
formulation techniques to improve water solubility such as use of different salt and 
crystalline forms or reducing particle size are not always successful, necessitating the use 
of new strategies.  Examples of prodrug modifications to improve aqueous solubility 
include addition of phosphate groups via an ester bond, addition of amino acids via ester 
bonds or conjugation to PEG [98].  For example, phosphate prodrugs of Buparvaquone, 
used to treat leishmaniasis, increase the aqueous solubility from 0.03 µg/ml to greater 





cytochrome P450.  Unfortunately, these methods can also potentially decrease membrane 
permeability due to the addition of charged groups in the case of phosphates or amino 
acids or increased size, in the case of PEG.  Therefore, solubility-enhancing prodrug 
modifications must be used in delicate balance with maintaining sufficient membrane 
permeability [100].    
 Prodrugs have also been used to overcome permeability limitations in oral drug 
administration [101].  Conjugation of lipophilic constituents to polar functional groups on 
the parent drug serves to increase the overall lipophilicity of the drug and improve 
passive permeability through the intestinal barrier [101].  This is especially important 
when the polar groups are ionizable in the pH of the small intestine, as charge can 
severely limit intestinal permeability. These groups can be designed to be cleaved during 
first-pass metabolism in the liver so that the free drug is liberated prior to reaching the 
general circulation.  Finally, if passive diffusion across the intestinal barrier is not 
possible, prodrugs can be designed to be substrates of gastrointestinal transporters, taking 
advantage of carrier-mediated transport pathways [101].    
 
2.5.2 Efflux and Metabolic Inhibitors 
 In addition to poor solubility and poor passive permeability, drugs can have poor 
intestinal absorption due to efflux or metabolism in the intestinal barrier.  These problems 
are especially prevalent with anti-cancer drugs which are often effluxed by P-
glycoprotein (P-gp) or multidrug resistance proteins (MDR), or metabolized by 
Cytochrome P-450 (CYP) enzymes [102].  To address this issue, these drugs are often co-





For example, Paclitaxel, a taxane anti-cancer drug, shows in vivo bioavailability of only 
10%, mostly due to efflux by P-gp.  Co-administration of P-gp inhibitors SDZ PSC833, a 
cyclosporine D analogue or GF120918, a non-immunosuppressive P-gp blocker, showed 
significant improvements in oral Paclitaxel bioavailability [103].  In the case of 
Docetaxel, which is a P-gp substrate and metabolized by CYP3A4, co-administration of 
Ritonavir, a CYP3A4 inhibitor, led to significant gains in oral bioavailability [103].  
Similar improvements in oral bioavailability have been observed by co-administration of 
CYP3A4 inhibitors with Irinotecan [104] and HIV-protease inhibitors [105].  These 
examples illustrate the potential of co-administration of metabolic and efflux inhibitors to 
improve oral bioavailability.   
 
2.5.3 Tight Junction Modulators 
 For hydrophilic molecules that cannot permeate the intestinal barrier by passive 
diffusion, but are too large for the paracellular route, tight junction opening serves as a 
novel mechanism to enhance intestinal permeability.  Several molecules have been 
developed to transiently open the tight junctions in the intestinal barrier.  Medium chain 
fatty acids such as sodium caprate have been shown to open the tight junctions, as 
indicated by increased paracellular flux of markers such as mannitol.  These fatty acids 
are thought to activate phospholipase C on the plasma membrane, which then causes an 
increase in intracellular calcium concentration [106]. This elevated calcium concentration 
causes contraction of calmodulin-dependent actin filaments, which subsequently opens 
the tight junctions.  In vivo studies of sodium caprate have been completed in several 





drugs were seen with minimal damage to the intestinal barrier, suggesting the potential of 
sodium caprate as a safe absorption enhancer [107].   
 Similar to sodium caprate, medium chain mono- and di-glycerides and medium- 
and long-chain fatty acid esters of carnitine and choline can also open tight junctions, as 
evidenced by reduced TEER and increased permeation of low molecular weight 
paracellular markers [108].  Nitric oxide donors such as S-nitroso-N-acetyl-DL-
penicillamine (SNAP), have been shown to increase permeability of 4 kDa FITC-dextran 
and influence the expression and localization of tight junction proteins, suggesting their 
potential as absorption enhancers [62].  While SNAP showed promising results in rabbits 
and rats, the mechanism of tight junction modulation is still unknown.  Finally, zonnula 
occludens toxin (Zot), a protein derived from Vibrio cholerae, has demonstrated tight 
junction modulation.   Fasano and colleagues report that Zot selectively opens tight 
junctions in the small intestine in a dose-dependent and reversible manner [109].  Studies 
in rats showed a significant increase in insulin and immunoglobulin bioavailability in rats 
treated with Zot.  Tight junction modulators can improve delivery of large, water-soluble 
drugs via the paracellular route.  
 
2.5.4 Macromolecules 
 In addition to the above-mentioned permeation enhancers there are several 
macromolecular permeation enhancers that are currently being investigated.  
Polyacrylates, or synthetic high molecular weight polymers of acrylic acid, have been 
shown to be mucoadhesive and to modulate tight junction integrity [110].  It is 





ions that are required for tight junction maintenance.  Importantly, studies in rats showed 
that long term oral administration of polyacrylates did not cause any significant toxicities 
in vivo, suggesting the safety of this strategy [111].  
 Chitosan and chitosan derivatives have also been shown to modulate tight junction 
integrity [107].  Studies on Caco-2 cells showed that treatment with chitosan and chitosan 
derivatives caused enhanced paracellular flux of small molecules such as mannitol and 
large markers such as FITC-dextran.  The precise structure of chitosan can vary both in 
molecular weight and in the amount of deacetylation, as well as the addition of methyl 
groups for enhanced solubility in basic pH conditions.  All of these changes alter the 
degree to which chitosan can enhance paracellular transport.  It has been shown that 
chitosan binds to the intestinal cells, causing redistribution of cytoskeletal F-actin and 
ZO-1 tight junctional proteins [112].  The toxicity of chitosan is directly related to its 
degree of deacetylation and there exists an optimum amount of deacetylation that causes 
tight junction opening with minimal toxicity.   
 Recently, poly (amdio amine) (PAMAM) dendrimers have been identified as potent 
tight junction modulators.  Treatment of Caco-2 cells with PAMAM dendrimers of 
different sizes and surface functionalities has been shown to increase the paracellular flux 
of mannitol, reduce TEER and increase accessibility of actin and occludin proteins [15, 
16].  PAMAM dendrimers are transported across the intestinal barrier, making them both 
permeation enhancers and potential oral drug delivery carriers [113].  The following three 
sections will describe a detailed background on dendrimers, applications of PAMAM 
dendrimers in drug delivery and the current knowledge of these constructs as oral drug 






2.6.1 History of Dendrimer Development 
Dendrimers are unique polymeric structures that are highly-branched, nanoscale 
in size and have a wide range of applications in the field of nanobiotechnology.  The term 
dendrimer is derived from the greek “dendra” meaning tree and “meros” meaning part 
[114].  Dendrimers were first conceived of in the late 1970’s by the groups of Vogtle, 
Denkwalter, Tomalia and Newkome and were first presented to the public by Tomalia in 
1983 [14].  Since then, the number of dendrimer-related publications and technologies 
has increased rapidly, illustrating the utility of this nanoscale structure [115].  Several 
commercial applications of dendrimers have shown promise in the past decade.  
VivagelTM, a vaginal topical microbiocide for the prevention of HIV transmission, was 
granted fast track status for clinical trials in 2006 [116].  SuperFect®, developed by 
Qiagen, uses dendrimer technology to improve transfection in a wide range of cell lines 
[117].  Finally, Stratus CS® Acute Care Diagnostic System, uses dendrimers to rapidly 
detect myoglobin, a sensitive marker for acute coronary diseases [118].  
One of the most promising areas of application of dendrimers is in the field of 
nanomedicine.  Dendrimers have many unique physical properties including near 
monodispersity and nanoscopic size [12, 13].  With each increase in dendrimer 
generation, the diameter increases linearly while the number of surface groups increases 
exponentially.  This creates high density surface groups that can be conjugated to drug 
molecules [20, 119-124], targeting moieties [125-128], and imaging agents [129-131], or 
complexed with DNA [132, 133], making dendrimers versatile drug delivery platforms 






Figure 2.7. Dendrimers as Multifunctional Nanocarriers.  Targeting moieties can be 
attached to the dendrimer surface groups while drugs and imaging agents can be 
conjugated to the surface, encapsulated in the dendrimer core or complexed (such as 





2.6.2 Dendrimer Synthesis 
In the early stages of development, dendrimers were synthesized by the divergent 
method, wherein repeating units were progressively added to an initiator core, increasing 
the generation number with each reaction step (Figure 2.8) [115]. While straightforward, 
this synthetic strategy is somewhat tedious, requires purification after each step and is 
difficult to scale-up.  Subsequently, dendrimers were produced by convergent synthesis 
methods where reactive dendrons are synthesized and then attached to a multifunctional 
initiator core to generate the final product (Figure 2.8) [134].  Convergent synthetic 
strategies are useful for larger dendrimers as they contain fewer steps than divergent 
approaches. 
Recent innovations in dendrimer synthesis have facilitated commercial production 
of dendrimers, focusing on producing high yields of intermediates and minimizing toxic 
byproducts.   “Lego chemistry” uses branched monomers, which facilitates production of 
dendrimers by minimizing the number of reaction and purification steps.  In addition 
“click chemistry” has been developed to produce dendrimers with specific surface 
chemistries using a copper catalyst. These innovations have allowed several families of 
dendrimers to be produced commercially, which has had a significant impact on the use 
of dendrimers in biomedical research [13].    
 
2.6.3 Types of Dendrimers 
More than 100 different types of dendrimers with more than 1,000 different 
surface modifications have been developed to date [13].  These dendrimers differ in the 






Figure 2.8. Divergent and Convergent Syntheses of Dendrimers.  In divergent synthesis, 
monomeric branches are repeatedly added to the initiator core, increasing the dendrimer 
generation with each addition.  In convergent synthesis, reactive dendrons are added to a 





profound impact on their biological properties.  In addition, the synthetic strategy used to 
produce each type of dendrimer is often different.  Some of the most common types of 
dendrimers, including poly (propylene amine) (PPI), polyether and poly (amido amine) 
(PAMAM) dendrimers, are illustrated in Figure 2.9.  PPI dendrimers were first produced 
by Vogtle and are synthesized by the divergent method (Figure 2.9 A) [135].  They are 
commercially available and can be amine or nitrile terminated, which significantly 
impacts their biological properties [115].   Polyether dendrimers or “Frechet-type” 
dendrimers are synthesized by the convergent method (Figure 2.9 B) and have been used 
in applications such as light harvesting and catalysis [115]. PAMAM dendrimers, 
commercially available as Starburst® PAMAM dendrimers, have an ethylene diamine 
core and amido amine branching units with carboxyl or amine terminal groups (Figure 
2.9 C,D).  They are described in detail in the following section.  
 
2.7 Poly (amido amine) Dendrimers 
2.7.1 Structure of PAMAM Dendrimers  
Poly (amido amine) (PAMAM) dendrimers were originally developed by Tomalia 
at Dow Laboratories in 1979.  PAMAM dendrimers have numerous applications in 
nanobiotechnology and are some of the most commonly used since they are both fully 
characterized and commercially available [136-138].  Starburst® PAMAM dendrimers 
have an ethylene diamine core, an amido amine repeat branching structure and are 
available in generations 0.5 through 10.  As generation number is increased, the number 
of active terminal groups doubles, while the diameter increases by approximately 1 nm, 











Figure 2.9. Chemical Structures of Common Dendrimers.  A) G4 PPI dendrimer with a 
1,4-diamnobutate core, B) G4 polyether dendrimer, C) G2 PAMAM dendrimer with 
amine terminal groups and an ethylenediamine core and D) G1.5 PAMAM dendrimer 





dendrimers “full” generations (G1, G2, G3, etc.) have amine-terminated branches 
whereas “half” generations (G1.5, G2.5, G3.5, etc.) have carboxylic acid terminated 
branches (Figure 2.9 C,D).  They can also be modified with terminal hydroxyl groups to 
neutralize the surface charge.  The surface charge and chemistry of PAMAM dendrimers 
have a significant impact on their biological properties including toxicity and 
biodistribution.  Table 2.2 summarizes the physical properties of G0-G5 dendrimers 
commercially available from Dendritech.   
 
2.7.2 Biocompatibility and Biodistribution of PAMAM Dendrimers 
 In order to be suitable for clinical use, polymeric carriers must be non-toxic and 
non-immunogenic [139].  In addition, polymeric carriers must display biodistribution 
properties that allow for uptake in the target tissue with minimal off-site accumulation 
[139].  One of the first tests for biocompatibility is performance in in vitro toxicity 
screens against different cell lines.  In vitro toxicology studies have shown that dendrimer 
cytotoxicity is primarily governed by surface chemistry, although the core identity can 
play a role.  In general, cationic PAMAM dendrimers show increasing toxicity with 
increases in concentration and generation, while anionic dendrimers have been found to 
be non-toxic against a large variety of cell lines [139].  This charge-dependent effect is 
consistent with PAMAM dendrimer impact on red blood cells.  Cationic dendrimers have 
been shown to cause changes in red blood cell morphology at lower concentrations and 
significant hemolysis at higher concentrations.  In contrast, anionic PAMAM dendrimers 
of generations 3.5 through 9.5 have been found to show no toxicity against red blood 














-0.5 -COOH 4 436 - 
0 -NH2 4 517 15 
0.5 -COOH 8 1,269 - 
1 -NH2 8 1,430 22 
1.5 -COOH 16 2,935 - 
2 -NH2 16 3,256 29 
2.5 -COOH 32 6,267 - 
3 -NH2 32 6,909 36 
3.5 -COOH 64 12,931 - 
4 -NH2 64 14,215 45 
4.5 -COOH 128 26,258 - 
5 -NH2 128 28,826 54 





impact of dendrimer surface chemistry on the toxicological properties of these novel 
carriers. 
 Malik and co-workers investigated the biodistribution of 125I-labeled anionic 
(generations 2.5, 3.5, 5.5) and cationic (generations 3,4) PAMAM dendrimers in Wistar 
rats after intravenous administration [140].  Cationic dendrimers were cleared rapidly 
from the circulation, while anionic dendrimers showed longer retention times in the blood 
stream.  In addition, both cationic and anionic dendrimers were found to have significant 
accumulation in the liver.   Passive accumulation of polymeric carriers at the tumor site 
due to the enhanced permeability and retention effect is critical for the applicability of 
dendrimers as anti-cancer drug delivery carriers.  In a separate work, Malik et al. showed 
that G3.5 PAMAM dendrimer-Cisplatin conjugates showed significant tumor 
accumulation at a 50-fold increase relative to IV administered free drug at the maximum 
tolerated dose, suggesting the potential of G3.5 PAMAM dendrimers for tumor delivery 
of anti-cancer agents [141].  While there are still many in vivo studies necessary to 
characterize the toxicity and biological fate of PAMAM dendrimers, it is clear that 
surface charge significantly influences both toxicity and biodistribution. 
 
2.7.3 Applications of PAMAM Dendrimers as Drug Carriers 
 Because of their high water solubility and large number of ionizable surface 
groups, dendrimers can be used to encapsulate drugs with poor aqueous solubility. It has 
been well established that dendrimers have a core-shell architecture, allowing for 
encapsulation of drug molecules in the voids of the dendrimer core [13].  Encapsulation 





presentation of the drug to the biological membrane and subsequent internalization.  In 
addition, the dendrimer can also protect the encapsulated drug cargo from degradation.  
Kannan et al. improved solubility of ibuprofen by encapsulation in G3 dendrimers [142].  
Ibuprofen encapsulated in dendrimers showed a much higher rate of cellular 
internalization in A549 lung cells compared to free ibuprofen.  Drug loading was 
approximately 50% for the G3-ibuprofen complexes, indicating the high capacity of 
PAMAM dendrimers for incorporation of small molecular weight bioactive agents. 
 Despite their ease of synthesis, PAMAM dendrimer-drug complexes are plagued 
by non-specific drug release, which can lead to unwanted toxicity in vivo, especially in 
the case of anti-cancer drugs. Therefore, there has been much research done on PAMAM 
dendrimer-drug conjugates where drugs are covalently attached to dendrimer periphery 
groups by chemical linkers.  These linkers can be designed to maximize drug release at 
the site of action.  Wiwattanapatapee and colleagues studied PAMAM dendrimer-5-
aminosalisyclic acid conjugates for targeted colonic delivery [122].  The conjugates had 
two different azo spacers, which are susceptible to degradation by azoreductase, an 
enzyme that is abundant in the colonic environment.  The conjugates showed free drug 
release in the presence of rat cecal contents, but not in the gastric fluid, indicating the 
specificity of the release mechanism. This study illustrates that the choice of the spacer 
can have a profound impact on the ability of the dendrimer-drug conjugate to release the 
drug in the appropriate environment and time after administration.  
 Finally, targeting and imaging agents can be attached to dendrimer-drug 
conjugates for multifunctional delivery strategies.  Majoros and co-workers conjugated 





Paclitaxel, a chemotherapeutic agent, and FITC, a fluorescent ligand, to G5 PAMAM 
dendrimers, creating a tri-functional therapeutic agent [143].  The cytotoxicity and 
cellular uptake of this dendrimer system was evaluated in KB cells.  The folate-labeled 
dendrimers were found to selectively internalize in folate-receptor-expressing KB cells 
and those containing Paclitaxel caused cytotoxicity similar to the free drug.  In contrast, 
folate receptor- negative cells did not internalize the dendrimers, indicating the strong 
targeting ability.  This work illustrates the potential of using dendrimers as 
multifunctional nanodevices for drug delivery.   
 
2.8 PAMAM Dendrimers as Oral Drug Delivery Systems 
2.8.1 Transepithelial Transport of PAMAM Dendrimers 
 The potential of PAMAM dendrimers as oral drug delivery carriers was first 
reported in 2000 by Wiwattanapatapee et al [144]. In this study, the tissue uptake and 
serosal transfer rates of anionic (G2.5, G3.5 and G5.5) and cationic (G3, G4) PAMAM 
dendrimers were measured in in vitro everted rat intestinal sacs.  Anionic dendrimers 
were found to have high serosal transport rates and minimal tissue uptake, while cationic 
dendrimers had lower serosal transport rates and more tissue uptake, most likely due to 
nonspecific binding.  Importantly, the dendrimer transport rates were higher than what is 
typically seen for large macromolecules, suggesting the unique potential of PAMAM 
dendrimers as polymeric drug carriers.   
 This report of dendrimer transepithelial transport was followed by a 
comprehensive investigation of the influence of dendrimer size, charge and incubation 





dendrimer transport. As described in Section 2.4.3, Caco-2 cell monolayers serve as a 
model of the intestinal barrier and can be used to elucidate the degree and mechanisms of 
intestinal permeability without the confounding factors associated with in vitro intestinal 
sac models.  El-Sayed et al. first explored transepithelial transport of cationic dendrimers 
across Caco-2 cell monolayers in 2002 [145].  In this study, PAMAM dendrimer 
generations G0-G4 were investigated for their potential in oral delivery.  Permeability of 
the dendrimers was found to increase with concentration and incubation time.  G0-G2 
dendrimers were found to be non-toxic with appreciable permeability, suggesting the 
potential of these constructs as oral drug carriers. Kitchens et al. studied the 
transepithelial transport of cationic (amine-terminated), anionic (carboxylic acid-
terminated) and surface neutral (hydroxyl-terminated) dendrimers across Caco-2 cell 
monolayers [15].   When comparing dendrimers of the same size, cationic dendrimers 
showed the highest permeability, followed by anionic dendrimers and neutral dendrimers. 
Increasing the generation of anionic dendrimers caused an increase in permeability while 
increasing the generation of cationic dendrimers lead to decreased permeability and 
increased toxicity.  These studies indicate that within a specified size, charge and 
concentration window, dendrimers can enhance transepithelial transport. 
In addition to determining the transport rates of PAMAM dendrimers across 
Caco-2 cells, several studies have been performed to elucidate the mechanism of 
transport. Studies have shown that dendrimers are transported by a combination of 
transcellular and paracellular mechanisms.  Tight junction opening can be monitored by 
several different methods including a reduction in transepithelial electrical resistance 





yellow and an increase in exposure of tight junction proteins such as occludin [15].  El-
Sayed et al. reported that G2.5 and G3.5 dendrimers reduced TEER and increased [14C]-
mannitol flux up to 6 fold compared to the control [146].  In contrast, OH-terminated 
dendrimers did not cause a significant change in TEER or mannitol permeability.  
Kitchens et al. reported that cationic dendrimers increased [14C]-mannitol flux and 
reduced TEER to a greater extent than anionic dendrimers, indicating a strong charge 
dependence of dendrimer tight junction opening ability [16].  In addition, higher 
generation dendrimers of both cationic and anionic dendrimers opened the tight junctions 
to a greater degree than lower generations.  Finally, increasing incubation time from 90 to 
210 minutes increased tight junction opening for all dendrimer generations.  In a parallel 
study, both cationic and anionic dendrimers were found to interact with tight junction 
proteins, increasing occludin and actin staining, thus further establishing the ability of 
dendrimers to open tight junctions [15].  These studies illustrate that the size and charge 
of PAMAM dendrimers have a significant impact on their interaction with differentiated 
enterocytes.  In addition, there may be an optimal window of size, charge and incubation 
time that will lead to the best dendrimer system for a specific oral drug delivery 
application. 
In addition to opening the tight junctions, dendrimers are also transported across 
the intestinal barrier by the transcellular route.  In 2003 El-Sayed et al. reported energy-
dependent transport of G2 dendrimers, suggesting the involvement of transcytosis in 
addition to transport via the paracellular route [147].  Jevprasephant et al. further 
confirmed this phenomenon by investigating internalization of G3 dendrimers into Caco-





dendrimers using flow cytometry and confocal microscopy and gold-labeled G3 
dendrimer by transmission electron microscopy (TEM) [19]. These studies showed a 
significant amount of dendrimer cellular internalization with minimal non-specific 
binding on the cell surface, suggesting transport of G3 dendrimers by the transcellular 
route.  In addition, Kitchens and colleagues examined the impact of endocytosis 
inhibitors on cellular internalization and transepithelial transport of G4 dendrimers in 
Caco-2 cells [148].  Inhibitors including brefeldin A, colchicine, filipin, and sucrose all 
decreased the uptake and transport of the dendrimers, indicating the involvement of 
endocytosis mechanisms in the transport of G4 dendrimers. 
 
2.8.2 Cytotoxicity of PAMAM Dendrimers 
 In order to be useful as oral drug delivery carriers, it is crucial that dendrimers do 
not cause toxicity to intestinal cells during transport.  Toxicity of PAMAM dendrimers to 
Caco-2 cells has been investigated using cell viability assays.  El-Sayed et al. established 
cationic dendrimers are significantly more toxic than anionic dendrimers and this toxicity 
increases with dendrimer generation and incubation time [146].  In contrast, anionic 
dendrimers are much less toxic and only displayed slight increases in LDH release when 
cells were treated with 10 mM concentrations of G3.5 and G4.5 dendrimers for a 90 
minute incubation time [146].  Since anionic dendrimers are much less toxic they can be 
used at higher concentrations and longer incubation times without causing damage to the 
intestinal cells. 
In addition to cell viability assays, Kitchens et al. investigated the impact of 





examining the effect on the microvilli by TEM [18].  G2 cationic dendrimers, with 16 
amine terminal groups, did not cause appreciable damage to the cell monolayer, even up 
to 1 mM concentration.   In contrast, G4 dendrimers, which have 64 amine terminal 
groups, showed significant toxicity at 1 mM.  When the concentration of G4 dendrimers 
was reduced to 0.01 mM, they were non-toxic, illustrating that G4 dendrimers can be 
used safely at lower concentrations.  Finally, even high generation G3.5 anionic 
dendrimers, which have 64 terminal carboxylic acid groups, did not cause a change in 
cell morphology up to 1 mM, indicating the low intrinsic toxicity of anionic dendrimers. 
Thus, in choosing a dendrimer carrier for oral drug delivery, one must choose a 
generation and concentration that maximizes transport, while minimizing toxicity.  In 
addition, it is critical to first assess the toxicity of the dendrimers before assessing 
permeability since a toxic treatment could compromise the integrity of the monolayer, 
causing artificially high permeability measurements.  
 
2.8.3 Surface Modification of PAMAM Dendrimers 
 Because of their large number of terminal groups, PAMAM dendrimers have been 
modified with different ligands in order to alter their biological properties including 
cytotoxicity and permeability.  Jevprasesphant and co-workers conjugated lauroyl 
chloride chains to cationic dendrimers and measured their toxicity towards Caco-2 cells 
and their permeability across Caco-2 cell monolayers [17].  Modification with lauroyl 
chains decreased the cytotoxicity of cationic dendrimers and increased their permeability 
as well as their tight junction opening ability.  It was hypothesized that the significant 





some of the positive charges.  In a similar study, Kolhatkar et al. investigated the impact 
of modifying G2 and G4 dendrimers with acetyl groups, effectively neutralizing half or 
all of the surface charges [149].  Acetylation of G2 and G4 dendrimers significantly 
reduced their cytotoxicity towards Caco-2 cells, with full acetylation causing the greatest 
decrease in cytotoxicity.  In addition, the partially acetylated dendrimers showed 
comparable permeability to unmodified dendrimers, indicating that acetylation can 
reduce cytotoxicity without compromising permeability.  These studies illustrate that 
surface modification of PAMAM dendrimers can be a powerful tool to modulate both 
cytotoxicity and transepithelial transport to create an optimized oral drug delivery system. 
 
2.8.4 PAMAM Dendrimer Internalization 
 Because dendrimers are thought to cross the epithelial barrier by transcellular and 
paracellular routes, the mechanisms of dendrimer internalization in Caco-2 cells and 
subsequent trafficking have been studied.  After El-Sayed et al. established the energy 
dependent cellular internalization mechanism of G2 dendrimers [147], Kitchens and 
colleagues further evaluated the cellular internalization of G1.5 and G2 dendrimers in 
Caco-2 cells and monitored their colocalization with markers for clathrin, early 
endosomes and lysosomes [18].  Both G1.5 and G2 dendrimers were internalized after 20 
minutes and showed colocalization with all three markers, indicating that they are likely 
internalized by clathrin-mediated endocytosis.  Interestingly, G1.5 and G2 dendrimers 
showed slightly different trafficking patterns, with G1.5 dendrimers showing greater 
colocalization with the lysosomes at earlier time points, illustrating the importance of 





early endosomes and lysosomes, these studies suggest that these organelles could 
potentially be targeted for drug release. 
  
2.8.5 PAMAM Dendrimers as Oral Drug Delivery Systems 
 While there has been significant progress on studying the transport characteristics 
of PAMAM dendrimers, there have been comparatively few studies using dendrimers to 
improve the oral bioavailability of therapeutics.  D’Emanuele et al. investigated G3 
dendrimers to improve the oral bioavailabilty of Propranolol, which has low water-
solubility and is a P-gp efflux transporter substrate [113].  By conjugating Propranolol to 
the G3 dendrimers, the apical to basolateral flux of Propranolol increased while the 
basolateral to apical transport decreased, indicating that G3 dendrimers were able to 
prevent Propranolol efflux by P-gp.  This study illustrates that PAMAM dendrimers can 
be used to both improve drug solubility and avoid efflux, thus improving overall 
bioavailabilty.  
 One of the most promising areas for drug delivery is directing chemotherapy to 
the site of action.  Chemotherapeutics often have poor bioavailabilty due to low water 
solubility and can also cause intestinal toxicity.  In 2008, Kolhatkar et al. reported the 
complexation of PAMAM G4 with SN38, which enhanced the solubility, transepithelial 
transport and cellular uptake of SN38 relative to free drug, suggesting its potential as an 
oral drug delivery system [150].  Ke and co-workers examined the ability of G3 
dendrimers to improve the oral bioavailability of Doxorubicin, an anthracycline antibiotic 
used to treat a wide range of cancers [151]. The dendrimer-drug complexes were found to 





free drug.  In addition, oral bioavailability of Doxorubicin in rats was increased 200-fold 
relative to free drug.  These studies illustrate the utility of dendrimers to improve the oral 
bioavailabilty of chemotherapeutics. 
 
2.8.6 Designing PAMAM Dendrimer-Drug Conjugates for Oral Delivery  
 Combining our knowledge of PAMAM dendrimer transepithelial transport with 
the challenges associated with the oral delivery of chemotherapeutics, we can begin to 
envision the requirements for an optimized dendrimer-drug oral delivery system.  Several 
elements of the system will affect the ultimate performance of the DDS including the 
choice of dendrimer generation, drug and drug linker.  As described in Section 2.8.1 there 
have been many studies examining the impact of size and charge on dendrimer transport.  
While cationic dendrimers show enhanced transport, their cytotoxicity restricts their use 
to lower concentrations.  Therefore, anionic dendrimers, which have very low intrinsic 
toxicity and have shown promising in vitro results in everted rat intestinal sacs as well as 
Caco-2 cell monolayers, may be a better choice for the carrier.   
 The choice of drug cargo is also critical for having a successful dendrimer drug 
delivery system.  In addition to having low solubility and poor bioavailabilty, the drug 
must have functional groups such as amines, acids or alcohols available for conjugation 
to the dendrimer.  The drug must be highly potent, ensuring that even if only a fraction of 
the administered dose is transported across the intestinal barrier that the ultimate 
concentration in the bloodstream is still within the therapeutic window of the drug. 
 The final element of a successful dendrimer drug delivery system is the drug 





is released at the site of action in the tumor environment.  In order to stay intact through 
the gastrointestinal environment, the linker must be stable under low pH in the stomach 
(pH 1-2) as well as the elevated pH in the small intestine (7.5-8).  In addition, the linker 
must be resistant to the peptidases in the gastric environment and in the brush border of 
the intestinal mucosa.  However, in order for the drug to be active, the free drug must be 
released at the site of action.  Finally, the linker chemistry can be adjusted by the use of a 
spacer.  A spacer can allow for increased access of enzymes to the bond of interest, 
allowing for release in the tumor environment.  Selection of the proper dendrimer, drug, 
linker and spacer has the potential to create a smart dendrimer drug delivery system, 
which can enhance the oral bioavailability of chemotherapeutics, thus improving patient 
lives and treatment.   
 
2.9 Colorectal Cancer 
2.9.1 Prevalence 
According to the American Cancer Society Facts and Figures 2010, there are 
more than 140,000 new cases of colorectal cancer each year and over 51,000 deaths 
projected in 2010 [152].  Colorectal cancer is the third most diagnosed cancer in men and 
women and the third leading cause of cancer death in the United States [153].  Although 
development of colorectal cancer is usually sporadic, risk factors include increasing age, 
male gender, diseases such as diabetes and inflammatory bowl syndrome and 
environmental factors including high fat / low fiber diets, excessive alcohol consumption, 
smoking, obesity and a sedentary lifestyle.  In addition, approximately 6% of colorectal 





significant burden on the healthcare system, comprising approximately 12% of cancer-
related healthcare costs in the United States with total costs estimated between $4.5 and 
$9.6 billion dollars per year [153].  Reduction in treatment costs by novel therapies could 
improve the quality of life of patients and dramatically reduce the burden on the 
healthcare system.      
 
2.9.2 Colorectal Cancer Screening  
Current colorectal cancer screening guidelines recommend testing for men and 
women over the age of 50.  Colorectal cancer screening tests include fecal occult blood 
tests (FOBT), sigmoidoscopies and colonoscopies, which are recommended for every 
one, five and ten years, respectively [154].  An FOBT detects blood in a stool sample, 
which may be an indication of colorectal cancer.  It is the simplest and lowest cost test, 
but positive results can indicate other pathologies such as hemorrhoids, anal fissures, 
polyps, inflammatory bowl disease or Crohn’s disease.  For this reason, a positive FOBT 
result is followed up with a more extensive test such as a colonoscopy.  A sigmoidoscopy 
is an endoscopic examination of the rectum and the lower portion of the colon where 
60% of colorectal cancers occur.  A sigmoidoscopy involves relatively little patient 
preparation, only requiring self-administration of a single enema.  A colonoscopy is the 
most extensive screening test and involves an endoscopic examination of both the upper 
and lower colon, requiring extensive patient preparation 48 hours before the procedure 
and a specialized doctor to perform the exam.   While it is both invasive and expensive, a 
colonoscopy is also the most sensitive diagnostic tool and is becoming the standard of 





effective ways of reducing the incidence of colorectal cancer by allowing physicians to 
remove polyps before they become cancerous and reducing mortality by diagnosing the 
cancer at an earlier, more treatable stage [153].   
 
2.9.3 Colorectal Cancer Diagnosis and Staging 
 After colorectal cancer is detected by a colonoscopy, it is further characterized by 
a biopsy of the tumor as well as a CT scan to detect any metastatic sites [154].  The 
cancer is then staged according to three separate factors, known as the TNM 
classification system.  The “T” or tumor factor, ranks the invasiveness of the primary 
tumor.  The “N” or lymph node factor, ranks the number of regional lymph nodes that 
have been invaded.  Finally, the “M” or metastasis factor, ranks the presence and number 
of distant metastases [154].  These three scores are combined to yield an overall stage, 
which can be used to provide the patient with a five year prognosis.  For example, in 
Stage 1 where the primary tumor is adherent to the submucosa but there are no lymph 
node invasions or distant metastases, the five-year survival rate is over 97%.  In contrast 
in late Stage III where many regional lymph nodes show metastatic disease, the five year 
survival rate is less than 30% [154].  These dramatic survival differences based on the 
stage of disease highlight both the importance of early detection and the great need for 
therapies to treat metastatic disease. 
 
2.9.4 Colorectal Cancer Metastasis and Treatment 
 The most common site of colorectal cancer metastasis is the liver, with over 20% 





the disease [23].  In addition, liver metastases are responsible for two-thirds of all 
colorectal cancer deaths, indicating the grave need for novel treatments for this condition.  
Unlike early stage colorectal cancer where the tumor is confined to a small area and can 
be removed by surgery, hepatic metastases are much more difficult to remove and often 
require a combination of surgery and chemotherapy.  After a patient is diagnosed with 
hepatic metastases, the size and location of the tumors are measured to determine 
resectability.  Patients must be left with 20-40% of the initial liver volume in order to 
have a functioning liver after surgery [23].  If the metastatic tumors are small, the tumors 
can be resected immediately and followed by adjuvant chemotherapy to prevent 
recurrence.  If the tumors are initially unresectable, patients are often given neoadjuvant 
chemotherapy to shrink the tumors, making them removable.   
 Several different chemotherapy drugs have been approved for the treatment of 
colorectal cancer hepatic metastases.  5-fluorouracil was first approved by the FDA in 
1962 and has played an important role in the treatment of metastatic colorectal cancer.  
Originally used as a single agent and now combined with leucovorin to enhance activity, 
5FU works by disrupting RNA synthesis and inhibiting the enzyme thymidylate synthase 
[155].  In 2001, Capecitabine, an oral prodrug of 5FU, was approved and has shown 
higher response rates than IV administered 5FU in patient groups with advanced disease 
[156].  Recently, combination therapies using 5FU/Leucovorin coupled either with 
Irinotecan, a topoisomerase inhibitor (FOLFIRI), or Oxaliplatin, a platinum-based 
cytotoxic agent (FOLFOX), have become the standard of care for advanced metastatic 
disease.  While there is some debate on which treatment regimen is better, they both 





often used together as first and second line treatments [155].  In addition, both of these 
treatment regimens have shown great potential for reducing tumor size in a neoadjuvant 
setting as well as preventing tumor recurrence when used after surgery.  Depending on 
the patient, biological agents such as Cetuximab, an anti-VEGF therapy or Bevacizumab, 
an anti-EGFR antibody, can be added to the treatment regimens to improve response.  
Coupled with surgical resection, chemotherapy plays a key role in the treatment of 
colorectal cancer hepatic metastases and serves to extend patient life and reduce potential 
relapse.   
 
2.10 SN38 
 7-Ethyl-10-hydroxy-camptothecin, or SN38, is the active metabolite of Irinotecan, 
a water-soluble analogue of camptothecin that is commonly used for treatment of 
metastatic colorectal cancer.  Camptothecin, a naturally occurring alkaloid extract from 
the plant Camptotheca acuminata, was first discovered in the 1960’s [21].  Camptothecin 
showed promising anti-tumor activity in vitro and appeared to strongly inhibit DNA and 
RNA synthesis.  By the 1980’s, topoisomerase I, an enzyme required for DNA coiling 
and uncoiling, was identified as the target of camptothecin.  Since then, many different 
camptothecin analogues have been synthesized, including Irinotecan, and Topotecan 
which have been approved to treat colorectal and ovarian cancers, respectively, as well as 






2.10.1 Mechanism of Action of Irinotecan and SN38 
 In order to cause anti-tumor activity, Irinotecan must be cleaved by 
carboxylesterase to release SN38 (Figure 2.10) [157].   Carboxylesterases are present in 
many sites of the body with the highest expression in the liver, where majority of free 
SN38 is released.  After release, SN38 acts as a topoisomerase poison, effectively 
inhibiting the action of topoisomerase I, which is heavily involved in DNA and RNA 
synthesis. Importantly, the lactone ring on SN38 and CPT-11 is in dynamic equilibrium 
between the closed ring lactone form (active) and the open ring carboxylate form 
(inactive) (Figure 2.10).  Interconversion of the lactone and carboxylate forms is pH 
dependent with the lactone form favored at low pH and in the presence of human serum 
albumin.  Finally, SN38 metabolism occurs by glucoronidation by UDPGA and UDPGT, 
converting SN38 to SN38-glucoronide [157].  
 SN38 has significantly higher activity than the parent Irinotecan prodrug.  In 
particular, SN38 has been shown to have greater topoisomerase I inhibition, more 
significant reduction in DNA and RNA synthesis and an increase in DNA strand breaks 
relative to Irinotecan at equivalent concentrations [158].  This highlights the importance 
of free SN38 release from the prodrug for anticancer activity.  Designing a prodrug of 
SN38 with more efficient release properties would have the potential to create a drug that 






Figure 2.10. Conversion of Irinotecan to SN38 by Carboxylesterase and Equilibrium of 
Carboxylate and Lactone forms of SN38 and Irinotecan.  The closed ring/ lactone form of 





2.10.2 Current SN38 Drug Delivery Systems 
 While SN38 shows 100-1000 fold greater in vitro activity than Irinotecan, it has 
had limited success in the clinic due to poor water solubility and significant 
gastrointestinal side effects.  Several drug delivery systems have been synthesized to 
overcome these limitations.  Zhao and colleagues reported using a 4-arm-PEG system to 
improve the water solubility of SN38 [159].  Using several different amino acid spacers 
to alter stability, these SN38-PEG conjugates showed favorable release profiles under 
neutral pH conditions, high efficacy in vitro and in vivo in a mouse xenograft model.  In 
addition, PEG conjugation at the 20-OH position on SN38 helped to stabilize the lactone 
ring until the point of release. The PEG-SN38 conjugate using a glycine spacer showed 
the most promising therapeutic profile and is currently in Phase I clinical trials (ENZ-
2208) [44].  Meyer-Losic et al. reported a cationic peptide-linked SN38 prodrug designed 
to reduce the gastrointestinal toxicity and hepatic metabolism of Irinotecan.  The peptide 
was linked to SN38 in the 10-hydroxyl position by an ester bond [160].  The conjugates 
were tested in vitro and in vivo in a human xenograft model in mice and dogs.  In 
addition to showing promising in vitro toxicity against a variety of colon, lung and breast 
cell lines, the SN38-peptide conjugate showed higher activity than Irinotecan in vivo with 
fewer gastrointestinal side effects.   
To date there have been two dendrimer-based drug delivery systems developed 
for SN38.  As described in Section 2.8.5, Kolhatkar and co-workers reported the use of 
G4 dendrimers complexed with SN38 through non-covalent interactions as a potential 
oral drug delivery system [150].  The complexes enhanced the solubility, transepithelial 





released 40% of the drug within 24 hours in PBS and 90% of the drug within 30 minutes 
at pH 5.  Because of the instability in acidic conditions, these dendrimer-SN38 complexes 
would require enteric coating for use in oral administration.   In addition, Vijayalakshmi 
et al. recently reported conjugation of SN38 via glycine and β-alanine spacers to 
carboxylic-acid terminated G3.5 PAMAM dendrimers at the 20-OH position [161].  
These G3.5-SN38 conjugates showed promising in vitro activity against colorectal 
adenocarcinoma HCT-116 cells and produced nuclear fragmentation and cell cycle arrest 
in the G2/M phase similar to free drug.  The conjugates were stable in PBS, and showed 
up to 20% release in cell culture media and rat plasma during a 72-hour incubation 
period.  These initial studies established the potential of PAMAM dendrimers as drug 
delivery systems of SN38 for the treatment of colorectal cancer.  Importantly, PAMAM 
dendrimers have the potential to not only improve the oral bioavailability of SN38, but 
they can also reduce its non-specific toxicity and enhance accumulation at the tumor site. 
Taken together, these studies illustrate the potential for improvement of the therapeutic 
efficacy of SN38 by using PAMAM dendrimers.  
 
2.11 Unresolved Issues in Oral Delivery by Dendrimers 
Despite the wealth of research on dendrimers as oral drug carriers, there are still 
many remaining questions that must be resolved for their successful use in oral drug 
delivery.  While PAMAM dendrimers are thought to be transported by a combination of 
transcellular and paracellular pathways, the mechanism of tight junction opening and 
precise endocytosis and trafficking pathways are still unknown.  In depth knowledge of 





constructs as oral drug carriers.  In addition, while there is a significant body of work on 
the transepithelial transport of native dendrimers, there have been comparably few studies 
on dendrimer-drug conjugates.   Detailed studies of the transport, cellular uptake and 
toxicity of PAMAM dendrimer-drug conjugates are necessary to further establish their 
utility in oral drug delivery.  In addition, chemical linkers that promote stability of the 
dendrimer-drug conjugates in the gastrointestinal milieu while favoring release of drug in 
the presence of carboxylesterase must be developed to achieve a functional delivery 
system for the treatment of colorectal cancer hepatic metastases.  Finally, the impact of 
surface chemistry and conjugation chemistry on the degree and mechanism of dendrimer 







Chapter 3 : Cellular Entry of G3.5 Poly (amido amine) Dendrimers by 
Clathrin- and Dynamin-Dependent Endocytosis Promotes Tight Junctional 
Opening in Intestinal Epithelia 
 
3.1 Introduction 
 As discussed in Chapter 2, poly (amido amine) (PAMAM) dendrimers have shown 
promise as drug delivery carriers due to their unique physical properties including 
nanoscale size and near monodispersity [114].  With each increase in dendrimer 
generation, the diameter increases linearly while the number of surface groups increases 
exponentially, creating high density surface groups that can be conjugated to drugs, 
imaging agents and targeting moieties, making dendrimers versatile multifunctional 
nanocarriers [12, 24].  Reports from our laboratory [15, 16, 145, 146] and others [17, 19, 
20, 162] have demonstrated that PAMAM dendrimers in a specified size and charge 
window can effectively cross the epithelial layer of the gut, showing potential as oral 
drug delivery carriers.  Conjugation or complexation of therapeutics with poor solubility 
and low permeability to water-soluble dendrimers that can permeate the epithelial layer 
of the gut has the potential to render these drugs orally bioavailable [113, 150, 151].  Oral 
drug administration has many advantages including the convenience of at-home 
administration, reduction of direct and indirect costs, and a more flexible dosing regimen, 
resulting in higher patient compliance and a lower burden on hospitals and the healthcare 





 PAMAM dendrimers are known to cross the epithelial barrier by a combination of 
transcellular and paracellular mechanisms.  As described in Chapter 2, transport of 
cationic dendrimers has been found to be energy-dependent and is reduced in the 
presence of endocytosis inhibitors, signifying the importance of endocytosis in dendrimer 
transport [148].  In addition, dendrimers were found to colocalize with clathrin and early 
endosome markers, suggesting the involvement of clathrin-mediated endocytosis in 
dendrimer internalization [18].   Dendrimers have also been reported to interact with tight 
junctions, transiently opening them to allow for paracellular transport [15].  While there 
has been significant progress in understanding the mechanisms by which dendrimers 
enter cells and are transported across the epithelial barrier, several important questions 
remain to be addressed.  In particular, the contributions of different endocytosis pathways 
to dendrimer cellular uptake and transcytosis and the specific mechanisms by which 
dendrimers open tight junctions have yet to be elucidated.   Additionally, the majority of 
mechanistic studies to date have focused on cationic dendrimers, which are promising 
due to their high transport rates, but are limited by their significant cytotoxicity.  Anionic 
dendrimers show comparably low cytotoxicity but still appreciable transport rates, 
making them well suited for oral delivery [27, 144].   
 In this Chapter, the mechanisms of cellular uptake, transepithelial transport and 
tight junctional modulation of anionic G3.5 PAMAM dendrimers are investigated by 
examining the impact of endocytosis inhibitors on dendrimer interaction with Caco-2 
cells and differentiated Caco-2 monolayers.  In addition, we present the intracellular 





specific pathways of endocytosis, intracellular trafficking and transepithelial transport 
will aid in rational design of dendrimers for oral delivery. 
 
3.2 Materials and Methods 
3.2.1 Materials 
G3.5 PAMAM dendrimers (reported molecular weight=12,931), lucifer yellow 
CH dipotassium salt (LY), oregon green carboxylic acid succinimidyl ester (OG), 
monodansyl cadaverine (MDC), phenylarsine oxide (PAO), filipin (FIL), genistein 
(GEN) and dynasore (DYN) were purchased from Sigma Aldrich (St. Louis, MO). 
Superose 12 HR 10/300 GL column was obtained from Amersham Pharmacia Biotech 
(Piscataway, NJ) and WST-1 cell proliferation reagent from Roche Applied Sciences 
(Indianapolis, IN). Caco-2 cells were obtained from American Type Cell Culture 
(Rockville, MD).  
 
3.2.2 Synthesis of G3.5-OG  
Purified G3.5 PAMAM dendrimers were first modified with pendant primary 
amine groups to facilitate OG labeling [144].  50 mg dendrimer was dissolved in 
deionized (DI) water to a final concentration of 10 mg/ml and the pH was adjusted to 6.5. 
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) was added at a 5:1 molar ratio 
to the dendrimer and stirred for 30 minutes at room temperature, after which ethylene 
diamine was added at a 5:1 molar ratio and stirred for 4 hours at room temperature.  The 
sample volume was reduced to 1 ml by rotoevaporation of water and then run through a 





to remove the EDC and ethylene diamine.  Size exclusion chromatography was used to 
confirm the absence of low molecular weight impurities.  The number of amines per 
dendrimer was determined to be 2.5 by the ninhydrin assay.  10 mg of amine-modified 
dendrimer was dissolved in 25 ml of DI water and 1 equivalent of OG per dendrimer was 
added and stirred for 30 minutes.  The water was removed by rotoevaporation and the 
product was redissolved in methanol and added dropwise to diethyl ether to precipitate 
the G3.5-OG conjugate. The solution was centrifuged, the ether decanted and then the 
precipitate was dried overnight under vacuum.  The precipitate was then redissolved in 1 
ml of water, and passed through a PD10 column to remove unreacted OG.  Size exclusion 
chromatography was used to confirm the absence of free dye.  OG content was 
determined by a fluorescence standard curve (λexcitation= 485 nm, λemission= 535 nm) to be 
0.75 molecules of OG per dendrimer on average.   
 
3.2.3 Caco-2 Cell Culture 
Caco-2 cells (passages 30–45) were grown at 37°C in an atmosphere of 95% 
relative humidity and 5% CO2. Cells were maintained in T-75 flasks using Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
1% non-essential amino acids, 10,000 units/mL penicillin, 10,000 µg/mL streptomycin 
and 25 µg/mL amphotericin B. Media was changed every other day and cells were 
passaged at 80–90% confluence using a 0.25% trypsin/ethylenediamine tetraacetic acid 
(EDTA) solution. Incubation buffer used in assays consisted of Hank's balanced salt 
solution  (HBSS), supplemented with 1.0 mM N-(2-hydroxyelthyl)piperazine-N′-179 (2 





3.2.4 Cytotoxicity of Endocytosis Inhibitors 
Potential short-term cytotoxicity of endocytosis inhibitors was assessed in Caco-2 
cells to ensure cell viability during uptake and transport assays.  Chemical inhibitors were 
prepared at a range of concentrations known to reduce clathrin-mediated endocytosis 
(phenylarsine oxide (1-20 µM), monodansyl cadaverine (100-300 µM)), caveolin-
mediated endocytosis (filipin (1-4 µM), genistein (100-300 µM)) or dynamin-dependent 
endocytosis (dynasore (40-80 µM)) [163-165].  Cytotoxicity of the inhibitors was 
assessed by the water soluble tetrazolium salt (WST-1) assay.  Caco-2 cells were seeded 
at 50,000 cells per well in 96 well cell culture plates (Corning, Corning, NY) and 
maintained at 37°C, 95% relative humidity and 5% CO2 for 48 hours. Cells were washed 
with warm HBSS buffer and incubated for 2 hours with 100 µL of varying concentrations 
of endocytosis inhibitors. After 2 hours, the inhibitor solutions were removed and the 
cells were washed with warm HBSS buffer. 10 µL WST-1 cell proliferation reagent in 
100 µL of HBSS buffer was added to each well and incubated for 4 hours at 37°C. 
Absorbance at 460 nm and background at 600 nm were measured using a SpectraMax 
384 plate reader (Molecular Devices, Sunnyvale, CA).  HBSS was used as a negative 
control for 100% cell viability. Cytotoxicity of inhibitor concentration was assessed in 
four replicates.  Cell viability of greater than 85% was classified as acceptable for uptake 
and transport assays.   
 
3.2.5 Cellular Uptake  
Cellular uptake of G3.5-OG dendrimers was determined in the presence and 





minimum of 85% cell viability during the 2-hour assay period.  Caco-2 cells were seeded 
at 300,000 cells per well in 12 well plates (Corning, Corning, NY) and maintained for 48 
hours at 37ºC, 95% relative humidity and 5% CO2.  Cells were washed with HBSS and 
pretreated with endocytosis inhibitors or HBSS for 1 hour at 37ºC.  Endocytosis 
inhibitors were removed and 25 µM G3.5-OG, 5 µM Transferrin-AF488 (Molecular 
Probes, Carlsbad, CA) or 5 µM Cholera Toxin B-AF488 (Molecular Probes, Carlsbad, 
CA) was added in the presence of endocytosis inhibitor solutions or HBSS for one hour 
at 37ºC.  Cells were washed once with cold HBSS, trypsinized for 5 minutes and then 
complete cell culture media was added to halt the trypsinization process.  The cells were 
removed from plates, collected in microcentrifuge tubes and were centrifuged for 5 
minutes at 1,000 rpm after which the supernatant was removed.  The cells were washed 
with PBS and finally fixed in 1% paraformaldehyde in PBS at a final concentration of 
500,000 cells/ml.  Flow cytometry was used to assess cellular fluorescence using a BD 
LSR II flow cytometer (Becton Dickenson, Franklin Lakes, NJ) with a 530/30 bandpass 
filter.  Twenty-five thousand to forty-five thousand events were collected per sample.  
Percent uptake was determined for two different cell populations by the shift in mean 
fluorescence in the presence of endocytosis inhibitors compared to HBSS control. 
 
3.2.6 Colocalization and Intracellular Trafficking 
Caco-2 cells were seeded at 40,000 cells/cm2 on collagen-coated 8-chamber 
slides.  Slides were used when cells were 90% confluent, typically 4-5 days after seeding.  
Cells were washed with DPBS and then incubated in DPBS for 30 minutes at 37°C. Cells 





4ºC to allow for attachment but not internalization (pulse).  Subsequently, the cells were 
washed three times with ice cold DPBS to remove unbound ligand and incubated with 
warm DPBS at 37ºC for 5, 15, or 30 minutes (chase) after which they were fixed with 4% 
paraformaldeyde, 4% sucrose in DPBS for 20 minutes.  All subsequent steps were carried 
out at room temperature.  The cells were washed twice with 25 mM glycine and then 
once with DPBS, permeabilized with 0.2% Triton X-100 in blocking solution (3% 
Bovine Serum Albumin (BSA)/DPBS) and then incubated with blocking solution to 
prevent non-specific binding.  Primary antibodies for early endosomes (rabbit polyclonal 
early endosome antigen-1 (EEA-1)) and lysosomes (rabbit polyclonal lysosome-
associated membrane protein 1 (LAMP-1)) (Molecular Probes, Carlsbad, CA) were 
added to separate chambers and incubated for one hour.  The antibodies were removed, 
cells were washed three times with blocking solution and Alexa Fluor-568 goat anti-
rabbit IgG (Molecular Probes, Carlsbad, CA) was added at 1:400 in blocking solution for 
one hour.  The cells were then washed three times with DPBS, and incubated with 300 
nM 4',6-diamidino-2-phenylindole (DAPI) 10 minutes to stain the nuclei.  The cells were 
then washed once with DPBS, once with DI water and the chambers were removed.  The 
slides were mounted, covered with glass coverslips, allowed to dry for a minimum of 2 
hours before sealing and stored at 4ºC prior to visualization.  
Images were acquired using a Nikon Eclipse TE2000 inverted confocal laser 
scanning microscope (Nikon Instruments, Melville, NY).  Excitation and emission 
wavelengths for DAPI, OG/ AF488 and AF568 were 405/450, 488/515 and 543/605, 
respectively.  Four Z-stacks were obtained for each treatment using the following 





image size.  Z-stacks contained 41, 0.5 µm slices to encompass the entire cell layer.   
Detector gains were set to be constant between samples to facilitate sample comparison.   
 Colocalization between G3.5-OG or Transferrin-AF488 with early endosomes 
and lysosomes was quantified using Volocity 3D Imaging software (Improvision, 
Lexington, MA).  The extent of colocalization between the green and red channels (Mx) 















where xi,coloc is the value of voxel i of the overlapped red and green components and xi is 
the value of the green component.  Mx is reported for each treatment as an average of the 
four regions.  Transferrin-AF488 was used as an endocytosis control ligand to establish 
the validity of the assay methods for monitoring intracellular trafficking over time. 
 
3.2.7 Transepithelial Transport  
Caco-2 cells were seeded at 80,000 cells/cm2 onto polycarbonate 12-well 
Transwell® filters of 0.4 µm mean pore size with 1.0 cm2 surface area (Corning, Corning, 
NY).  Caco-2 cells were maintained under standard incubation conditions where media 
was changed every other day and cells were used for transport experiments 21-25 days 
post-seeding.  Prior to experiments, the transepithelial electrical resistance (TEER) of 
each monolayer was measured with an epithelial voltohmmeter (World Precision 
Instruments, Sarasota, FL).  Monolayers with TEER > 600 Ω·cm2 were used for assays.  
Cell monolayers were washed with HBSS and then incubated in the presence of HBSS or 





showed a minimum of 85% cell viability during the 2-hour assay period.  The solutions 
were removed and G3.5-OG (10 µM) was added to the apical compartment in the 
presence of HBSS or endocytosis inhibitor and the corresponding solution was added to 
the basolateral compartment.  After incubating for one hour, samples were taken from the 
basolateral compartment. Transport was quantified by measuring fluorescence in the 
basolateral compartment using a SpectraMax Gemini XS spectrofluorometer (Molecular 
Devices, Sunnyvale, CA) with excitation and emission wavelengths of 485 and 535 nm, 
respectively.  Percent transport is reported comparing dendrimer transport in the presence 
of inhibitors to dendrimer transport in HBSS alone.  The standard deviation for each 
reported value is calculated using propagation of error for the quotient of two 
experimentally determined values. 
LY permeability was also monitored in the presence of HBSS and endocytosis 
inhibitors to ensure the integrity of the monolayers.  LY apparent permeability was less 
than 1 x 10-6 for all conditions tested, which is within the accepted range of LY 
permeability for differentiated monolayers [166]. There was not a significant difference 
between LY permeability in the presence of HBSS or inhibitors, confirming that 
endocytosis inhibitors do not affect tight junctional integrity (data not shown). 
 
3.2.8 Caco-2 Monolayer Visualization and Occludin Staining 
After acquisition of samples for transport assays, Caco-2 cell monolayers were 
prepared for visualization by confocal microscopy. In particular, Caco-2 cell monolayers 
treated with G3.5-OG or HBSS in buffer or in the presence of dynasore were analyzed for 





permeabilized and blocked by the same procedures used in the immunofluorescence 
studies (Section 3.2.6).  Subsequently, monolayers were treated with mouse anti-occludin 
(2 µg/ml) overnight at 4ºC.  The next day, the monolayers were washed twice with 
blocking solution and incubated with the same solution for 30 minutes.  Alexa Fluor 568 
goat anti-mouse IgG (1:400) was added in blocking solution for one hour. The cells were 
then washed and stained with DAPI.  The membranes were carefully excised from the 
Transwell® supports using a scalpel, mounted on glass slides, covered with a glass 
coverslip and then sealed with clear nail polish.  Slides were stored at 4ºC prior to 
visualization. 
Images were acquired using a Nikon Eclipse TE2000 inverted microscope using 
the same settings as described in Section 3.2.6.  To visualize the G3.5 dendrimer 
interaction with the cell monolayer, Z-stacks were obtained with 51 0.5 µm slices using 
red, green and blue channels.  To quantify occludin staining, four z-stacks were obtained 
per region, and only the red channel was used.  Images were processed using Volocity 
software.   Red voxels, corresponding to occludin staining, were quantified by 
thresholding the intensity between 20% and 100%. The number of red voxels was 
quantified for four z-stacks for each treatment. Results are reported as mean ± standard 
deviation and statistical significance was determined by a one-way analysis of variance 







3.3.1 Cytotoxicity of Endocytosis Inhibitors 
Five endocytosis inhibitors were chosen to examine the pathways of cellular 
uptake and transepithelial transport of G3.5 PAMAM dendrimers.  Before initiating 
uptake and transport studies, Caco-2 cell viability during the 2-hour assay time was 
confirmed in the presence of these inhibitors, whose concentrations were chosen based on 
literature reported values [163-165].  Inhibitors included chemicals known to prevent 
clathrin-mediated endocytosis (phenylarsine oxide (1-20 µM); monodansyl cadaverine 
(100-300 µM)), caveolin-mediated endocytosis (filipin (1-4 µM); genistein (100-300 
µM)) and dynamin-dependent endocytosis (dynasore (40-80 µM)).  We have shown 
previously that G3.5 dendrimers do not cause a reduction in Caco-2 cell viability up to 
100 µM.  Since the maximal dendrimer concentration used in these experiments was 25 
µM, toxicity due to the dendrimers was not a concern.  
Short-term cytotoxicity of endocytosis inhibitors was assessed by the WST-1 cell 
viability assay at 5 different concentrations in the reported range of each inhibitor (Table 
3.1).  85% cell viability was chosen as the minimum allowable for use in uptake and 
transport assays.  Monodansyl cadaverine and filipin did not show appreciable toxicity at 
any concentration tested and were used at their maximum reported concentrations of 300 
µM and 4 µM, respectively.   Phenylarsine oxide and genistein showed significant 
toxicity and were used at their lowest effective concentrations.  Dynasore showed 
increasing toxicity over the range of concentrations tested, with the most acceptable (i.e. 









% Cell Viability 
Phenylarsine Oxide (PAO) 1  90.0 ± 5.7% Clathrin 
Inhibiting Monodansyl Cadaverine (MDC) 300 92.7 ±  3.4% 
Filipin (FIL) 4 95.9 ± 2.7% Caveolin 
Inhibiting Genistein (GEN) 100 86.7 ± 2.9% 
Dynamin 
Inhibiting 
Dynasore (DYN) 50 106.1 ± 5.0% 






3.3.2 Cellular Uptake of G3.5-OG Dendrimers in the Presence of Endocytosis Inhibitors 
As chemical inhibitors have varied effectiveness in different cell lines and can be 
somewhat non-specific, we took a multi-pronged approach, selecting one inhibitor for the 
general process of dynamin-dependent endocytosis and two inhibitors for distinct 
clathrin- and caveolin-mediated processes. In addition, we monitored the cellular uptake 
of transferrin and cholera toxin B, control ligands for clathrin- and caveolin-mediated 
endocytosis, respectively, to determine the efficacy and specificity of the selected 
inhibitors. Dynasore was used to block vesicular endocytosis by selectively inhibiting 
dynamin 1 and dynamin 2 GTPases, which are responsible for vesicle scission during 
both clathrin- and caveolin-mediated endocytosis [164].  Monodansyl cadaverine and 
phenylarsine oxide were used to block clathrin-mediated endocytosis.  Monodansyl 
cadaverine is known to stabilize clathrin coated pits on the cell membrane, thereby 
preventing internalization [167].  Phenylarsine oxide has also been shown to inhibit 
clathrin endocytosis at low micromolar concentrations, but its mechanism is unknown 
[168, 169].  Filipin and genistein were selected to inhibit caveolin-mediated endocytosis.  
Filipin binds cholesterol and has been shown to disrupt caveolae-mediated endocytic 
pathways [170].  Genistein inhibits protein tyrosine kinases and, amongst other effects, 
has been shown to block internalization by caveolae [171]. The percent uptake relative to 
buffer control was calculated for G3.5 and control ligands in the presence of five 







Table 3.2. Percent Uptake of G3.5-OG Dendrimers and Control Ligands in Caco-2 Cells 
in the Presence of Endocytosis Inhibitors. 
 Percent Uptake 
Endocytosis Inhibitors G3.5 Transferrin Cholera Toxin B 
Phenylarsine Oxide (PAO) 84.4 ± 0.6% 112.3 ± 1.5% 100.5 ± 4.0% Clathrin 
Inhibiting Monodansyl Cadaverine (MDC) 57.8 ± 2.1% 65.6 ± 2.5% 61.8 ± 5.1% 
Filipin (FIL) 81.0 ± 0.2% 110.2 ± 0.1% 114.4 ± 3.4% Caveolin 
Inhibiting Genistein (GEN) 22.4 ± 0.7% 69.8 ± 2.4% 20.4 ± 0.7% 
Dynamin 
Inhibiting 
Dynasore (DYN) 20.4 ± 3.5% 15.0 ± 2.7% 57.1 ± 19.6% 





 G3.5 PAMAM dendrimers show reduction in cellular uptake in the presence of all 
endocytosis inhibitors tested, suggesting the involvement of both clathrin- and caveolin-
mediated endocytosis pathways in dendrimer cellular uptake.  As expected, dendrimers 
showed the greatest reduction in uptake in the presence of dynasore, a selective chemical 
inhibitor of dynamin, a protein integral to the hallmark event of vesicle pinching from the 
plasma membrane during receptor-mediated endocytosis. The significant decrease in 
uptake of dendrimers and control ligands in the presence of dynasore confirms the 
endocytosis of G3.5 PAMAM dendrimers by dynamin-dependent pathways. Dendrimers 
showed decreased uptake in the presence of both clathrin inhibitors, with a greater 
decrease seen in the presence of monodansyl cadaverine.  Transferrin uptake was not 
reduced in the presence of phenylarsine oxide, indicating that this is not an effective 
clathrin-endocytosis inhibitor in Caco-2 cells at the concentration used and the decrease 
in dendrimer uptake may be due to a non-specific effect. Alternatively, dendrimer 
trafficking may be more sensitive to phenylarsine oxide compared to transferrin, which is 
affected only at higher phenylarsine oxide concentrations.  In contrast, transferrin shows 
reduced uptake in the presence of monodansyl cadaverine, illustrating the efficacy of 
monodansyl cadaverine in Caco-2 cells.  Cholera toxin B also shows reduced uptake in 
the presence of monodansyl cadaverine, but this decrease in uptake was expected since 
cholera toxin B can be endocytosed by clathrin- and caveolin-mediated pathways in 
Caco-2 cells [172].  Dendrimers also showed reduced uptake in the presence of both 
caveolin inhibitors, markedly seen with genistein; however, filipin did not reduce uptake 
of cholera toxin B, and this may represent a cell-specific effect.  While genistein reduces 





making it an effective and relatively specific inhibitor of caveolin-mediated endocytosis. 
The most effective and specific inhibitors (monodansyl cadaverine, genistein and 
dynasore) were chosen for further investigation in transport assays. 
  
3.3.3 Intracellular Trafficking 
 In addition to determining the mechanism of dendrimer uptake, we investigated 
the intracellular trafficking of G3.5 PAMAM dendrimers in Caco-2 cells. Dendrimers 
colocalized with early endosomes (EEA-1) and lysosomes (LAMP-1) over time (Figure 
3.1). Transferrin trafficking (Figure 3.2), which has been well-characterized in this cell 
line, was used as a control for the study [18].  Sample confocal images from each 
treatment and time point are included in Appendix 1. Five minutes after incubation, 
dendrimers showed initial localization in the early endosomes and lysosomes.  By 15 
minutes, however, they showed increasing localization in the lysosomes, indicating quick 
trafficking to these cellular compartments.  Interestingly, at 30 minutes, the level of 
accumulation in the lysosomes remained unchanged, while their presence in endosomes 
increased.  This suggests that the trafficking pathway was saturated, causing dendrimer 
retention in early endosomes once lysosomes were occupied.  In contrast, transferrin 
showed almost constant presence in the early endosomes with increasing presence in the 
lysosomes over time.  This is typical of transferrin, a classical ligand for clathrin-
mediated endocytosis known to accumulate in the early endosomes, confirming the 







Figure 3.1. Intracellular Trafficking of G3.5-OG Dendrimers over Time in Caco-2 Cells.  
Colocalization (Mx) with early endosomes (EEA-1) and lysosomes (LAMP-1) is shown.  






Figure 3.2. Intracellular Trafficking of Transferrin-AF488 over Time in Caco-2 Cells. 
Colocalization (Mx) with early endosomes (EEA-1) and lysosomes (LAMP-1) is shown.  





3.3.4 Transepithelial Transport of G3.5-OG Dendrimers in the Presence of Endocytosis 
Inhibitors  
 Transepithelial transport of G3.5-OG dendrimers was monitored in the presence 
of endocytosis inhibitors and at 4°C and compared to transport in buffer at 37°C (Figure 
3.3).  Transport of PAMAM G3.5 was significantly reduced at 4°C, illustrating strong 
energy dependence.  Similar to Caco-2 uptake studies, transport was also reduced in the 
presence of dynasore and monodansyl cadaverine, indicating the importance of dynamin-
dependent and clathrin-mediated endocytosis mechanisms in transepithelial transport. 
However, contrary to its effect on cellular uptake of dendrimers (Table 3.2), genistein 
does not significantly impact dendrimer transport across Caco-2 monolayers, suggesting 
that caveolin-mediated endocytosis may not play a significant role in this process. It has 
been suggested that fully differentiated Caco-2 cells lack caveolae [172], opening the 
possibility that, while caveolae play an important role in dendrimer endocytosis in 
undifferentiated Caco-2 cells, they are less important in dendrimer transepithelial 
transport because of their lower expression in differentiated enterocytes.  
 
3.3.5 Visualization of G3.5-OG Dendrimer Interaction with Caco-2 Cell Monolayers 
 After cell monolayers were used for transport assays, they were fixed and stained 
for occludin and nuclear DNA.  By excising the stained membranes from the Transwell® 
supports, we were able to visualize the dendrimer interacting with differentiated Caco-2 
cell monolayers.  Although there have been many studies documenting dendrimer 







Figure 3.3. Percent Transport of G3.5-OG Dendrimers across Caco-2 Monolayers in the 
Presence of Endocytosis Inhibitors or at 4ºC.Results are reported as mean +/- standard 








Figure 3.4. Visualization of G3.5-OG Dendrimer Interaction with Caco-2 Monolayers. 
Dendrimers are localized inside cell monolayers but avoid the nucleus (A) and small 






interaction with fully differentiated and confluent monolayers.  Figure 3.4 shows a 
representative image of the cell monolayer.  The nuclear staining was omitted from 
Figure 3.4 B to allow for easier visualization of the dendrimer and tight junctions.  In 
both figures, dendrimer staining is observed inside the confluent cells, confirming 
internalization.  In addition, there are punctate regions strongly resembling vesicles 
(circled in Figure 3.4 B), which confirm the involvement of vesicular endocytosis in 
dendrimer transepithelial transport.  Finally, dendrimers cannot be detected in the nuclear 
region of the cell, confirming their localization in the cell interior and without further 
trafficking into the cell nucleus.  These images serve as complementary evidence of the 
importance of the transcellular pathway in dendrimer transport. 
 
3.3.6 Occludin Staining in Presence of Dendrimers with and without Dynasore Treatment 
 Increased occludin staining is a well-established indicator for tight junctional 
opening in Caco-2 cell monolayers and has shown strong correlation with reduction in 
TEER and increase in paracellular marker permeability [173].  Previous studies have 
shown that monolayers treated with dendrimers showed increased occludin staining 
relative to cells treated with HBSS alone, indicating that dendrimers open tight junctions 
[15].  We examined occludin accessibility in Caco-2 cell monolayers treated with 
dendrimers or HBSS in the presence of dynasore or buffer alone (Figures 3.5 and 3.6).  In 
cells treated with buffer, dendrimers significantly increased occludin staining relative to 
untreated cells, indicating tight junction opening (Figure 3.5 A,B).  In contrast, in cells 






Figure 3.5. Occludin Staining in the Presence and Absence of G3.5-OG Dendrimers in 
Caco-2 Cells Treated with HBSS or Dynasore.  A) G3.5/ HBSS, B) HBSS only C) 
G3.5/Dynasore and D) Dynasore only. Main panels illustrate the xy plane; horizontal bars 






Figure 3.6. Quantification of Occludin Staining.  Cells treated with G3.5-OG dendrimers 
in the presence of HBSS show a significant increase in occludin staining from untreated 
cells.  (***) indicates p<0.001.  Cells treated with dendrimer in the presence of dynasore 
do not show a significant change in occludin staining relative to the control.  Results are 






treated with dendrimers or dynasore alone (Figure 3.5 C,D).  This illustrates that 
dendrimers are unable to open tight junctions in cells where dynamin-dependent 
endocytosis is inhibited, suggesting that dendrimers must first be internalized to modulate 
cellular tight junctions.   
Two major mechanisms have been established for opening tight junctions: 
depletion of divalent cations and disruption of intracellular tight junctional components.  
Disodium ethylenediaminetetraacetate, a calcium chelator, and polyoxyethelyne, a 
surfactant, both lower extracellular calcium levels, causing dissociation of tight junctions 
[55].   Other compounds such as sodium caprate increase tight junctional opening by 
initiating a biochemical signaling cascade which results in the contraction of actin 
microfilaments, effectively dilating the intracellular tight junctions [55]. While it is 
possible that dendrimers interact with the tight junctions in multiple ways, it is clear that 
prevention of dendrimer endocytosis reduces both transcellular and paracellular transport, 
suggesting that dendrimer endocytosis is at least in part responsible for tight junction 
modulation.  Dendrimers are most likely acting on intracellular cytoskeleton components 
to induce tight junction opening. 
 
3.4 Discussion 
 PAMAM dendrimers have shown promise as oral drug delivery carriers due to 
their ability to translocate across the epithelial layer of the gut, taking poorly-bioavailable 
drug cargo in tow [150].  While many studies have suggested that dendrimers transiently 
open tight junctions and are transported through the intestinal barrier by transcellular and 





In order to design dendrimers as oral drug delivery carriers, it is critical to know the 
detailed mechanisms of their cellular entry, trafficking, transport and interaction with 
cellular tight junctions.  In this Chapter, we have uncovered some of the details of anionic 
dendrimer transport, which can have significant implications for oral drug delivery. 
Caco-2 cellular uptake of G3.5 dendrimers was found to occur primarily through 
dynamin-dependent endocytosis pathways, specifically clathrin- and caveolin-mediated 
endocytosis.  Previous reports have suggested the involvement of clathrin in dendrimer 
endocytosis [18]. The present study confirms, for the first time, the involvement of 
caveolin-mediated endocytosis in dendrimer internalization.  This suggests that 
dendrimers are not relegated to a single means of cellular entry, but instead take 
advantage of several specific endocytosis pathways.  This has significant implications for 
drug delivery, as intracellular trafficking is largely dependent on initial pathway of cell 
entry. Therefore, it is to be expected that a portion of dendrimer dose applied to 
enterocytes will be trafficked to the lysosomes by the clathrin-mediated endocytosis 
pathway, while the dendrimers that enter via the caveolae may end up in the cell cytosol, 
allowing them to be targeted to either compartment depending on the desired effect.   
Dendrimer transport across differentiated Caco-2 cell monolayers was found to be 
dependent on dynamin- and clathrin-mediated endocytosis, but independent of caveolin-
mediated endocytosis. This result was expected since fully differentiated Caco-2 cells 
lack caveolae.  The differences between dendrimer transport across differentiated 
epithelial cells and uptake in undifferentiated cells can be potentially exploited by drug 





avoiding intestinal cells by designing linkers that would be cleaved in caveolae-mediated 
transport pathways.   
Intracellular trafficking studies shed further light on the environments that 
dendrimers encounter after cellular internalization.  Kitchens and co-workers [18] 
examined G1.5 and G2 dendrimer colocalization with endosomal and lysosomal markers 
in Caco-2 cells and reported that dendrimers show constant presence in the early 
endosomes at 20 and 60 minutes, with time-dependent trafficking to the lysosomes.  In 
this study G3.5 dendrimers were found to localize in the early endosomes and lysosomes 
after 5 minutes, displayed fast trafficking to the lysosomes after 15 minutes and increased 
endosomal and lysosomal accumulation at 30 minutes, likely due to pathway saturation.  
Often drugs are conjugated to dendrimers via pH-sensitive linkers that are cleaved in the 
acidic environment of mature endosomes or peptide linkers that are cleaved by lysosomal 
enzymes such as cathepsin B [174].  These intracellular trafficking studies corroborate 
the validity of such strategies, as dendrimers can be found in both environments 
following cellular internalization.  Cleavage of pH-sensitive linkers in the endosomes 
may be promising as dendrimers are shown to accumulate in these compartments over 
time.  Knowledge of the cellular uptake and intracellular trafficking pathways of 
dendrimers can have significant impact on designing them for use as drug delivery 
vehicles. In the context of oral drug delivery, knowledge of subcellular localization in 
intestinal cells can enable design of conjugates that are robust in these compartments and 
absorbed intact to the blood stream. 
One of the most intriguing attributes of PAMAM dendrimers is that within a 





via the paracellular pathway [16].  Previous reports have shown that dendrimers decrease 
TEER, increase paracellular marker flux (e.g. mannitol) and increase occludin 
accessibility in Caco-2 cells, confirming that they open tight junctions [16, 145, 146]. 
However the mechanism behind this phenomenon remained largely elusive.  In this 
Chapter we examined the role of dendrimer cellular internalization on tight junction 
opening by monitoring the effects of dendrimers on confluent monolayers in buffer or in 
the presence of dynasore.  While dendrimers were able to open tight junctions in the 
presence of buffer alone, they could not do so in the presence of dynasore, suggesting 
that dendrimer internalization is requisite for tight junction opening.   This has significant 
implications for oral delivery using dendrimers because it shows that tight junction 
opening is at least in part modulated by dendrimers within the cells. Whether affecting 
tight junctional structures from the apical environment outside the cells by dendrimers 
also plays a role remains to be examined.  Therefore, this mechanism (opening tight 
junction by internalization) results in temporary tight junction opening, which is 
consistent with our previous reports that TEER returns to pre-treatment values after 24 
hours [149].  Taken together, these data establish that dendrimers can be used safely as 
oral drug carriers or penetration enhancers since depending on generation, concentration 
and incubation time their effects on tight junctions can be transient, not permanent.  








Figure 3.7. Mechanisms of Dendrimer Transport Across Caco-2 Cell Monolayers. 
Once endocytosed, dendrimers can interact with tight junctions (A), allowing for 








In this Chapter we described the detailed mechanisms of cellular uptake, 
intracellular trafficking, transport and tight junction modulation of G3.5 PAMAM 
dendrimers in Caco-2 cells.  We found that G3.5 PAMAM dendrimers enter 
undifferentiated Caco-2 cells by clathrin-, caveolin-, and dynamin-dependent pathways 
but that their transepithelial transport across confluent monolayers is governed by  
clathrin- and dynamin-dependent pathways only.  Dendrimers were quickly trafficked to 
the lysosomes, but show increased endosomal accumulation once the lysosomal 
compartments become saturated.  Finally, it was demonstrated that dendrimer 
endocytosis promotes tight junction opening, illustrating the interconnected nature of the 
transcellular and paracellular pathways in dendrimer transepithelial transport.  
Knowledge of detailed mechanisms of dendrimer cellular uptake, intracellular and 
transepithelial transport will assist in the design of PAMAM dendrimer-based oral drug 
delivery strategies by providing appropriate linker chemistry consistent with 








Chapter 4 : G3.5 PAMAM Dendrimers Enhance Transepithelial Transport of 
SN38 While Minimizing Gastrointestinal Toxicity 
 
4.1 Introduction 
 Polymer-based drug delivery systems have shown promise due to their ability to 
improve the efficacy of traditional drugs [6].  Conjugation of small molecule therapeutics 
to a polymeric carrier can enhance the drug’s solubility, increase accumulation at the 
target site and minimize non-specific toxicity. Because chemotherapy drugs are often 
plagued by poor water solubility and dose-limiting toxicities, they are promising 
candidates for polymeric drug delivery strategies.  Attachment of chemotherapy drugs to 
water soluble polymers enhances solubility, allows for accumulation of the polymer-drug 
conjugate at the tumor site due to the enhanced permeability and retention effect, 
improves efficacy and reduces side effects [1].  Several polymer-drug conjugates using 
N-(2-hydroxypropyl)methacrylamide (HPMA) and poly (ethylene glycol) (PEG) as 
carriers are currently being evaluated in clinical trials [38, 44].  
While conjugation of chemotherapy drugs to water-soluble polymers can improve 
their solubility and tumor uptake, the large size of these macromolecular constructs 
necessitates intravenous administration.  Oral administration is typically limited to small, 
lipophilic drugs that can permeate the cell membrane, small, hydrophilic drugs that pass 
through the tight junctions or drugs that are substrates for intestinal transporters [175]. 
Studies have shown that compared to intravenous administration, oral chemotherapy is 





treatments [7]. Therefore, the combination of the distinct therapeutic advantages of 
polymer-drug conjugates with strong patient preference and lower costs of oral 
chemotherapy supports a significant need for orally bioavailable polymer therapeutics.  
 Because of its low water solubility and poor bioavailability, SN38 (7-ethyl-10-
hydroxy-camptothecin), a potent topoisomerase-1 poison used to treat colorectal cancer 
and hepatic metastases, is an ideal candidate for polymeric delivery strategies [158]. 
While SN38 shows 100-1000-fold higher activity than CPT-11 in vitro, its use is limited 
by low water solubility and significant intestinal toxicity including diarrhea [176, 177].  
Conjugation of SN38 to PAMAM dendrimers has the potential to allow for oral 
administration while also improving water solubility and minimizing gastrointestinal 
toxicity.  Synthesis, characterization, and bioactivity of G3.5 PAMAM-SN38 conjugates 
against colorectal carcinoma cell lines has been previously established [161]. To 
successfully advance these systems for oral administration, their stability in the 
gastrointestinal tract and transport across the epithelial barrier of the gut must be 
determined. In this Chapter we examine G3.5 PAMAM-SN38 conjugates for their in 
vitro release profiles, cytotoxicity against Caco-2 and HT-29 colorectal cancer cells, 
cellular uptake, and transepithelial transport across Caco-2 monolayers as models of the 
intestinal epithelial barrier. 
 
4.2 Materials and Methods 
4.2.1 Materials 
PAMAM G3.5 dendrimers (reported molecular weight=12,931), lucifer yellow 





pancreas and carboxylesterase from rabbit liver were purchased from Sigma Aldrich (St. 
Louis, MO). Simulated Intestinal Fluid (SIF) and Simulated Gastric Fluid (SGF) were 
obtained from Ricca Chemical Company (Arlington, Texas).  7-ethyl-10-hydroxy 
camptothecin (SN38) was obtained from AK Scientific Company (Mountain View, CA). 
WST-1 cell proliferation reagent was purchased from Roche Applied Sciences 
(Indianapolis, IN). Caco-2 cells and HT-29 cells were obtained from American Type Cell 
Culture (Rockville, MD).  
 
4.2.2 Synthesis and Characterization of G3.5-Gly-SN38 and G3.5-βAla-SN38 Conjugates 
 G3.5-Gly-SN38 and G3.5-βAla-SN38 were synthesized as previously described 
[161].  Briefly, SN38 was modified at the 20-OH position via an ester linker with glycine 
or β−alanine [178].  The modified SN38 molecules were then conjugated to carboxylic 
acid-terminated G3.5 dendrimers using EDC / NHS as a coupling agent.  The products 
were dialyzed against distilled water using 3,500 MWCO membranes to remove low 
molecular weight impurities and further purified using preparative fast protein liquid 
chromatography (FPLC).  1H NMR was used to quantify the number of SN38 molecules 
per dendrimer by comparing the area of the dendrimer protons between 2.1 and 3.8 ppm 
with the methyl protons of SN38 between 0.9-1.1 ppm. The drug loading per dendrimer 
was 2.9 and 4 for G3.5-Gly-SN38 and G3.5-βAla-SN38, respectively.  Figure 4.1 
illustrates the conjugation strategy used to synthesize G3.5-Gly-SN38 and G3.5-βAla-






Figure 4.1. Conjugation of SN38 to G3.5 Dendrimers via Glycine and β−Alanine 






4.2.3 Stability Studies 
 G3.5-Gly-SN38 and G3.5-βAla-SN38 conjugates were prepared at 0.15 and 0.10 
mg/ml respectively in the release buffer of interest and incubated at 37ºC with rotation in 
glass vials.  Release buffers included SGF with and without 0.32% w/v pepsin [179], SIF 
with and without 1% w/v pancreatin [179] and PBS with and without carboxylesterase 
(17.3 IU/ml) [180].  Release in gastric conditions was monitored for up to 6 hours and in 
the intestinal conditions for up to 24 hours, mimicking the expected residence time in 
each of these compartments [49].  Enzyme activity was confirmed at each time point 
using bovine serum albumin [181], Z-Arg-AMC [182] and p-nitrophenol acetate [183] as 
model substrates for pepsin, pancreatin and carboxylesterase, respectively.   
During the release experiment, 100 µL of sample was taken at each time point and 
added to an additional 400 µL of release buffer.  Released SN38 was separated from 
G3.5-SN38 conjugate by passing the sample through a 3,000 MWCO Amicon Ultra 0.5 
centrifugal concentrator (Millipore, Billerica, MA) by centrifuging at 14,000 x g for 30 
minutes.  Amicon concentrators were pre-treated with 5% v/v Triton X-100 to minimize 
non-specific binding as per the manufacturer’s instructions.  SN38 is known to exist in a 
pH-dependent equilibrium between a closed ring lactone form and an open ring 
carboxylate form, with the lactone form favored at low pH [157].  For SIF and PBS, 350 
µL of the filtrate was taken and acidified to pH 2 with the addition of an appropriate 
volume of 1 N HCl and subsequently incubated at 37ºC for 1 hour to convert SN38 to the 
lactone form.  This acidification step was omitted for SGF since it is at a pH of 1-2.  
Next, the acidified SN38 was extracted by adding 200 µL of acetonitrile followed by 200 





separate the layers.  The organic layer was isolated, the chloroform addition was repeated 
two more times, and the organic extracts were pooled.  The extracts were then dried 
under nitrogen gas, redissolved in 70 µL of 50/50 DMSO/0.1N HCl and then measured 
by high pressure liquid chromatography (HPLC).   
SN38 was quantified by HPLC using a system containing a Waters 1525 Binary 
Pump, Waters 717plus Autosampler and Waters 2487 dual wavelength UV detector 
(Waters Corporation, Milford, MA) set at 375 nm with a Phenomenex C18 column (250 
x 4.6 mm, 5 µm) (Phenomenex, Torrance, CA). A gradient method with methanol and 
water with 0.1% TFA was used with a total flow rate of 1 ml per minute and an injection 
volume of 20 µL.  A calibration curve using the peak area versus concentration was 
generated for each release buffer by extracting known concentrations of SN38.  Detailed 
HPLC methods and standard curves are included in Appendix 2.  Extraction efficiencies 
comparing extracted standards to direct injection of SN38 standards were found to be 
86%, 91%, 75%, 80%, 70% and 83% in SGF, SGF/ pepsin, SIF, SIF/ pancreatin, PBS, 
and PBS/ carboxylesterase, respectively, and were time and concentration-independent. 
 
4.2.4 Cell Culture 
Caco-2 cells (passages 20-40) were cultured as described in Section 3.2.3.  
HT-29 cells (passages 130-140) were cultured under the same incubation conditions as 
Caco-2 cells using McCoy’s 5A media supplemented with 10% fetal bovine serum (FBS), 
1% non-essential amino acids, 10,000 units/mL penicillin, 10,000 µg/mL streptomycin 





4.2.5 Potential Short-Term Cytotoxicity of G3.5-SN38 Conjugates 
Potential short-term cytotoxicity of G3.5-SN38 conjugates was assessed in Caco-
2 cells to ensure cell viability during uptake and transport assays.  Unmodified G3.5 
dendrimers, G3.5-Gly-SN38 and G3.5-βAla-SN38 were prepared at 10 and 100 µM in 
HBSS transport buffer.  SN38 was prepared as a concentrated stock in DMSO at 40,000 
µM and used to make solutions in HBSS at 4, 40, and 400 µM.  Cytotoxicity was 
assessed by the water soluble tetrazolium salt (WST-1) assay as described in Section 
3.2.4.  HBSS was used as a negative control for 100% cell viability and 0.01% Triton X-
100 was used as a positive control.  UV absorbance of G3.5-SN38 conjugates alone was 
also assessed to confirm that SN38 absorbance did not interfere with the cell viability dye 
(data not shown).  
 
4.2.6 Potential Delayed Cytotoxicity of G3.5-SN38 Conjugates 
 Potential delayed cytotoxicity of G3.5-SN38 conjugates was assessed in Caco-2 
cells by measuring cell viability 24 hours post-exposure.  Cell viability 24 hours after 
short-term exposure mimics the potential long-term effects of the conjugates on the 
intestinal cells that may not be apparent when cell viability is measured immediately 
post-treatment.  Caco-2 cells were prepared and treated the same as in Section 4.2.5.  
After the 2-hour exposure, the cells were washed twice with HBSS and incubated with 
100 µL of cell culture media for an additional 24 hours.  The WST-1 assay was used to 
assess the cell viability 24 hours later, with HBSS used as a negative control for 100% 





4.2.7 Transepithelial Transport  
Caco-2 cell monolayers were grown as described in Section 3.2.7.  Monolayers 
were washed with HBSS and then 0.5 ml of 10 or 100 µM G3.5-Gly-SN38, G3.5-βAla-
SN38 or 4 µM SN38 was added to the apical compartment and 1.5 ml HBSS was added 
to the basolateral compartment. After a 2-hour incubation, samples were taken from the 
basolateral compartment. Transport was quantified by measuring fluorescence in the 
basolateral compartment using a SpectraMax Gemini XS spectrofluorometer (Molecular 
Devices, Sunnyvale, CA) with excitation and emission wavelengths of 375 and 550 nm, 
respectively, and compared to fluorescence standard curves for each conjugate and free 
SN38. Presence of free SN38 in the basolateral compartment of monolayers treated with 
G3.5-SN38 conjugates was determined by the extraction methods described in Section 
4.2.3.  Equivalent SN38 flux was calculated by multiplying the measured molar flux of 
the conjugates with the number of SN38 molecules per dendrimer.  Apical to basolateral 
flux is reported as the average of four replicates.  Statistical significance was determined 
by analysis of variance followed by Tukey’s multiple comparison test. LY permeability 
was also monitored in the presence of HBSS to ensure the integrity of the monolayers.  
LY apparent permeability was less than 1 x 10-6 cm/s, which is within the accepted range 
of LY permeability for differentiated monolayers (data not shown).  
 
4.2.8 Cellular Uptake 
 Cellular uptake of G3.5-SN38 conjugates and free SN38 was assessed in 
differentiated Caco-2 monolayers.  After the transport assay, the cells were washed twice 





incubated for 2 hours at 37ºC to solubilize the cells.  The cells were then removed from 
the Transwell® by pipette and transferred to a microcentrifuge tube.  The cell debris was 
removed by centrifugation at 1000 RPM for 5 minutes.  100 µl of the clear supernatant 
was taken and the uptake of G3.5-SN38 conjugates and SN38 was quantified by 
fluorescence with excitation at 375 nm and emission at 550 nm as described in Section 
4.2.7. Presence of free SN38 in the cellular compartment was determined by the 
extraction methods described in Section 4.2.3.  Uptake is reported as an average of four 
replicates and normalized to total protein as determined by the Bradford Protein Assay 
(Bio-Rad, Hercules, CA). Statistical significance was determined by analysis of variance 
followed by Tukey’s multiple comparison test. 
 
4.2.9 IC50 in HT-29 Cells 
 The IC50 values of G3.5-SN38 conjugates and free SN38 were determined in HT-
29 cells to assess the efficacy of the conjugates in colorectal cancer cells compared to the 
free drug.  HT-29 cells were seeded at 2,500 cells/ per well in 96 well cell culture plates 
and incubated at 37ºC for 24 hours.  After 24 hours, the cells were treated with different 
concentrations of SN38, G3.5-Gly-SN38 and G3.5-βAla-SN38 in media and incubated 
for an additional 48 hours.  Cells were also treated with comparable concentrations of 
G3.5 dendrimer alone to ensure that the carrier did not cause any long-term cytotoxicity.  
After 48 hours, the media was aspirated by pipette, the cells were washed with HBSS 
buffer and the WST-1 assay was used to assess cell viability.  Cell viability was 





media alone.  GraphPad Prism software (La Jolla, CA) was used to generate the IC50 
curves and values using the sigmoidal dose-response non-linear curve fitting routine. 
 
4.3 Results 
4.3.1 Stability of G3.5-SN38 Conjugates 
 Stability of G3.5-SN38 conjugates in simulated gastric, intestinal and liver 
carboxylesterase conditions was assessed to determine the suitability of these conjugates 
for oral delivery of SN38 for the treatment of colorectal cancer hepatic metastases.  In 
particular, stability of the conjugates was monitored in the presence of SGF with and 
without pepsin (Figure 4.2), SIF with and without pancreatin (Figure 4.3) and PBS with 
and without carboxylesterase (Figure 4.4).   
Both G3.5-Gly-SN38 and G3.5-βAla-SN38 showed little to no release of free 
SN38 in the gastric environment (Figure 4.2).  G3.5-βAla-SN38 did not release more 
than 0.5% SN38 during 6 hours in SGF with or without pepsin.  In contrast, G3.5-Gly-
SN38 showed a burst release of SN38 after 1 hour in SGF with and without pepsin and 
ultimately released approximately 9% in SGF with pepsin and 6% in SGF without pepsin.  
This small amount of gastric release could be prevented by use of enteric coating.  These 
studies illustrate that although G3.5-Gly-SN38 released more SN38 than G3.5-βAla-
SN38 in the gastric environment, they were both relatively stable in acidic conditions and 






Figure 4.2. Stability of G3.5-Gly-SN38 and G3.5-βAla-SN38 Conjugates in Simulated 
Stomach Conditions for 6 hours.  Results are reported as mean +/- standard deviation 
(n=2).  G3.5-Gly-SN38 is represented by squares and G3.5-βAla-SN38 is represented by 
circles.  Release in SGF with 0.32% w/v pepsin is depicted by solid lines with filled 






Figure 4.3. Stability of G3.5-Gly-SN38 and G3.5-βAla-SN38 Conjugates in Simulated 
Intestinal Conditions for 24 hours.  Results are reported as mean +/- standard deviation 
(n=2).  G3.5-Gly-SN38 is represented by squares and G3.5-βAla-SN38 is represented by 
circles.  Release in SIF with 1% w/v pancreatin is depicted by solid lines with filled 







Figure 4.4. Stability of G3.5-Gly-SN38 and G3.5-βAla-SN38 Conjugates in Simulated 
Liver Conditions for 48 hours.  Results are reported as mean +/- standard deviation (n=2).  
G3.5-Gly-SN38 is represented by squares and G3.5-βAla-SN38 is represented by circles.  
Release in PBS with carboxylesterase (17.3 IU/ml) is depicted by solid lines with filled 






In comparison to SGF, G3.5-SN38 conjugates showed increased susceptibility for 
free drug release in the presence of SIF (Figure 4.3).  G3.5-βAla-SN38 showed up to 4% 
SN38 release in 24 hours in the presence of SIF, but the addition of pancreatin did not 
increase this release.  In contrast, G3.5-Gly-SN38 released up to 10% SN38 in the 
presence of SIF and up to 20% with the addition of pancreatin.  These results show that 
both conjugates are inherently more susceptible to hydrolysis in the basic pH of SIF 
compared to the acidic pH of SGF, which is common for ester linkages.  In addition, 
while G3.5-βAla-SN38 did not appear to be a substrate for pancreatin, G3.5-Gly-SN38 
showed increased release in the presence of pancreatin compared to SIF alone.  However, 
with a maximum of 20% release after 24 hours, both of these conjugates showed a low 
extent and slow rate of release in the intestinal environment. 
Finally, we examined the stability profile of the conjugates in the presence of liver 
carboxylesterase and in PBS alone (Figure 4.4).  Carboxylesterase is highly expressed in 
the liver environment and can be used to estimate the release in this milieu.  Both 
conjugates showed similar release profiles in PBS and SIF up to 24 hours, and the linear 
release kinetics continued until 48 hours, suggesting similar rates of hydrolysis in SIF and 
PBS without enzymes.  G3.5-βAla-SN38 did not show any additional release in the 
presence of carboxylesterase, suggesting that it is not a substrate for this enzyme.  In 
contrast, G3.5-Gly-SN38 showed a significant increase in SN38 release in the presence of 
carboxylesterase, achieving 56% release after 48 hours, illustrating that the ester bond in 
G3.5-Gly-SN38 can be cleaved by carboxylesterase to release free SN38 in the liver 
environment.  Taken together, these stability studies show that G3.5-βAla-SN38 is stable 





while G3.5-Gly-SN38 shows less stability in the gastric and intestinal environments and 
the greatest release in the presence of carboxylesterase, making it a potential candidate 
for oral delivery of SN38 to colorectal hepatic metastases. 
 
4.3.2 Short-Term Cytotoxicity 
Short-term cytotoxicity of G3.5 dendrimers, G3.5-SN38 conjugates and SN38 
was assessed in Caco-2 cells by the WST-1 cell viability assay.  This assay is predictive 
of the short-term effects of the conjugates on the intestinal barrier and also serves to 
ensure that cell viability is not compromised during the 2-hour time needed for transport 
and uptake assays.  Figure 4.5 shows the cell viability of Caco-2 cells treated for 2 hours 
with unmodified G3.5 dendrimers and G3.5-SN38 conjugates.  SN38 is also tested at 4, 
40 and 400 µM for comparison, corresponding to 1, 10 or 100% of the drug loading on 
the G3.5-βAla-SN38 conjugate.   
G3.5 dendrimers and G3.5-SN38 conjugates did not cause a significant reduction 
in cell viability up to 100 µM.  In contrast, despite the short treatment time, SN38 shows 
a significant reduction in cell viability at 40 and 400 µM, corresponding to approximately 
10% and 100% of the drug loading on the conjugates.  This suggests that conjugation of 
SN38 to G3.5 dendrimers is able to significantly reduce intestinal toxicity of SN38.  In 
addition, it is observed that G3.5-Gly-SN38 and G3.5-βAla-SN38 can be used in 







Figure 4.5. Caco-2 Cell Viability after Treatment for 2 hours with G3.5 Dendrimers, 
G3.5-SN38 Conjugates and SN38.  Results are reported as mean +/- standard deviation 
(n=6).  (**) and (***) indicate a statistically significant decrease in cell viability 
compared to HBSS control with p<0.01 and p<0.001, respectively.  G3.5 dendrimers and 
G3.5-SN38 conjugates do not show a reduction in cell viability up to 100 µM while 







4.3.3 Delayed Cytotoxicity 
In order to assess the potential long-term effects of G3.5 dendrimers and G3.5-
SN38 conjugates on the intestinal barrier, a delayed cytotoxicity assay was performed.  In 
this assay, Caco-2 cells were treated for 2 hours, the treatment was removed and the cells 
were incubated for an additional 24 hours in cell culture media.  This allows for the 
assessment of any potential delayed-onset responses of the cells to dendrimer treatment 
(e.g. apoptosis), which can be detected after 24 hours (Figure 4.6). Even after 24 hours, 
G3.5 dendrimers and G3.5-SN38 conjugates did not cause a statistically significant 
decrease in cell viability, with the exception of G3.5-Gly-SN38 at a 10 µΜ concentration, 
which displayed 85.4 % +/- 8.1% viability.  While this is a statistically significant 
decrease from the HBSS control, 85% viability is still considered to be acceptable in such 
viability assays and 10 µM treatment with G3.5-Gly-SN38 does not show a significant 
difference from 100 µM treatment with the same conjugate.  In contrast, SN38, which is 
known to cause apoptosis by inhibition of topoisomerase-1 [158], had a significant 
impact on cell viability 24 hours post treatment at 4, 40 and 400 µM concentrations.  This 
illustrates that by conjugating SN38 to dendrimers, intestinal toxicity is minimized 
compared to the free drug and that G3.5-SN38 conjugates should be safe for oral 
administration. 
 
4.3.4 Transepithelial Transport 
Transepithelial transport of G3.5-SN38 conjugates and free SN38 was measured 
across differentiated Caco-2 monolayers in the apical to basolateral direction and 






Figure 4.6. Caco-2 Cell Viability 24 hours after 2-hour Treatment with G3.5, G3.5-SN38 
Conjugates and SN38.  Results are reported as mean +/- standard deviation (n=6). (*) and 
(***) indicate a statistically significant decrease in cell viability relative to HBSS control 






Figure 4.7. Equivalent SN38 Flux across Differentiated Caco-2 Monolayers Treated with 
G3.5-SN38 Conjugates and SN38. Treatment concentrations of conjugates were 10 and 
100 µM, corresponding to 29, 290 and 40, 400 µM equivalents of SN38 for G3.5-Gly-
SN38 and G3.5-βAla-SN38 conjugates, respectively.  Equivalent SN38 flux was 
calculated by multiplying the measured molar flux of the conjugates with the number of 
SN38 molecules per dendrimer. Results are reported as mean +/- standard deviation 





SN38 was tested at 4 µM concentration since significant cytotoxicity was observed in 
Caco-2 cells treated with SN38 at 40 and 400 µM.   It has been shown that SN38 is 
transported across Caco-2 cell monolayers by an active transport pathway, and that 
increasing the concentration from 2.5 µM to 25 µM does not increase transepithelial flux 
[184].  This suggests that 4 µM SN38 should be beyond the saturation limit for transport 
and uptake, thus permitting direct comparison of SN38 flux to that of G3.5-SN38 
conjugates despite the difference in total drug concentration. 
Presence of free SN38 in the basolateral compartment was found to be less than 
5% of the amount transported for G3.5-Gly-SN38 and G3.5-βAla-SN38 conjugates (data 
not shown). Hence the measured flux is due almost entirely to transport of intact 
conjugate.  G3.5-Gly-SN38 at 100 µM and G3.5-βAla-SN38 at 10 µM and 100 µM 
showed a statistically significant increase in apical to basolateral SN38 flux relative to 
free drug (p<0.001).  Taking into account the drug loading on each conjugate (2.9 SN38 
per dendrimer for G3.5-Gly-SN38 and 4.0 SN38 per dendrimer for G3.5-βAla-SN38), the 
overall SN38 flux increase compared to free drug is 13, 159, 69 and 89-fold for G3.5-
Gly-SN38 at 10 µM and 100 µM and G3.5-βAla-SN38 at 10 µM and 100 µM, 
respectively.   These significant increases in the amount of SN38 transported across the 
monolayer indicate that G3.5 dendrimers are effective oral drug delivery carriers and can 





Interestingly, the impact of concentration on transport is different for G3.5-Gly-
SN38 and G3.5-βAla-SN38 conjugates.  G3.5-Gly-SN38 shows approximately a 10-fold 
increase in transport with a 10-fold increase in concentration, indicating that diffusion-
driven processes (i.e. paracellular transport) are predominantly involved.  In contrast, 
G3.5-βAla-SN38, shows minimal increase in transport with a 10-fold increase in 
concentration, suggesting that its epithelial flux may be controlled by a saturable, energy-
dependent mechanism with minimal paracellular transport.  Dendrimers have been shown 
to cross epithelia both by transcellular and paracellular pathways and the relative 
importance of each has been shown to be charge and surface chemistry dependent [149]. 
Factors such as the number of conjugated surface groups as well as the ability of these 
groups to shield the dendrimer surface charge have been found to impact the ability of 
dendrimers to open tight junction and overall mechanism of transport. Therefore, both the 
number of SN38 molecules conjugated and the identity of the linker could potentially 
impact the ultimate transport pathway.  These studies further confirm the importance of 
dendrimer surface chemistry and drug linker chemistry in the degree and mechanism of 
transport.  More detailed mechanistic studies, however, are required to explain the 
differences in transepithelial transport profiles of the two conjugates.  
 
4.3.5 Cellular Uptake 
Cellular uptake studies shed light on the contribution of the transcellular pathway 
to overall transepithelial transport as well as the ability of the carrier to promote drug 
uptake.  Cellular uptake of G3.5-SN38 conjugates and SN38 was measured in 






Figure 4.8. Cellular Uptake of G3.5-SN38 Conjugates and Free SN38 in Differentiated 
Caco-2 Monolayers after 2-hour Treatment on the Apical Side.  Results are reported as 
mean +/- standard deviation (n=4).  (*), (**), and (***) show statistical differences in 
uptake between groups with p < 0.05, 0.01 and 0.001, respectively.  All conjugates show 






Similar to the transport studies, free SN38 in the cells after a 2-hour treatment was 
found to be less than 5% of conjugate uptake (data not shown).  All conjugates tested 
showed a significant increase in uptake relative to free SN38.  This illustrates that G3.5 
dendrimers can enter cells more efficiently than SN38, and thus are suitable for cellular 
delivery.  Both G3.5-Gly-SN38 and G3.5-βAla-SN38 conjugates showed a significant 
increase in uptake (p<0.001) with increase in concentration.  However, for both 
conjugates the increase in uptake was less than the corresponding increase in 
concentration, suggesting the involvement of a saturable uptake mechanism, such as 
receptor-mediated endocytosis.  Interestingly, both conjugates showed similar uptake for 
the 100 µM treatment, suggesting that differences in overall transport may be due to 
differences in paracellular transport rather than transcellular transport at this 
concentration.  These results confirm that cellular uptake of G3.5-SN38 conjugates by 
Caco-2 cells plays a significant role in G3.5-SN38 conjugate transport.   
 
4.3.6 IC50 in HT-29 Cells 
Toxicity of G3.5-SN38 conjugates and free SN38 was determined in HT-29 cells 
for 48 hours in order to compare the activity of the free drug and dendrimer-drug 
conjugates (Figure 4.9). HT-29 cells are derived from human colon adenocarcinoma, are 







Figure 4.9. IC50 Curves of SN38, G3.5-Gly-SN38 and G3.5-βAla-SN38 in HT-29 Cells.  
SN38 is represented by inverted triangles, G3.5-Gly-SN38 by squares and G3.5-βAla-
SN38 by circles. Results are reported as mean +/- standard deviation (n=6).  IC50 values 
were determined from nonlinear sigmoidal dose response curve fitting by GraphPad 







SN38 showed the highest activity against HT-29 cells with an IC50 value of 66.3 
nM.  In contrast, SN38 conjugated to G3.5 dendrimers showed much lower activity with 
IC50 values of 0.60 µM and 3.59 µM for G3.5-Gly-SN38 and G3.5-βAla-SN38 
conjugates, respectively, corresponding to approximately 10 and 60 times less potency 
than the free drug.  Treatment with comparable G3.5 dendrimer concentrations did not 
cause any reduction in cell viability (data not shown), confirming that the carrier does not 
cause toxicity.  Since cytotoxicity is dependent on free drug release from the dendrimer 
backbone, the lower IC50 value for G3.5-Gly-SN38 compared to G3.5-βAla-SN38 is 
consistent with the higher release rate of SN38 from the G3.5-Gly-SN38 conjugate.  
Because the conjugates showed some release under acidic conditions and greater release 
at neutral pH, it is likely that the activity in HT-29 cells is due to a combination of 
extracellular release of SN38 in cell culture media and intracellular release. Further 
detailed studies are required to examine the relative contribution of extra- and 
intracellular drug release to cytotoxicity.  Importantly, despite the loss in efficacy 
compared to the free drug, the IC50 values of the G3.5-SN38 conjugates are still in the 
nanomolar to micromolar range, which is acceptable for therapy.  
 
4.4 Discussion 
Dendrimers have shown promise as oral drug delivery carriers due to their ability 
to translocate across the epithelial layer of the gut.  The impact of dendrimer properties 
such as generation, charge and concentration on transepithelial transport have been 
described in detail, but comparatively few reports have been published using dendrimers 





reported the use of G4 dendrimers complexed with SN38 through non-covalent 
interactions as a potential oral drug delivery system [150].  While the conjugates 
increased the transepithelial transport and cellular uptake of SN38, they released 40% of 
the drug within 24 hours in PBS and 90% of the drug within 30 minutes at pH 5.  
Because of the instability in acidic conditions, these dendrimer-SN38 complexes would 
have significant limitations for oral administration.  In addition, because of the high 
intrinsic toxicity of the G4 dendrimer carrier [16], these complexes could only be used up 
to a 10 µM concentration, limiting the amount of drug transported across the intestinal 
barrier and into the bloodstream.  
Vijayalakshmi and colleagues reported the preliminary synthesis and 
characterization of G3.5-SN38 conjugates with glycine and β−alanine linkers [161].  In 
this Chapter, we investigated the potential of these G3.5-SN38 conjugates for oral 
therapy of colorectal hepatic metastases.  The G3.5-SN38 conjugates have several 
advantages compared to the previously reported G4-SN38 complexes.  Because the drug 
is covalently conjugated to the dendrimer rather than complexed, the conjugates are 
relatively stable in the gastric and intestinal environments, minimizing premature drug 
release upon oral administration. In addition, the G3.5-Gly-SN38 conjugates release the 
drug in the presence of carboxylesterase, allowing for the targeted treatment of colorectal 
hepatic metastasis.  These systems can be used at higher concentrations (100 µM vs. 10 
µM) due to the low intrinsic toxicity of G3.5 dendrimers, allowing for greater drug 
transport across the gastrointestinal barrier and a higher dose at the site of action.  





dendrimer-SN38 complexes and are a significant step towards a functional dendrimer-
based oral drug delivery system. 
In order to determine their suitability for oral delivery, the stability of the 
conjugates in the gastrointestinal milieu as well as in the presence of liver 
carboxylesterase was investigated. G3.5-βAla-SN38 conjugates were significantly more 
stable than G3.5-Gly-SN38 under the conditions studied, releasing a maximum of 1% 
drug in SGF after 6 hours, 4% in SIF after 24 hours and 8% in carboxylesterase after 48 
hours.  In addition, in each of the release buffers, the addition of an enzyme did not 
increase the release of SN38, illustrating that G3.5-βAla-SN38 is not susceptible to 
enzymatic cleavage.  In contrast, G3.5-Gly-SN38 showed much higher release in all of 
the conditions and showed increased rate and extent of release in the presence of 
pancreatin and carboxylesterase compared to buffer alone.  Previous studies conjugating 
CPT to poly(l-lysine) dendrimers using glycine and β-alanine linkages at the 20-OH 
position showed similar results with the glycine linker indicating higher rates of 
hydrolysis than the stable β−alanine linker [185]. Although the β−alanine linker provides 
an extra methyl group as a spacer, this group appears to stabilize the bond against 
hydrolysis and enzymatic degradation.   
The impact of linker chemistry on SN38 release shows a direct correlation with 
the IC50 values in which the G3.5-Gly-SN38 conjugates had six-fold greater efficacy than 
G3.5-βAla-SN38 conjugates, illustrating the importance of SN38 release for anti-cancer 
activity.  Since the conjugates were relatively stable at lower pH it is likely that only a 
small percentage of the drug was released in the intracellular acidic environment with the 





showed a two-fold increase in SN38 release from G3.5-Gly-SN38 compared to G3.5-
βAla-SN38, suggesting additional enzymatic mechanisms may play a role in enhancing 
G3.5-Gly-SN38 efficacy by 6-fold.  Comparing the release profiles with and without 
enzymes, an increased release of SN38 from G3.5-Gly-SN38 in the presence of 
pancreatin and carboxylesterase was observed, but no such increase for G3.5-βAla-SN38 
was seen, indicating the increased susceptibility of the glycine linker to enzymatic 
degradation.  
In addition to differing release and toxicity profiles, G3.5-Gly-SN38 and G3.5-
βAla-SN38 conjugates showed significant differences in transepithelial transport.  Both 
conjugates showed increased flux of SN38 relative to free drug, which is critical for 
improving the oral bioavailability of SN38.  In addition, neither conjugate showed short- 
or long-term effects on Caco-2 cells after a 2-hour treatment, illustrating that conjugation 
of SN38 to G3.5 dendrimers can minimize intestinal toxicity while maximizing transport.   
Interestingly, transport of G3.5-Gly-SN38 was highly concentration-dependent while 
G3.5-βAla-SN38 flux was unchanged between treatment with 10 and 100 µM 
concentrations.  This suggests that G3.5-Gly-SN38 may be transported primarily by a 
concentration gradient-driven process, such as paracellular diffusion, whereas a saturable 
process, such as transcellular transport, governs G3.5-βAla-SN38 transport. This 
phenomenon, however, needs further examination.  While the uptake data suggests 
comparable uptake of the conjugates at 100 µM this measurement could include surface 
bound dendrimer or dendrimer that would be degraded in the cell and not transcytosed.  
Therefore, reduction in G3.5-βAla-SN38 transport at 100 µm compared to G3.5-Gly-





In Chapter 5 we will show the impact of surface chemistry on the mechanism of transport 
and uptake of PAMAM dendrimers.  Specifically, reduction of surface charge on G3.5 
dendrimers by the addition of low molecular weight poly (ethylene glycol) is found to 
reduce tight junction opening, transepithelial transport and uptake in Caco-2 cells.  Thus, 
it is possible that addition of a methyl group in the β-alanine linker as well as the increase 
of drug loading from 2.9 to 4.0 molecules of SN38 increased the hydrophobicity of the 
conjugates, hence reducing the degree to which G3.5-βAla-SN38 conjugates opened the 
tight junctions, resulting in an overall transport mechanism dominated by the transcellular 
route.  Importantly, these studies illustrate the choice of drug linker and the degree of 
drug loading not only impact drug release and ultimate efficacy but can also impact 
transport.  Therefore, dendrimer-drug conjugates for oral delivery must be carefully 
designed to meet transport, release and efficacy demands.   
 
4.5 Conclusion 
In this Chapter we investigated G3.5-SN38 conjugates for oral delivery of SN38 
by determining their in vitro release profiles in simulated gastric and intestinal conditions 
and in the presence of carboxylesterase, their toxicity against intestinal cells and target 
colorectal cancer cells, and their transepithelial transport and cellular uptake in Caco-2 
monolayers.  We demonstrated that conjugation of SN38 to G3.5 dendrimers increased 
the transepithelial transport while simultaneously reducing intestinal toxicity compared to 
free SN38, illustrating the potential for these conjugates in oral drug delivery.  A 
significant impact of linker chemistry on drug release and efficacy in HT-29 cells was 





G3.5-βAla-SN38 conjugates.  The drug linker chemistry and drug loading also impacted 
the transport pathway with G3.5-Gly-SN38 having a concentration-dependent transport 
profile and G3.5-βAla-SN38 conjugates having a saturable transport profile.  G3.5-Gly-
SN38 shows promise for oral delivery of SN38 for the treatment of colorectal hepatic 
metastases.  Treatment with 100 µM G3.5-Gly-SN38 caused a 159-fold increase in SN38 
transepithelial transport compared to free SN38 illustrating its potential to enhance SN38 
bioavailability.  In addition, G3.5-Gly-SN38 was relatively stable in gastric and intestinal 
milieu with increased release in the presence of liver carboxylesterase.  Finally, G3.5-
Gly-SN38 shows an IC50 of 0.60 µM in HT-29 cells, which is acceptable for cancer 
therapy. Together these results show that PAMAM dendrimers have the potential to 
improve the oral bioavailability of potent anti-cancer therapeutics and that appropriate 









Chapter 5 : Transepithelial Transport of PEGylated Anionic Poly (amido 
amine) Dendrimers: Implications for Oral Drug Delivery 
 
5.1 Introduction 
As illustrated in Chapter 4, PAMAM dendrimers can effectively enhance 
transepithelial transport of SN38.  Previous studies in our laboratory [15, 18, 24, 148, 
149] and others [19, 144, 186, 187] indicate that dendrimers in a specified size and 
charge window can effectively translocate across the gastrointestinal epithelia.  In 
addition, several studies have demonstrated that conjugation or complexation of drugs 
with PAMAM dendrimers can enhance the oral bioavailabilty of drugs normally limited 
to intravenous administration, supporting dendrimers as viable oral drug delivery carriers 
[20, 113, 150, 151].  Due to their intrinsically low cytotoxicity and appreciable 
transepithelial permeation characteristics across Caco-2 monolayers and everted rat 
intestinal sac models [15, 144], anionic dendrimers show distinct advantages as vehicles 
for oral drug delivery, with higher generation dendrimers showing the greatest potential 
because of their large number of modifiable surface groups.  As demonstrated in Chapter 
4, in addition to the surface charge, the drug linker can also play a significant role in 
transport and drug release.  This Chapter aims to evaluate the potential of G3.5 and G4.5 
dendrimers in facilitating the delivery of drugs across the gastrointestinal tract, 
specifically examining the effect of poly (ethylene glycol)  (PEG) surface modification. 
PEGylation of drug delivery systems and bioactive agents is known to reduce 





enhance water solubility [188].  Okuda and colleagues [189, 190] showed that 
PEGylation of dendritic systems produces desirable biodistribution effects upon 
intravenous administration; however, the impact of PEGylation on transepithelial 
transport of PAMAM dendrimers across intestinal cells is presently unknown.  In the 
context of oral drug delivery, PEG can be used as a surface modifier to modulate the 
degree and mechanism of transport or it can act as drug linker, altering release properties 
from the polymer backbone. In this Chapter we describe the synthesis and 
characterization of differentially PEGylated G3.5 and G4.5 anionic PAMAM dendrimers 
and evaluate their cytotoxicity, cellular uptake and transport across Caco-2 cell 
monolayers. In addition, the effect of PEGylation on tight junction modulation was 
investigated. These studies provide the first evidence of the impact of PEG conjugation 
on dendrimer transepithelial transport.  
 
5.2 Materials and Methods 
5.2.1 Materials 
PAMAM G3.5 (reported molecular weight=12,931) and PAMAM G4.5 (reported 
molecular weight 26,258), [14C]-mannitol (specific activity 50mCi/mmol), D2O, and 
Hank’s balanced salt solution (HBSS buffer) salts were purchased from Sigma Aldrich 
(St. Louis, MO). [3H]-Acetic anhydride was purchased from American Radiolabeled 
Chemicals (St. Louis, MO). Superose 12 HR 10/300 GL column was purchased from 
Amersham Pharmacia Biotech (Piscataway, NJ). Caco-2 cells were purchased from 





purchased from Roche Applied Science (Indianapolis, IN). The BD Biocoat Caco-2 
Assay was purchased from BD Biosciences (San Hose, CA).  
 
5.2.2 Conjugation of mPEG750 to PAMAM Dendrimers  
PEGylation of PAMAM G3.5 and G4.5 was achieved by formation of ester bonds 
between surface carboxyl groups of the dendrimers and hydroxyl terminated PEG 
(Molecular Weight (Mw) 750) using benzotriazole-1-yl-oxy-tris-(dimethylamino)-
phosphoniumhexafluorophosphate (BOP) as a coupling agent and methanol as a solvent 
(Figure 5.1). 1, 2 and 4 equivalents of methoxy polyethylene glycol (mPEG) were reacted 
with dendrimers to yield samples G3.5-P1, G3.5-P1.4 and G3.5-P2.3, G4.5-P.85, G4.5-
P1.9 and G4.5-P2.8 respectively, where G represents the generation number and P 
represents the number of PEG chains conjugated. For each reaction, 75 mg of dendrimer 
and three equivalents of BOP per equivalent of mPEG were dissolved in anhydrous 
methanol. mPEG750 was dissolved in methanol to a concentration of 100 mg/mL and the 
appropriate molar equivalent was added to the mixture. The solution was stirred at room 
temperature for 72 hours, after which methanol was evaporated to leave the crude 
product. This product was dissolved in distilled water and purified by dialysis against 
distilled water using 3,500 molecular weight cut off (MWCO) membranes (Spectrum 
Laboratories, Rancho Dominguez, CA). Subsequently, the product was freeze dried and 














5.2.3 Characterization of PEGylated G3.5 and G4.5 Dendrimers 
Dendrimer-PEG conjugates were characterized by size exclusion chromatography 
(SEC) using an Acta FPLC system (Acta UPC 900, P-920, INV-907 from GE 
Healthcare) and phosphate buffered saline (PBS, pH 7.4) with 0.05% sodium azide as the 
eluent.  Samples were injected onto the FPLC system at 5 mg/mL and simultaneously 
monitored for Ultra-Violet (UV), Refractive Index (RI), Multi-Angle Laser Light 
Scattering (MALLS) and Dynamic Light Scattering (DLS) detection.  SEC was used to 
confirm the absence of low molecular weight impurities and to compare the elution 
volumes of modified and native dendrimers.  In addition, the dendrimer peak was 
analyzed to determine the hydrodynamic radius using a Wyatt Quasi-Elastic Light 
Scattering Detector (QELS) and the calculations were performed using the Astra 5.3.4 
software.  All samples were run in duplicate. 1H NMR was used to determine the 
number of PEG chains conjugated per dendrimer.  1H NMR samples were prepared at 
approximately 8 mg/mL in D2O with 0.05 wt % 3-(trimethylsilyl) propionic-2,2,3,3-d4 
acid (TSP-d4). 1H Nuclear Magnetic Resonance (NMR) spectra were obtained using 
Varian 500 MHz FT NMR and were processed using Spinworks software (Kirk Marat, 
University of Mannitoba, Winnipeg, Canada, © 2008). The number of PEG chains per 
dendrimer was determined from ratios of integral values for peaks assigned to PEG (3.6-
3.7 ppm) and dendrimer (2-3.6).  Finally, the zeta potential of PEGylated dendrimers was 
obtained using the Malvern Nano-ZS system.  Dendrimer solutions were prepared at 5 







5.2.4 Synthesis of Radiolabeled Dendrimers 
Dendrimers and dendrimer-PEG conjugates were radiolabeled using [3H]-acetic 
anhydride (American Radiolabeled Chemicals, St. Louis, MO) which reacts with internal 
amines known to be present in carboxyl terminated dendrimers due to defects formed 
during their synthesis [191]. Dendrimers and dendrimer-PEG conjugates were dissolved 
in methanol and reacted with three equivalents of [3H]-acetic anhydride in the presence of 
excess triethylamine overnight. The methanol was dried under a stream of nitrogen and 
the product was redissolved in distilled water. Triethylamine and unreacted acetic 
anhydride were removed by Sephadex G-25 protein desalting (PD10) columns. Specific 
activities of the radiolabeled compounds were also calculated. 
 
5.2.5 Caco-2 Cell Culture 
Caco-2 cells (passages 20-40) were cultured as described in Section 3.2.3.  
 
5.2.6 Cytotoxicity Assay 
Cytotoxicity of unmodified and differentially PEGylated PAMAM dendrimers 
was assessed by the water soluble tetrazolium salt (WST-1) assay as described in Section 
3.2.4. 
 
5.2.7 Cellular Uptake Studies 
The effect of PEGylation on cellular uptake of radiolabeled dendrimers was 
investigated. Caco-2 cells were seeded at 40,000 cells/ well in 24-well cell culture plates 





48 hours. Cells were washed with warm HBSS buffer and 300 µL of 0.02 mM dendrimer 
solution in HBSS was added for 30 or 60 minutes. After the given incubation period, the 
cells were washed twice with ice cold HBSS to halt the uptake process. They were then 
lysed with NaOH and neutralized with HCl. Uptake was measured by quantifying the 
cell-associated radioactivity using a liquid scintillation counter (Beckman Coulter, 
Fullerton, CA) with Econosafe scintillation cocktail (Research Products International, 
Mount Prospect, IL). Uptake was normalized to total protein content using the 
Bicinchoninic acid (BCA) protein assay kit (Pierce, Evanston, IL). Statistical significance 
was determined by a two-way analysis of variance and Bonferroni post-hoc correction. 
 
5.2.8 Transepithelial Permeability Assessment 
The effect of differential PEGylation on transport of radiolabeled dendrimers 
across Caco-2 cell monolayers was assessed in the BD Biocoat HTS Caco-2 Assay 
System (BD Biosciences, San Hose, CA). The three-day assay protocol defined by the 
manufacturer was used to prepare the monolayers. Briefly, Caco-2 cells were grown past 
confluency to a density of >250,000 cells/cm2 in T-25 flasks. Cells were seeded at 
200,000 cells per well, in 24-well Transwell® plates with fibrillar collagen-coated cell 
culture inserts in basal cell seeding medium supplemented with MITO+ (mitogenic 
stimulating) serum extender and 10% FBS. After 24 hours, the medium was switched to 
entero-STIM, a fully defined media containing butyric acid, which induces differentiation 
of intestinal epithelial cells and form a competent monolayer [192]. After an additional 
48 hours, the monolayers were used for experiments. Cells were washed twice with warm 





was added to the apical compartment and 600 µL of HBSS added to the basal 
compartment. After 2 hours, 400 µL from the basal compartment was taken for 







 (Eq. 5.1) 
where dQ/dt is the change in the amount of solute over time (permeability rate), A is the 
surface area of the insert, and C0 is the donor concentration. [14C]-Mannitol was used to 
monitor monolayer integrity. The transepithelial flux of the paracellular marker [14C]-
mannitol was 2.6 x 10-6 cm/s, which demonstrates monolayer integrity as shown 
previously [193, 194]. Statistical significance was determined by Tukey’s Multiple 
Comparison test. 
 
5.2.9 Occludin Staining 
Caco-2 cells were seeded at 20,000 cells/cm2 on collagen-coated four chamber 
culture slides (BD Biosciences, Bedford MA), maintained under normal cell culture 
conditions for 5 days and used for experiments when the cells reached confluence. The 
cells were equilibrated in HBSS for 2 hours prior to the experiment. The cells were 
incubated with 300 µl of 0.1 mM dendrimer solutions for 2 hours at 37ºC and then 
washed three times with ice cold PBS to remove the dendrimers. G3.5, G3.5-P1, G4.5 
and G4.5-P.85 were used with HBSS as a control. The cells were then fixed with 300 µl 
of 4% paraformaldehyde solution for 20 minutes at room temperature, washed twice with 
25 mM glycine and once with PBS and then permeabilized with 300 µl of 0.2% Triton X-
100 in blocking solution made of 1% bovine serum albumin (BSA) in PBS for 20 





incubated with blocking solution for 30 minutes. The blocking solution was removed and 
the cells were incubated with 300 µl of 2 µM mouse anti-occludin (Invitrogen (Zymed), 
Carlsbad, CA) and kept at 4ºC overnight. Cells were washed three times with blocking 
solution and then incubated with the same solution for 30 minutes. After the blocking 
solution was removed, the cells were incubated with 300 µl of 10 µg/mL Alexa Fluor 568 
goat anti-mouse IgG (H+L) (Invitrogen, Molecular Probes, Carlsbad, CA) for 1 hour. 
They were then washed three times with PBS and the chambers were removed. Gel 
mount was added to each region and allowed to dry for 2 hours at room temperature. The 
slides were then sealed with clear nail polish and kept at 4ºC prior to visualization.  
Slides were visualized using a Zeiss LSM510 META confocal laser scanning 
microscope (Carl Zeiss, Jena, Germany). Alexa Fluor 568 was visualized with excitation 
and emission wavelengths of 543 and 603 nm respectively. Z-stacks were obtained with 
the following microscope settings: 63x oil objective, 1 airy unit pinhole, 543 nm laser set 
to 20% power with 1000 gain, 0.1 amplifier offset and 1 amplifier gain. The scan speed 
was set to 8 in line mode with mean averaging set to 4. Z-stack sections were taken 0.5 
µm apart with 15 sections per region. Three z-stacks were acquired per treatment and 
analyzed using Volocity 3D imaging software. (Version 4.3.2; Improvision, Inc., 
Lexington, MA). Red voxels, corresponding to occludin staining, were quantified by 
thresholding the intensity between 25% and 100%. The number of red voxels was 
quantified for each region and normalized to the number of cells. Results are reported as 
mean ± standard deviation and statistical significance was determined using a one-tailed 







5.3.1 Synthesis and Characterization of PEGylated Anionic PAMAM Dendrimers 
1H NMR studies confirmed the formation of the conjugates with new peaks 
corresponding to the protons from PEG.  1H NMR spectra are shown in Appendix 3. 1H 
NMR quantification showed a concomitant increase in the number of PEG moieties 
conjugated with the number of equivalents of PEG, but this increase was less than the 
stoichiometric amount used (Table 5.1). This may be attributed to steric hindrance, which 
was more evident in lower generation dendrimers likely due to their lower number of 
available acid groups and smaller surface area. 
Characterization by SEC showed the absence of free PEG and other small 
molecular weight impurities (data not shown).  Elution volumes of native and PEGylated 
dendrimers are shown in Table 5.1.  While there is a decrease in elution volume from 
G3.5 dendrimers to G4.5 dendrimers due to the larger size, native and modified 
dendrimers of the same generation do not show any significant differences in elution 
volume.  This illustrates that PEGylation does not increase the hydrodynamic volume of 
the dendrimers, suggesting that PEG is preferentially wrapped around the dendrimer 
rather than protruding from the surface.  Hydrodynamic radii of the conjugates measured 
by dynamic light scattering support this hypothesis (Table 5.1).  Increasing the degree of 
PEGylation does not increase the hydrodynamic radii. In fact, the hydrodynamic radii are 
slightly decreased, indicating that PEG may shield the surface charge and decrease 
charge-charge repulsion of functional groups and therefore the size of the polymers in 

























G3.5 - - 12931 1.06 13.2 1.90 ± 0.00 
G3.5-P1 1 1.01 13688 3.25 13.2 1.65 ± 0.07 
G3.5-P1.4 2 1.36 13951 3.96 13.2 1.65 ± 0.07 
G3.5-P4.5 4 2.32 14671 3.91 13.2 1.70 ± 0.00 
G4.5 - - 26258 2.64 12.8 2.35± 0.07 
G4.5-P.85 1 0.85 26896 4.47 12.5 2.10 ± 0.00 
G4.5-P1.9 2 1.86 27653 5.11 12.6 2.15 ± 0.07 
G4.5-P2.8 4 2.80 28358 4.81 12.6 2.10 ± 0.00 
*Calculated from NMR data 





Zeta potential measurements shed light on the impact of PEGylation on dendrimer 
surface charge.  Figure 5.2 illustrates that zeta potential becomes less negative upon 
further PEGylation, with G3.5 and G4.5 dendrimers showing similar behavior, 
confirming that PEG shields surface charge. Shcharbin et al. [195] reported a zeta 
potential for G4.5 PAMAM dendrimers in deionized water as -56 ± 0.5 mV.  Comparing 
this with our data shows that even one PEG is able to shield a significant amount of 
charge on the dendrimer surface.  
 
5.3.2 Short-Term Cytotoxicity  
While amine-terminated PAMAM dendrimers are known to be highly cytotoxic at 
higher generations, anionic dendrimers have been found to be much less toxic [16]. In 
this study we examined whether PEGylation of anionic dendrimers would influence their 
toxicity profile. G3.5 and G4.5 dendrimers and dendrimer-PEG conjugates were tested at 
concentrations up to 0.1 mM and did not show appreciable cytotoxicity (cell viability > 
90%) over the entire range of concentrations tested (Figures 5.3, 5.4). This toxicity 
profile confirmed that treatment of Caco-2 cells with up to 0.1 mM of the dendrimer-PEG 
conjugates would not affect cell viability during uptake or transport experiments.  In 








Figure 5.2. Zeta Potential of PEGylated G3.5 and G4.5 PAMAM Dendrimers.  Zeta 
potential becomes less negative with addition of PEG to G3.5 and G4.5 dendrimers. 







Figure 5.3. Caco-2 Cell Viability in the Presence of G3.5 Native and PEGylated 
Dendrimers after a 2-hour Incubation Time.  Results are reported as mean +/- standard 







Figure 5.4. Caco-2 Cell Viability in the Presence of G4.5 Native and PEGylated 
Dendrimers after a 2-hour Incubation Time.  Results are reported as mean +/- standard 








5.3.3 Cellular Uptake 
The impact of PEGylation on time-dependent cellular uptake of dendrimers was 
assessed in Caco-2 cells (Figures 5.5, 5.6). Uptake studies shed light on the degree to 
which the dendrimers are transported through transcellular pathways (passive diffusion 
and vesicular mechanisms) in the gastrointestinal epithelium and their eventual uptake in 
tumor cells at the site of action. In general, PEGylation decreased uptake of G3.5 
dendrimers, but this effect is statistically significant only after 60 minutes. Notably, there 
is no significant impact of the degree of PEGylation on uptake, i.e. a single PEG chain 
can reduce dendrimer uptake by almost 50% after a 60-minute incubation period. In 
contrast, for G4.5 dendrimers, conjugation of 1 PEG chain appears to increase uptake, 
with further addition of PEG decreasing uptake from this point.  
 
5.3.4 Transepithelial Transport 
In order to assess the suitability of PEGylated dendrimers for oral drug delivery, 
their transport across Caco-2 cell monolayers was studied and compared to unmodified 
dendrimers. Transport experiments complement the uptake studies, giving an overall 
picture of transepithelial transport including both transcellular and paracellular pathways. 
PEGylation significantly decreased transport of both G3.5 and G4.5 dendrimers (Figures 
5.7, 5.8), yielding apparent permeabilities approximately 60-70% lower than unmodified 
dendrimers. Despite this decrease in overall transport flux, PEGylated dendrimers still 
show appreciable transport compared to traditional linear polymers [196], indicating that 
the PEGylated dendrimers continue to enhance their own transport to some degree. 






Figure 5.5. Uptake of G3.5 Native and Differentially PEGylated Dendrimers. 
Caco-2 cells were treated at 0.02 mM for 30 and 60 minutes. Results are reported as 
mean +/- standard deviation (n=3). (**) and (***) denote significant differences from 






Figure 5.6. Uptake of G4.5 Native and Differentially PEGylated Dendrimers.  Caco-2 
cells were treated at 0.02 mM for 30 and 60 minutes. Results are reported as mean +/- 
standard deviation (n=3).  (*),(**) and (***) denote significant differences from 






Figure 5.7. Apparent Permeability of G3.5 Native and Differentially PEGylated 
Dendrimers.  Caco-2 cell monolayers were treated at 0.1 mM for a 2-hour incubation 
time. Results are reported as mean +/- standard deviation (n=3).  (*) denotes a significant 






Figure 5.8. Apparent Permeability of G4.5 Native and Differentially PEGylated 
Dendrimers.  Caco-2 cell monolayers were treated at 0.1 mM for a 2-hour incubation 
time. Results are reported as mean +/- standard deviation (n=3).  (*) denotes a significant 







5.3.5 Tight Junction Opening Monitored by Occludin Staining 
To further assess the influence of dendrimer PEGylation on tight junctional 
modulation, Caco-2 cells were pretreated with native and PEGylated dendrimers and 
stained for occludin, a marker protein for tight junction integrity [15].  Previously, it was 
shown that Caco-2 cells treated with 1 mM G1.5, G2.5 and G3.5 dendrimers showed 
disrupted occludin staining patterns and increased occludin accessibility as compared to 
cells with no polymer treatment [15]. In this study, we used a ten-fold lower 
concentration (0.1 mM) in order to mimic the conditions used in the transport assay. 
Control cells treated with HBSS alone (Figure 5.9 E) show thin lines of red staining 
corresponding to occludin proteins linking cell membranes. In contrast, dendrimer-treated 
cells (Figure 5.9A-D) show brighter, wider bands of staining with increased intracellular 
staining, indicating accessibility of occludin protein to its antibody due to the opening of 
the tight junctions. In the case of G3.5 (Figure 5.9 A) confocal images show some 
amount of cell detachment, indicating tight junction opening. All dendrimers studied 
showed a statistically significant increase in occludin staining compared to the HBSS 
control (p<0.05) (Figure 5.10), illustrating that native and PEGylated dendrimers open 
tight junctions to some degree, even at relatively low concentrations (0.1 mM).  
 
5.4 Discussion 
In this chapter, we investigated the impact of differential PEGylation of G3.5 and 
G4.5 dendrimers on uptake, transport and tight junction modulation in the context of oral 
delivery. Differential PEGylation of G3.5 and G4.5 dendrimers led to significant 






Figure 5.9. Staining of the Tight Junction Protein Occludin in the Presence and Absence 
of Dendrimers Visualized by Confocal Microscopy.  Caco-2 cells incubated for 2 hours 
with 0.1 mM (A) G3.5, (B) G3.5-P1, (C) G4.5, (D) G4.5-P.85 and (E) with no polymer 
treatment. Main panels illustrate the xy plane; horizontal bars illustrate the xz plane; 






Figure 5.10. Quantification of Occludin Staining in the Presence and Absence of 
Dendrimers.  Results reported are number of “red” voxels per region normalized to the 
number of cells in each region, mean +/- standard deviation (n=3). One-tailed Student’s t-
tests were used to determine statistical significance. (*) and (**) denote significant 





PEG.  The flexible chain of PEG can wrap around the rigid, spherical dendrimer and 
shield some of the negative charge on the dendrimer surface. Methoxy-terminated 750 Da 
PEG contains 16 subunits, giving it an overall extended chain length of 5.7 nm based on 
calculated bond lengths and angles. In comparison, G3.5 dendrimers have a reported 
diameter of approximately 4 nm and G4.5 dendrimers approximately 5 nm [136]. This 
suggests that the PEG chain, due to its flexible random coil conformation, is of 
comparable size to the dendrimers. For the smaller G3.5 dendrimers, one PEG chain is 
enough to reduce the interactions with the cells, leading to decreased cellular uptake for 
all PEGylation ratios.  This may be due to a stealth-like effect imposed by PEG, creating 
fewer interactions between the dendrimers and the cells. In contrast, for G4.5 dendrimers, 
addition of 1 PEG chain actually increases uptake as compared to unmodified G4.5. This 
may be explained by the charge density of the dendrimers, which can be calculated by 
dividing the number of charges (64, 128) by the surface area of the dendrimer, assuming 
a spherical conformation [197].  The higher charge density of G4.5 dendrimers (1.6 
charges/nm2) compared to G3.5 dendrimers (1.3 charges/nm2) can presumably cause 
repulsion with the negatively charged cell membrane.  Addition of 1 PEG chain reduces 
the charge on the surface, increasing the uptake to a point comparable to G3.5 
dendrimers.  However, addition of more PEG shields more of the negative charge, again, 
creating a stealth system and decreasing cellular uptake.   
Correlating the uptake of the dendrimers with the zeta potential data shows that 
there may be an ideal zeta potential around -30 mV that promotes cellular uptake.  In 
general, dendrimers with zeta potentials more negative than -30 mV had reduced cellular 





G3.5) also show lower uptake.  Interestingly, incubation time-dependent behavior was 
observed between dendrimer generations. While there is no statistical difference between 
uptake of unmodified or PEGylated G3.5 at 30 and 60 minutes, there is a significant 
increase (p<0.01) in uptake for the G4.5 dendrimers, suggesting that steady-state uptake 
of these larger dendrimers has not yet been achieved.  
Dendrimers are known to be transported across Caco-2 cell monolayers by both 
transcellular and paracellular pathways [16, 18, 147, 148]. Uptake studies and tight 
junction modulation experiments in Caco-2 cells help to elucidate the relative 
contributions of these processes.  Because PEGylation of G3.5 dendrimers decreases 
uptake, this surface modification may be of use in cases where it is desirable to transport 
the cargo across the cells while avoiding entrapment within the cells.  Combining the 
uptake results with the occludin staining results allows us to understand the relative 
contributions of paracellular and transcellular transport of PEGylated dendrimers 
compared to unmodified dendrimers. In the case of G3.5 dendrimers, PEGylation causes 
a significant decrease in uptake and a moderate decrease in tight junction modulation, 
indicating that these dendrimers have less paracellular and less transcellular transport 
compared to unmodified dendrimers. By contrast, PEGylation of G4.5 dendrimers causes 
a modest increase in uptake and has only slightly more occludin accessibility than the 
control, suggesting that PEGylated G4.5 dendrimers have more transcellular transport 
and much less paracellular transport than unmodified G4.5 dendrimers. This sheds light 
on how PEGylation can impact transport mechanisms as well as overall transport rates. 





suggest that overall, anionic dendrimers are transported primarily through the paracellular 
route. 
PAMAM dendrimers can be used for oral drug delivery to release drugs in the 
gastrointestinal tract and transport drugs into or across the intestinal barrier. PEGylation 
of PAMAM dendrimers can modulate toxicity, functionalize the surface for drug 
conjugation and facilitate drug release. While PEGylation decreases the transepithelial 
transport of anionic dendrimers, the conjugates still show appreciable transport, 
compared to traditional linear polymers [196], and have the potential for increased 
functionality. This work demonstrates that degree of PEGylation and dendrimer 
generation can modulate the mechanisms of transport, and can be custom tailored for 
different oral drug delivery applications.  
 
5.5 Conclusion 
In this Chapter we described the effect of PEGylation on cytotoxicity, uptake and 
transport of G3.5 and G4.5 anionic PAMAM dendrimers across Caco-2 cells. In the 
concentration range studied, PEGylation of these dendrimers maintained cell viability. 
PEGylation decreased uptake and transport for G3.5 dendrimers, whereas PEGylated 
G4.5 dendrimers demonstrated increased uptake with a concomitant decrease in overall 
dendrimer transport. Occludin staining of Caco-2 cell monolayers in the presence of 
conjugates showed that PEGylated dendrimers opened the tight junctions to a lesser 
extent than native dendrimers, indicating a reduction in paracellular transport. While 
PEGylated dendrimers showed decreased transport rates, they were still transported to an 





advantages of facilitated drug conjugation and release as well as potential for improved 
biodistribution. Together these studies demonstrate that in the design of PAMAM-PEG 
conjugates for oral drug delivery, the extent of transepithelial transport, uptake as well as 
the mechanism of transport can be controlled by a judicious choice of dendrimer 
generation and degree of PEGylation.  These parameters can be custom- tailored to the 








Chapter 6 : Conclusions and Future Directions 
 
6.1 Conclusions 
Oral administration of polymer-drug conjugates for cancer treatment has the 
potential to improve the lives of cancer patients by reducing hospital visits and treatment 
costs while improving therapeutic efficacy of the drug by minimizing side effects and 
enhancing drug concentration at the tumor site.  Due to the large number of emerging 
small molecule chemotherapy drugs with poor water solubility, low bioavailability and 
significant off-target toxicities, there is a significant need for orally administrable 
polymer therapeutics.  As described in Chapter 2, it has been previously established that 
within a size and charge window, poly (amido amine) (PAMAM) dendrimers can 
permeate the epithelial layer of the gut.  In this dissertation we evaluated anionic 
PAMAM dendrimers for their potential as oral drug delivery carriers and investigated the 
mechanisms by which they are transported across the epithelial barrier. 
In Chapter 3 we demonstrated that G3.5 dendrimers are endocytosed by dynamin-
dependent mechanisms, and that cellular internalization occurs by clathrin- and caveolin-
mediated endocytosis while transcytosis is governed by clathrin-mediated pathways.  We 
further confirmed the clathrin-endocytosis mechanism by monitoring G3.5 trafficking to 
the endosomes and lysosomes up to 30 minutes after cellular internalization.  These 
studies illustrate that dendrimers take advantage of receptor-mediated mechanisms for 
cellular entry and can be found in the lyososomal and endosomal compartments after 
cellular uptake.  This knowledge will aid in the design of PAMAM dendrimers for oral 





locally targeted to the intestinal tissue for the treatment of diseases such as Crohn’s, a 
pH-sensitive or lysosomal enzyme-cleavable linker could be used to promote drug release 
in the intestinal cells.  Alternatively, in the case of a chemotherapy drug that must be 
targeted to a distant tumor site, the linker could be designed to avoid release in these 
compartments to minimize intestinal toxicity. Thus, knowledge of the cellular entry route 
and sub-cellular trafficking of the dendrimer carrier will aid in rational design of 
dendrimers for drug delivery applications.  In Chapter 3, we monitored tight junction 
opening by dendrimers in the presence and absence of dynasore, a compound that inhibits 
dynamin-dependent endocytosis.  Tight junction opening was found to be significantly 
decreased in the presence of dynasore suggesting that dendrimer cellular internalization 
may be a requisite step prior to opening of tight junctions by dendrimers.  This implies 
that dendrimer modulation of tight junctions is not simply due to chelation of 
extracellular calcium, but may be a more complicated mechanism triggered by an 
intracellular signaling cascade that acts on the tight junction proteins. This illustrates the 
interconnectedness of the transcellular and paracellular routes. Importantly, this type of 
intracellular regulation is reversible, preventing permanent damage to the tight junctions 
and suggesting the safety of dendrimers as permeation enhancers.  
In Chapter 4 we investigated G3.5-SN38 conjugates for oral delivery of the 
poorly-bioavailable chemotherapy drug SN38 in targeting colorectal hepatic metastases.  
In particular, we examined G3.5-Gly-SN38 and G3.5-βAla-SN38 conjugates.  These 
conjugates reduced the toxicity of SN38 towards intestinal cells and maintained Caco-2 
cell viability with treatment concentrations of up to 100 µM for 2 hours.  This illustrates 





gastrointestinal toxicities associated with SN38.  In addition, both conjugates increased 
the transport of SN38 across Caco-2 cell monolayers, improving transport up to 160-fold 
compared to free drug, showing their potential in improving the oral bioavailability of 
SN38.  Release profiles of the conjugates showed that G3.5-βAla-SN38 was very stable, 
with only 1%, 4% and 8% release in SGF with pepsin, SIF with pancreatin and PBS with 
carboxylesterase at 6, 24 and 48 hours respectively.  In contrast, G3.5-Gly-SN38 showed 
lower gastrointestinal stability with 10% and 20% released in the simulated gastric and 
intestinal environments with increased release in the presence of pancreatin compared to 
SIF alone.  In addition, G3.5-Gly-SN38 released up to 56% of SN38 in the presence of 
liver carboxylesterase, suggesting the potential for controlled release in the liver 
environment.  Finally, G3.5-Gly-SN38 and G3.5-βAla-SN38 conjugates showed IC50 
values of 0.60 and 3.59 µM in HT-29 cells treated for 48 hours, suggesting their efficacy 
in the micromolar range in target colorectal cancer cells.  These studies demonstrate that 
conjugation of SN38 to G3.5 dendrimers can reduce intestinal toxicity and improve oral 
bioavailability.   Importantly, the linker chemistry (glycine vs. β-alanine) impacted the 
release profiles as well as the concentration-dependence in transport, illustrating the 
importance of choosing the appropriate linker for a given drug delivery application.  
G3.5-Gly-SN38 conjugates showed reasonable gastrointestinal stability with increased 
release in the presence of carboxylesterase, and an IC50 of 0.6 µM in HT-29 cells 
suggesting their potential for oral therapy of colorectal hepatic metastases.    
Finally, in Chapter 5 we investigated the impact of PEGylation on G3.5 and G4.5 
dendrimers in the context of oral delivery.  Conjugation of small PEG chains to 





potential drug spacer.  PEGylation decreased transport of G3.5 and G4.5 dendrimers and 
reduced tight junction opening, illustrating the importance of charge in tight junction 
modulation and transport.  In addition, incremental PEGylation had differential effects on 
cellular uptake, with PEGylation decreasing G3.5 uptake while small amounts of 
PEGylation increased G4.5 uptake with additional PEGylation decreasing uptake.  This 
suggests a balance between reducing charge-charge repulsion between anionic 
dendrimers and the negative cell membrane, enhancing cellular uptake, and creating a 
stealth system, reducing cellular uptake.  These studies illustrate that even small changes 
in surface chemistry, particularly changes that cause reduction in dendrimer charge, can 
have significant impacts on cellular uptake, tight junction opening and overall 
transepithelial transport.  Therefore, dendrimer-drug conjugates must be carefully 
designed in oral delivery applications to balance drug loading with permeability to create 
an effective drug delivery carrier.  Taken together, these studies illustrate that anionic 
PAMAM dendrimers show potential in oral drug delivery and that with careful design 
they can be custom-tailored to a given application, enhancing intestinal permeability of 
the cargo while promoting specific release at the site of action.   
 
6.2 Future Directions 
While we have elucidated some details of the mechanism of transport and tight 
junction opening of G3.5 dendrimers, further studies should focus on identifying the 
signaling pathways involved in tight junction opening and the tight junction proteins that 
are affected.  In particular, the impact of dendrimer treatment on claudin, ZO-1 and JAM 





opening should be determined.  In addition, it is important to distinguish if tight junction 
modulation is due to reorganization of the tight junction proteins or if protein expression 
is being impacted.  Comparison to permeation enhancers with known mechanisms of 
action such as EGTA and sodium caprate will also be useful to delineate the precise 
mechanism of dendrimer-mediated tight junction opening.  
G3.5-Gly-SN38 shows promising in vitro results suggesting potential for oral 
therapy of colorectal hepatic metastases.  Future studies should evaluate G3.5-Gly-SN38 
in vivo activity including biodistribution after oral administration and efficacy studies in a 
colorectal hepatic metastasis mouse model.  In addition, alternative linker chemistries 
should be investigated in order to optimize SN38 release in the presence of liver 
carboxylesterase.  Since Gly-SN38 appears to be a substrate for carboxylesterase, 
peptide-Gly linkers or PEG-Gly linkers may enhance SN38 release by increasing 
accessibility of the ester bond to the active site of carboxylesterase.  Computational 
modeling of the dendrimer-SN38 conjugate interaction with carboxylesterase may also be 
useful for linker selection.  Strategies to improve drug loading on anionic dendrimers 
should also be investigated.  Sub-optimal drug loading of SN38 was presumably due to 
low reactivity of the carboxylic acid terminal groups, low reactivity of the SN38 OH and 
steric hindrance.  As an alternative strategy, the drug could be conjugated to amine-
terminated dendrimers with subsequent modification of the remaining amine groups to 
carboxylic acid groups to complete the half-generation.  Detailed studies should address 
the balance of drug loading with intestinal permeability. 
Finally, while PEGylation decreased transport compared to unmodified 





applications.  Dendrimer-drug conjugates using PEG spacers should be synthesized to 
investigate if PEG can improve drug release in the presence of target enzymes without 
significantly decreasing permeability.  In addition, higher generation dendrimers should 
be investigated for their greater potential of drug loading and enhanced EPR effect.  In 
particular, it would be interesting to investigate the influence of polymer architecture as 
dendrimer generation increases on drug release and intestinal permeability.  These 
proposed studies would serve to build upon the conclusions of this work and advance this 





      
Appendix 1: Visualization of Intracellular Trafficking of G3.5 Dendrimers 
and Transferrin in Caco-2 Cells 
 
In Chapter 3, intracellular trafficking of Oregon Green-labeled G3.5 dendrimers 
and Alexa-Fluor-488-labeled transferrin (control) over time in Caco-2 cells was 
described.  The presence of G3.5 and transferrin in the early endosomes and lysosomes at 
different time points was quantified by colocalization of green (dendrimer/ transferrin) 
and red (endosome/ lysosome) fluorescence by confocal microscopy. Mx, the 
colocalization coefficient, was reported as the average of four z-stacks for each treatment 
and time point.  Colocalization of dendrimers with early endosomes and lysosomes 
provides further confirmation of clathrin-mediated endocytosis [18].  In addition, 
comparison of dendrimer trafficking patterns to transferrin, a classical clathrin RME 
ligand, allows for better understanding of the trafficking pathway and time course [198].   
Figures A1.1 and A2.2 show sample images from each treatment and time point 
in the trafficking study.  The early endosomes are present in the cells as punctate vesicles, 
often clustered toward the outside of the cell, away from the nucleus.  In contrast, 
lysosomal proteins are found in close proximity to the nucleus and often overlap with the 
blue nuclear signal.  These observations provide visual confirmation of the proper 
labeling of endosomal and lysosomal compartments.  These images provide visual 
evidence of G3.5 dendrimer trafficking over time and are complementary to the 







Figure A1.1. Visualization of G3.5 Dendrimer Trafficking over Time in Caco-2 Cells by 
Confocal Microscopy.  G3.5 dendrimer is labeled with Oregon Green (green), early 
endosomes (EEA-1) and lysosomes are labeled with secondary antibody Alexa Fluor-568 
goat anti-rabbit IgG (red) and the cell nuclei are labeled with DAPI (blue). Yellow 
regions indicate overlapping green and red signals (colocalization).  Z-stacks are depicted 
as a main panel (xy plane), vertical panel (xz plane) and horizontal panel (yz plane). 







Figure A1.2. Visualization of Transferrin Trafficking over Time in Caco-2 Cells by 
Confocal Microscopy.  Transferrin is labeled with Alexa Fluor-488 (green), early 
endosomes (EEA-1) and lysosomes are labeled with secondary antibody Alexa Fluor-568 
goat anti-rabbit IgG (red) and the cell nuclei are labeled with DAPI (blue). Yellow 
regions indicate overlapping green and red signals (colocalization).  Z-stacks are depicted 
as a main panel (xy plane), vertical panel (xz plane) and horizontal panel (yz plane). 







Appendix 2: Quantification of SN38 by High Pressure Liquid 
Chromatography 
 
In Chapter 4, stability studies of G3.5-SN38 conjugates were described where 
release of free SN38 over time was monitored by high pressure liquid chromatography 
(HPLC).  Several HPLC methods to detect SN38 have been described in the literature 
[199, 200].  In this Appendix we will describe the detailed HPLC methods used to 
quantify SN38 release which have been adapted from Vijayalakshmi et al. [161]. 
As described in Chapter 4, release samples were dissolved in 50/50 DMSO/0.1 N 
HCl before HPLC analysis.  This injection buffer was used to ensure that all SN38 is in 
the lactone, or closed ring form, which is favored at low pH.  DMSO was used to 
solubilize the SN38 since SN38 has very low water solubility. A gradient method, with 
methanol and HPLC-grade water with 0.1% TFA as solvents, was used with a total flow 
rate of 1 ml per minute and an injection volume of 20 µL.  Table A2.1 shows the details 
of solvent flow during the 20-minute gradient method.  Transitions between solvent 
compositions were accomplished by a linear gradient.   The average retention time of 
SN38 was found to be 16.200 ± 0.014 min.  A characteristic elution profile of SN38 is 
shown in Figure A2.1.  Note that negative peaks were observed around 4-5 minutes due 









(Water, 0.1% TFA) 
% B 
(Methanol) 
Total Flow Rate 
(ml/min) 
0 (start) 90 10 1 
14 20 80 1 
16 0 100 1 
16.1 90 10 1 





















Figure A2.1. Typical HPLC Elution Profile of SN38.  SN38 retention time was found to 
be 16.195 for this sample.  Small negative peaks are typically seen around 4-5 minutes 





In order to quantify SN38 for release studies, a standard curve was developed for 
concentrations of SN38 from 0.05 µg/ml to 12 µg/ml, corresponding to 0.5%-100% of 
drug content in G3.5-SN38 conjugates.  Standard samples were prepared at 0.05, 0.1, 0.5, 
1, 2, 4 and 12 µg/ml with more focus on the lower concentrations as most of the release 
samples were found to occur in this concentration range.  SN38 was prepared in a 
concentrated DMSO stock at 100 µg/ml and used to make the direct injection standards 
in 50/50 DMSO/ 0.1 N HCl injection buffer.  Standards were measured in triplicate and 
the concentration versus peak area was used to develop a linear correlation.  Figure A2.2 
shows the elution profiles of the 7 standard samples and Figure A2.3 shows the standard 
curve based on these direct injection standards.  Finally, Figure A2.4 displays a single 






Figure A2.2. Standard Curve Elution Profiles.  Samples are prepared at SN38 






Figure A2.3. HPLC Standard Curve Comparing SN38 Concentration and Peak Area.  
Samples are prepared at SN38 concentrations of 0.05, 0.1, 0.5, 1, 2, 4 and 12 µg/ml and 






Figure A2.4. Precision of HPLC Detection.  The HPLC chromatogram displays three 
separate injections of 12 µg/ml SN38.  Peak areas were 444,763, 436,916 and 435,529 
AU-min, yielding a standard deviation of 4,979 or 1% of the average value.   Retention 
times for the three peaks were 16.199, 16.201, 16.212, corresponding to an average value 






Appendix 3: Quantification of PEG Content of PAMAM G3.5 and G4.5-
PEG Conjugates by Proton Nuclear Magnetic Resonance 
 
 
Nuclear Magnetic Resonance (NMR) has been applied to the characterization of 
dendrimers [201].  In particular, it is useful for monitoring conjugation reactions when 
the proton signals of the conjugated ligand are distinct from the proton signals of the 
dendrimer [149, 187].  As described in Chapter 5, 1H NMR was used to quantify the 
number of PEG chains conjugated to G3.5 and G4.5 dendrimers by comparison of 
integration areas of dendrimer peaks (2.0-3.6 ppm) and PEG peaks (3.6-3.7 ppm). The 
general relationship comparing measured dendrimer and PEG areas with known numbers 











 (Eqn. A3.1) 










 (Eqn A3.2) 
Substituting known proton content for PEG750 (66), G3.5 (740) and G4.5 (1508) we 
derive equations A3.3 and A3.4 which can be used to calculate the number or PEG chains 




























 (Eqn. A3.4) 
 Table A3.1 lists the dendrimer areas and PEG areas for each dendrimer-PEG 
conjugate along with the calculated number of PEGs per dendrimer.  Figures A3.1 and 
A3.2 show the NMR scans of G3.5-1P, G3.5-1.4P, G3.5-2.3P, G4.5-.85P, G4.5-1.9P and 
G4.5-2.8P with the integration areas analyzed by Spinworks Software.  These spectra 
illustrate that an incremental increase in the stoichiometric ratio of PEG used leads to an 

































G3.5-P1 1 1.97 21.83 1.01 
G3.5-P1.4 2 3.01 24.71 1.36 
G3.5-P4.5 4 5.48 26.48 2.32 
G4.5-P.85 1 0.49 12.99 0.85 
G4.5-P1.9 2 0.85 10.46 1.86 














Figure A3.1. NMR Spectra of G3.5-PEG Conjugates.  Feed molar ratios are 1 (A), 2 (B) 
and 4 (C) PEGs/ dendrimer.  Dendrimer signals occur between 2.0 and 3.6 ppm and PEG 













Figure A3.2. NMR spectra of G4.5-PEG Conjugates.  Feed molar ratios are 1 (A), 2 (B) 
and 4 (C) PEGs/ dendrimer.  Dendrimer signals occur between 2.0 and 3.6 ppm and PEG 
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